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Drug release and its relationship with kinetic and thermodynamic parameters of 
drug sorption onto biodegradable and biocompatible fibers made of polylactic acid 
(PLA), starch acetate (SA), wheat gluten (WG) and soy protein (SP) have been studied 
using Diclofenac, 5 Fluorouracil (5-Fu) and Metformin as drug models. To understand 
drug release from these four fibers using sorption, kinetic and thermodynamic 
parameters, such as the diffusion coefficient, activation energy for diffusion, affinity, and 
sorption enthalpy and entropy, have been investigated. Quantitative relationship between 
drug release and drug loading concentration, affinity, and activation energy for diffusion 
was established to predict initial bursts and later drug release. In addition, the dissolution 
method was used to compare with the sorption method. 
The study showed that high temperature led to high diffusion coefficient for three 
drugs and Diclofenac had the lowest diffusion coefficient on four different fibers. WG 
and SP fibers had fast drug sorption rates, followed by SA and PLA fibers. The results 
also showed that increasing temperature increased the sorption amount for all three drugs 
onto PLA and SA fibers and increased Diclofenac and Metformin sorption amount onto 
WG and SP fibers, while increasing temperature decreased 5-Fu sorption amount onto 
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WG and SP fibers. It also has been found that the sorption method has at least similar 
drug release rates with the dissolution method.  
The research showed that drug loaded PLA fibers had the lowest initial bursts and 
the most constant drug release rates, followed by SA, WG and SP. The results also 
showed that lower drug loading concentration led to the lower initial burst and more 
constant subsequent release. Diclofenac had the most constant release from PLA and SA 
fibers. It has been found that high drug loading temperature leads to the most constant 
release from PLA and SA fibers. Diclofenac and Metformin had high initial bursts in 
phosphorous buffered saline (PBS) but more constant release in artificial gastric juice 
(AGJ). It also has been found that drugs with lower activation energy for diffusion and 
higher affinity (especially van der Waals force) on fibers are more suitable for sorption 
loading to achieve higher loading capacity and more constant releasing rate. 
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CHAPTER 1: INTRODUCTION 
The cost for the tissue loss or end-stage organ failure in health care exceeds about 
$400 billion which is nearly one-half of all medical related costs annually in the United 
States (Kumar, 2006). According to data from the United Network for Organ Sharing 
(UNOS), the waiting list of candidates is 98,120 on February 3, 2008 
(http://www.optn.org/). In addition, 1.3 million bone grafts and 94, 000 soft tissue grafts 
were performed in the United States in 2003, based on figures from the American 
Association of Tissue Banks (AATB) (Kumar, 2006). The method of replacing a tissue or 
an organ from a non-identical member of the same species is called allograft, which may 
carry diseases or solicit immune response if not sufficiently pretreated (Morgan and 
Yarmush, 1999). Compared to the allograft, autograft is replacing tissues in the same 
individual as they come from. Using tissue engineering technology, the regeneration or 
repair of the tissue or organ can be approached using biocompatible synthetic materials 
and other required components that can be routinely assembled. With the autograft, the 
side effects or disadvantages of the allograft can be avoided (Kumar, 2006). Within the 
tissue engineering, the most extensively investigated method is using biomaterials in 
combination with cells in order to repair or regenerate the tissue or organ. Usually, the 
biomaterials were first developed into porous 3D scaffolds which guide the regeneration 
of the new tissue and provide the structural support (Kumar, 2006). Afterward, the 
exogenous cells will be seeded and proliferate on the scaffolds. While in the growth 
process of the cell, the biomaterials will be degraded and disappear resulting in the 
formation of the final tissues or organs.  
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There are several requirements for an ideal polymeric scaffold. They are (i) a 3D 
architecture with a desired volume, shape and mechanical properties, (ii) a high surface to 
mass ratio and highly porous and well interconnected open pore structure, (iii) the 
material itself and its degradation products are biocompatible and cause minimal immune 
or inflammatory response, (iv) the degradation time matches the cell growth time (Chung 
and Park, 2007). Currently, there are some methods to fabricate 3D scaffolds, for 
example fiber bonding, solvent casting/particulate-leaching, melt molding, 
polymer/ceramic fiber composite foam, electrospun fibers (Wen et al., 2005). Based on 
the requirements of the ideal scaffold, fibers (especially electrospun fibers) are one of the 
best choices, and the fibers have been studied in this research. 
1.1. Materials used in tissue engineering  
In tissue engineering, the requirements for the materials are that they must be 
biodegradable, biocompatible and highly cell adhesive (Chung and Park, 2007). Based on 
sources, the materials can be classified into natural polymers, synthetic polymers or a 
combination thereof.   
The natural polymers are mainly divided into protein-based polymers, 
polysaccharide-based polymers and polyhydroxyalkanoates. The protein-based polymers 
used in tissue engineering mainly include fibrin, collagen, gelatin, silk fibroin, elastin and 
soybean protein. While the polysaccharide-based polymers mainly include chitosan, 
alginate hyaluronic acid, starch, chondroitin sulphate, dextran, agar, carrageenans, gellan 
gum, and cellulose. In addition, polyhydroxyalkanoates are kinds of polyesters produced 
by a wide range of microorganisms. These polyesters mainly include poly(β-
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hydroxybutyrate) (PHB), polyhydoxyalkanoates (PHAs) and poly(hydroxybutyrate co-
valerate) (PHBV).  
The biodegradable synthetic polymers used in tissue engineering and drug 
delivery mainly include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic 
acid-co-ethylene glycol) (PLGA), poly(propylene fumarate) (PPF), poly(ethylene 
terephtalate)–poly(butylenes terephtalate) copolymer (PEOT/PBN), poly(amido-amine)s 
(PAAs), N-succinimidyl tartrate monoamine poly(ethylene glycol)-block–poly(D,L-lactic 
acid), and poly(depsipeptide-co-lactide). 
Several combinations of both natural and synthetic polymers were also 
investigated, such as the blend of collagen and PLA or PLGA. Generally speaking, 
protein based materials have better biocompatibility while others are barely satisfactory. 
However, since the sources for the protein based materials are limited, the price is very 
high (Bregg, 2005). Therefore it is necessary to develop other protein-based materials 
with inexpensive prices. 
1.2. Drug delivery in general 
Drug delivery refers to the delivery of a pharmaceutical compound to humans or 
animals (Mashkevich, 2008). Since the drug is toxic if the concentration is higher than 
the toxic level or has no therapeutic effect if the concentration is less than the minimum 
therapeutic level (Bruck, 1983), it is important to release the drug at a ‘controlled’ rate. 
The routes of the drug administration can broadly be divided into topical, enteral and 
parenteral methods (McCabe et al., 2003).  The topical method is a local effect and the 
drug is directly applied to where it is required. The enteral method is a systemic (non-
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local) effect and the drug is given through the digestive tract. While the parental method 
is also a systemic effect and the drug is given via other routes than the digestive tract.  
Within these routes, the topical method in which the drug is only given in the target area 
of the body and sustains over a period of time is most effective because the drug may be 
either degraded or not incorporated efficiently via other administration methods (Grassi 
et al., 2007). The drug delivery is also widely applied in other medical fields, such as 
tissue engineering, antitumor therapies. 
Since some drugs and growth factors are necessary to be released from the 
scaffold to facilitate the proliferation and differentiation, migration, adhesion and gene 
expression of the cells during their growth, the drug delivery is widely applied in tissue 
engineering (Chung and Park, 2007; Lee, 2006; Shi, 2006). In addition, anti-
inflammatory drug delivery is required after the replacement (Guilak et al., 2003).  
1.3. Need for sorption method to load drugs into/onto materials 
Generally speaking, there are two methods to load drugs onto the scaffold. One is 
the dissolution method that is to dissolve the drug in the polymer solution or molten 
polymer. The other is the sorption method that is to sorb drugs after fabricating the 
scaffold (Prabaharan et al., 2007).  
Both drug loading methods have limitations in their use. The dissolution method 
at a high temperature (molten) may damage drugs or cause safety problems because the 
flash points of drugs may be low or close to the melting temperature of the polymer. The 
dissolution method at room temperature also has limitations, e.g. solvents of the polymer 
may not dissolve drugs, and organic solvents may damage some sensitive drugs. In 
addition, it is difficult to use the dissolution method to produce fibers with similar 
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diameters when loading drugs carry charges in electrospinning. Electrospinning, one of 
the most common methods to fabricate fibers with small diameters, is highly dependent 
upon the conductivity of the spinning solution. It is difficult to use the same spinning 
parameters to produce fibers with a similar diameter when the dissolution method is used 
to load drugs carrying different charges in electrospinning. The concentration of drugs 
carrying charges will also influence the spinning parameters. The sorption method is 
more flexible than these other loading methods because it is not necessary to load drugs 
during the fibers fabrication. 
With the sorption method, the problems or limitations that occurred in the 
dissolution method can be avoided. PLA, a thermoplastic material, can only be loaded 
drugs inside of the material at high temperatures (higher than glass transition 
temperature, Tg) using the sorption method. With drugs loaded inside of the materials, 
sustained drug release is expected. However, the sorption method also has limitations. If 
the loading temperature is too high, it may lead to fast polymer degradation. With the 
sorption method, the kinetic and thermodynamic parameters can be obtained to 
understand the drug diffusion mechanism and analyze the drug release process.  
1.4. PLA and its application in drug delivery 
Polylactic acid (PLA) has been extensively investigated for medical applications 
since the 1970s because of its biocompatibility, biodegradability and non-toxic 
degradation byproducts at relative low concentration (Avgoustakis, 2004; Conti et al., 
1992; Hyon, 2000; Lassalle and Ferreira, 2007; Xu et al., 2006). Various formulations of 
PLA utilized in medical areas include microcapsules, microparticles, implants, 
peseudolatices, nanoparticles, scaffolds and ocular devices (Jalil, 1990). As one of the 
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most important applications, PLA scaffolds have been used to work as mechanical 
supports for cell differentiation and maintain space for both cell nesting and new tissue 
growth in tissue engineering in order to solve the shortage of donor tissue supply (Hu et 
al., 2002). Fibers have been widely used in scaffolds for its high surface area to mass 
ratio and high porosity (Agrawal et al., 2006). In addition, drugs have been loaded in the 
scaffold in order to achieve controlled release to promote tissue regeneration and 
functional recovery (Willerth and Sakiyama-Elbert, 2007).
 
Paul et al. studied the sorption isotherm of Pentamidine on PLA nanoparticles at 
20°C, though the kinetics was not studied. The study showed that the sorption fitted 
Langmuir isotherm with R
2
 equal to 0.998 (Paul et al., 1998). Similarly, Ueda et al. 
studied the sorption isotherm of loperamide (LPM) on PLA nanoparticles at room 
temperature. The study also showed that the sorption fitted Langmuir isotherm (Ueda et 
al., 1998). However, using the sorption method mentioned above, drugs can only be 
loaded on the surface of PLA fibers, not inside of PLA because the loading temperature is 
below the Tg of the polymer, resulting to a fast drug release. 
1.5. Starch acetate and its application in drug delivery 
Starch acetate (SA) is made by grafting starch with acetic acid or acetic 
anhydride, either alone or in the presence of catalysts (Smith and Treadway, 1944; Xu et 
al., 2005). Since starch is biodegradable, abundant and annually renewable, starch acetate 
is used in food products, fibers, plastics and other  goods (Feuer, 1998). Currently, SA is 
receiving attention as an excipient in drug delivery or scaffold in tissue engineering 
(Malafaya et al., 2007; Mulhbacher et al., 2001; Tuovinen et al., 2003). Tuovinen et al. 
studied drug release in vitro from SA films and microparticles using a dissolution method 
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to load drugs (Tuovinen et al., 2003; Tuovinen et al., 2004; Tuovinen et al., 2004). In the 
study, the effects of degree of substitution (DS), the size of drugs and the hydrophilicity 
of drugs on drug release from SA had been investigated. Mulhbacher et al. studied drug 
release in vitro from SA hydrogels, the relationship between swelling of SA and drug 
release, and factors for drug diffusion (Mulhbacher et al., 2001; Mulhbacher et al., 2004; 
Mulhbacher and Mateescu, 2005). Tarvainen et al. studied aqueous SA dispersion as a 
coating material for controlled release (Tarvainen, 2004). 
There were also several studies which focused on drug release from SA tablets. 
Korhonen et al. studied drug release in vivo from SA tablets using the mixing and 
compression drug loading method (Korhonen et al., 2004). In the study, the model drug, 
Diltiazem, was employed on healthy volunteers and the results showed that drug release 
in vivo was similar with drug release in vitro.  Another study, by Pohja et al., examined 
drug release and water penetration of SA tablets (Pohja et al., 2004). Multivariate data 
analyses were used to evaluate and predict drug release from SA tablets by Korhonen et 
al. (Korhonen et al., 2005). Van Veen studied the effects of SA powder blend and the 
tablet structure on drug release (van Veen et al., 2005). Maki et al. researched drug 
release from SA tablets formed via dry power agglomeration (Maki et al., 2007). Within 
the forms of SA studied, there was no report on drug release of SA fibers, although the 
fiber is widely used in scaffolds because it has high surface area to mass ratio and high 
porosity (Agrawal et al., 2006). In addition, the drug loading methods for SA that have 
been discussed only involve the mixing and compression method, and the dissolution 
method (Korhonen et al., 2004; Pohja et al., 2004; Tuovinen et al., 2003).  
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1.6. Wheat Gluten and its application in drug delivery. 
Wheat gluten (WG) is a composite of proteins conjoined with starch. The proteins 
are mainly gliadin and glutenin, and the total protein content in WG is about 80% on dry 
basis (Knight, 1965). Since WG is abundant, biodegradable, biocompatible, annually 
renewable and inexpensive, it has been widely used for various applications. WG has 
been successfully developed into fibers and electrospun fibers with or without other 
materials, such as poly(vinyl alcohol) or thiolated poly(vinyl alcohol) (Dong et al., 2006; 
Dong et al., 2007; Reddy and Yang, 2007; Woerdeman et al., 2007). As one of the most 
important forms, fiber has been widely used for scaffolds in tissue engineering for its 
high surface area to mass ratio and high porosity (Agrawal et al., 2006). Recently, drug 
controlled release from scaffolds attracts more attention (Bronzino, 2006). For the drug 
loading method, sorption is more suitable for WG fibers for less impurities left in the 
fibers after drug loading compared with the dissolution method. 
To our best knowledge, there is no report on drug controlled release using WG 
itself as a carrier. Although little applications of gluten have been developed in the drug 
delivery field (for instance, as a coating material), gliadin, one of the proteins in gluten, 
has been investigated (Duclairoir et al., 2003; Ramteke and Jain, 2008; Yu and Lee, 
1997). As early as in 1940s, gliadin acetate was investigated as a drug carrier to allow a 
restricted controlled release of the drug to the spinal fluid (Pitkin, 1944). The drug was 
encapsulated by the gliadin acetate and ultimately absorbed by the body. Stella et al 
studied the gliadin films as a carrier for controlled drug release in vitro (Stella et al., 
1995). In the study, soft capsules (GI.C) and chewable gums (GCG) of crude gliadin 
were prepared. The release profile of paracetamol from GI.C has three regions in 0.1M 
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hydrochloric acid media, initial latency period followed by a low release and essentially 
constant release, while there is only one region for paracetamol release from GCG with 
very slow release.  
Ezpeleta et al. studied the controlled release of all-tans-reionoic acid (RA) from 
gliadin nanoparticles (Ezpeleta et al., 1996). Gliadin nanoparticles about 500 nm were 
prepared using a desolvation method with a yield closed to 90% of initial protein. Zero 
order diffusion (release rate 0.065 mg RA/h) was observed after about a 20% initial burst. 
Duclairoir et al. optimized the parameters on the size of gliadin nanoparticles and the 
release profile of all-trans-retinoic acid (Duclairoir et al., 1999). Encapsulation and in 
vitro release of α-Tocopherol from gliadin nanoparticles had also been studied 
(Duclairoir et al., 2002). Umamaheshwari et al. studied the preparation of mucoadhesive 
gliadin nanoparticles (GNP) containing moxicillin and their effectiveness in eradicating 
Helicobacter pylori (Umamaheshwari et al., 2004). The study showed that the higher 
gliadin concentration gave a higher mucoadhesive property of GNP. Ramteke et al. 
studied oral mucoadhesive sustained release of clarithromycin and omeprazole from 
gliadin nanoparticles in phosphate buffered saline (PBS with pH 7.4) and simulated 
gastric fluid (pH 1.2) at 37 ± 1 °C (Ramteke and Jain, 2008). 
1.7. Soy protein and its applications in drug delivery. 
Soy protein isolate (SPI) is extracted from soy beans, which has a high content of 
proteins (40-50%) and is one of the most cultivated plants in the world (Gibbs et al., 
2004). The purified SPI has an at least 90% protein content on a dry weight basis. Since 
SPI is biodegradable, biocompatible, abundant and annually renewable, it attracts 
attention as a biomaterial in tissue engineering and drug delivery fields (Malafaya et al., 
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2007). SPI have been fabricated into films and fibers using several different methods 
(Cao and Chang, 2002; Huang, 1995). Within the various forms, fibers have been widely 
used in scaffolds for its high surface area to mass ratio and high porosity (Agrawal et al., 
2006). In addition, drugs have been loaded in the scaffold in order to achieve controlled 
release to promote the tissue regeneration and functional recovery (Willerth and 
Sakiyama-Elbert, 2007). Generally speaking, there are two methods to load drugs onto 
the scaffold. One is the dissolution method that is to dissolve the drug in the polymer 
solution or molten polymer. The other method is sorption that is to sorb drugs after 
fabricating the scaffold (Prabaharan et al., 2007). However, the sorption method is more 
suitable for SP fibers for fewer impurities left in the fibers after the drug loading 
compared with the dissolution method because the drug loaded SP fibers have to go 
through the coagulation and washing bath. 
SPI has been mixed with other polymers, such as dextran, chitosan, gelatin, 
carrageenan and starch in order to improve certain properties (Cao et al., 2007; Diftis and 
Kiosseoglou, 2006; Ortiz et al., 2004; Ryan and Brewer, 2005; Silva et al., 2006). The 
degradation behavior of SPI uncrosslinked and crosslinked with glyoxal has been studied 
in an isotonic saline solution either with or without bacterial collagenase (Vaz et al., 
2003). The study demonstrated that the weight loss of SPI was directly proportional to 
the crosslinking degree and the degradation of the SPI could be controlled by the 
crosslinking. Vaz et al. used double-layer co-injection moulded SPI-based materials as 
the drug delivery carrier (Vaz et al., 2003). The study showed that the drug release was 
affected by swelling, drug diffusion, and polymer dissolution. Vaz et al. also investigated 
the mechanical properties, degradation and drug release profile of SPI films non-
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crosslinked and crosslinked with glyoxal (Vaz et al., 2004). The study showed that the 
drug release rate was dependent on the pHs of buffered saline. In another study, Chen et 
al. studied the mechanical properties and drug release of SPI films crosslinked with 
formaldehyde (Chen et al., 2008). The study showed that the crosslink density was 
dependent on the formaldehyde concentration, and the initial burst was dependent on the 
drug solubility and zero order subsequent release was observed. SPI used in hydrogels by 
itself or combined with other materials has been investigated (Snyders et al., 2007; Song 
and Zhang, 2008). The hybrid microspheres based on alginate and SPI has been 
investigated as a drug delivery carrier by Zheng et al. (Zheng et al., 2007).  
1.8 Objectives 
The main objective of this research is to understand the relationship between the 
drug release and kinetic and thermodynamic parameters of drug sorption onto PLA, SA, 
WG and SP fibers. The goal is to achieve more constant drug release rates from the drug 
loaded fibers. The mechanism of the drug sorption onto four biofibers will be understood 
by calculating some physical parameters of sorption, such as the diffusion coefficient, 
activation energy for diffusion, affinity, enthalpy and entropy. The difference of drug 
release from the drug loaded fibers by the dissolution loading method and the sorption 
loading method will be analyzed using a selected model drug.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Materials 
PLA fibers with a diameter of approximately 28µm were obtained from Fiber 
Innovation Technology, Johnson City, TN. Maize starch with 70% amylase was 
purchased from American Maize Products Co., Hammon, IN. Whetpro 80 (wheat gluten) 
and Pro-FAM® 646 (soy protein) were purchased from Archer Daniels Midlands 
Company, Decatur, IL. Three drugs, Diclofenac, 5 Fluorouracil (5-Fu) and Metformin 
were chosen in this study based on the difference in the charge they carried and their 
structures were listed in Figure 2. Diclofenac, 5-Fu and Metformin are anti-inflammatory 
drug, anti-cancer drug and the drug for treating non-insulin-dependent diabetes, 
respectively. Diclofenac and 5-Fu used in this study were purchased from TCI 
AMERICA with purity greater than 98 and 99%, respectively. Metformin was purchased 
from Advanced Technology & Industrial Co., Ltd., with purity greater than 99%. Sodium 
phosphate monobasic (NaH2PO4) was purchased from Fisher Scientific Company with 
purity 100.2% based on NaH2PO4·H2O. Anhydrous sodium phosphate dibasic was 
purchased from J. T. Baker with the purity greater than 99.7%. Sodium chloride was 
purchased from EMD with purity larger than 99.5%. PBS and AGJ were used to mimic 
human fluid and gastric fluid, respectively.  
 
Figure 2.1 Structure of three model drugs 
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2.2. Methods 
2.2.1 SA and fiber production  
SA (DS 2.3) was made according to the method reported by Xu et al. (Xu et al., 
2004). SA (20% w/w) was dissolved in formic acid and left for 24 hours at 21°C. The SA 
fibers were extruded on a roller using a syringe and needle operated by a syringe pump. 
The fibers were collected after they were dry. The dry fibers were immersed in distilled 
water at 50°C for 2 hours and rinsed to remove any remaining impurities. The fibers were 
dried at room temperature and conditioned (21°C, 65%RH) for at least 24 hours before 
using them for drug loading. At this point, the fibers were measured and found to have a 
diameter of 50 ± 5 µm. 
2.2.2 .WG and SP fiber production  
The WG fibers were extruded according to the method reported by Reddy and 
Yang (Reddy and Yang, 2007). The SP fibers were extruded according to the method 
reported by Zhang et al. (Zhang et al., 2003). 
2.2.3. Drug loading using the sorption method  
About 10 mg of fibers were loaded into a centrifuge tube and an aqueous solution 
containing each drug at initial pH 8.0 (adjusted by Na2CO3) for Diclofenac and 5-Fu, and 
initial pH 6.3 for Metformin was added to the tube at a liquor-to-fibers ratio of 100:1. The 
tubes were held at a specified temperature with an oscillation of 120 rpm in a shaking 
water bath (Model: 1217 VWR). After specified loading times, the centrifuge tubes were 
immediately dipped in an ice bath for 2 minutes. The drug solution was removed from the 
tubes and the fibers were washed 3 times in a centrifuge at 9000 rpm with 1 ml of 0 °C 
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water for 30 seconds to remove the drugs that were not well attached on the surface of the 
fibers. The washed fibers were dried and then kept in a conditioning room (21°C, 
65%RH) for at least 24 hours before testing. 
2.2.4. Drug loading using the dissolution method  
PLA fibers were dissolved in chloroform at room temperature and certain amount 
of Diclofenac was added into the polymer solution. The polymer solution was transferred 
into a syringe and later extruded by a syringe pump. The extruded polymer jet was 
collected using a rotating drum with a suitable speed in order to obtain PLA fibers with 
an average diameter of 28 µm. The obtained PLA fibers were dried in the air, washed 3 
times in a centrifuge at 9000 rpm (5.8 g) with 1 ml of 0 °C water for 30 seconds, dried 
and then kept in a conditioning room for at least 24 hours before testing. 
2.2.5. Calibration curves of Diclofenac, 5-Fu and Metformin in water  
The calibration curve is the relationship between the drug absorbance at certain 
wavelength and the drug concentration. The purpose of creating a calibration curve is to 
measure the drug concentration in a solution. A certain amount of drugs was used to 
prepare the stock solution with water. The stock solution was used to prepare the drug 
solutions of different concentrations with water. The absorbance of solutions for 
Diclofenac, 5-Fu and Metformin was measured using UV/Vis spectrophotometer (Model 
DU
®
 720 Beckman Coulter) at 275nm, 265nm and 232nm, respectively. The absorbance 
and the corresponding concentration of the drugs was plotted and regressed into a linear 
line with an intercept equal to zero as seen in Figures 2.2, 2.3 and 2.4, respectively. 
15 
 
 
Figure 2.2. Absorbance as a function of Diclofenac concentration (µg/ml) in distilled 
water and regressed into a linear line with an intercept equal to zero. 
 
Figure 2.3. Absorbance as a function of 5-Fu concentration (µg/ml) in distilled water and 
regressed into a linear line with an intercept equal to zero. 
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Figure 2.4. Absorbance as a function of Metformin concentration (µg/ml) in distilled 
water and regressed into a linear line with an intercept equal to zero. 
Example: Drug amount in water or in fibers 
The linear regression equation of calibration curve for Diclofenac in water is 
Equation (1).  
y = 0.0308 x    (1) 
If the Diclofenac solution at unknown concentration has an absorbance of 0.503 at 
275nm, substituting this value into Equation (11) gives the following. 
x = 0.503 / 0.0308 ml/µg 
x = 16.3 µg/ml 
2.2.6. Calibration curve of Diclofenac in 0.1% PLA chloroform solution  
In order to measure the drug concentration in fibers, the fibers are dissolved in a 
suitable solvent. The drug concentration in the polymer solution is calculated based on 
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the absorbance of the drug and a calibration curve for the same drug in the same polymer 
solution.  
The Diclofenac stock solution was prepared with a certain amount of Diclofenac 
powder in 0.1% PLA chloroform solution. The stock solution was diluted into solutions 
of different concentrations with 0.1% PLA chloroform. The absorbance of Diclofenac 
was measured at 278nm. The absorbance and the corresponding concentration of the 
drugs were plotted and regressed into a linear line with an intercept equal to zero as seen 
in Figure 2.5. 
 
Figure 2.5. Absorbance as a function of Diclofenac concentration (µg/g) in 0.1% (wt.-%) 
PLA chloroform solution and regressed into a linear line with an intercept equal to zero. 
2.2.7. Calibration curve of 5-Fu and Metformin in PLA using the extraction method 
 Since chloroform had strong absorbance at the maximum absorbance wavelength 
of 5-Fu and Metformin, the extraction method was used to create calibration curves. The 
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5-Fu and Metformin stock solutions were each prepared with 0.5% PLA chloroform 
solution. The stock solutions were diluted into different concentration solutions with 
0.5% PLA chloroform solution. The diluted solutions were transferred to 8ml and 7ml 
distilled water for 5-Fu and Metformin solution, respectively. After shaking well, the top 
water layers were transferred to centrifuge tubes and be centrifuged at 10,000rpm for 10 
minutes. The top layers were used to measure the absorbance at 265nm and 232nm for 5-
Fu and Metformin, respectively. The absorbance and the corresponding concentration of 
the drugs were plotted and regressed into a linear line with an intercept equal to zero as 
shown in Figures 2.6. and 2.7., respectively. 
 
Figure 2.6. Absorbance as a function of 5-Fu concentration (µg/g) in 0.5% (wt.-
%) PLA chloroform solution and regressed into a linear line with an intercept equal to 
zero. 
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Figure 2.7. Absorbance as a function of Metformin concentration (µg/g) in 0.5% 
(wt.-%) PLA chloroform solution and regressed into a linear line with an intercept equal 
to zero. 
2.2.8. Calibration curve of Diclofenac, 5-Fu and Metformin in SA formic acid 
solution 
  The Diclofenac and 5-Fu loaded SA fibers were dissolved using formic acid and 
the absorbance of drug in the solution was measured with a UV spectrometer at 275 nm 
and 264 nm using virgin SA fibers as control. The absorbance and the corresponding 
concentration of the drugs were plotted and regressed into a linear line with an intercept 
equal to zero as seen in Figures 2.8. and 2.9. 
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Figure 2.8. Absorbance as a function of Diclofenac concentration (µg/g) in 0.05% 
(wt.-%) SA formic acid solution and regressed into a linear line with an intercept equal to 
zero. 
 
Figure 2.9. Absorbance as a function of 5-Fu concentration (µg/g) in 1.43mg/ml 
SA formic acid solution and regressed into a linear line with an intercept equal to zero. 
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Since formic acid had strong absorbance at the maximum absorbance wavelength 
of Metformin and it dissolved in water, the extraction with vaporizing method was used. 
Firstly, SA fibers were dissolved in formic acid at a liquor-to-solid ratio of 1 ml: 20 mg. 
The SA formic acid solution was mixed with distilled water with a SA solution-to-water 
ratio 1: 20. The mixtures were centrifuged and 6ml of each top clear layer was transferred 
to the vials. The vials were heated at 90°C for 6 hours to vaporize the solvents. After 
cooling down to the room temperature, 6 ml distilled water was added into the vials and 
was shaken for 3 minutes. The absorbance of the solutions was measured at 232 nm. The 
absorbance and the corresponding concentration of the drugs were plotted and regressed 
into a linear line with an intercept equal to zero as seen in Figure 2.10. 
 
Figure 2.10. Absorbance as a function of Metformin concentration (mg/g) in SA 
fibers and regressed into a linear line with an intercept equal to zero. 
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2.2.9. Calibration curves of Diclofenac, 5-Fu and Metformin in diluted AGJ  
The absorbance of Diclofenac, 5-Fu and Metformin in the solution of AGJ-to-
water ratio 1:5 was measured for different concentration at 275nm, respectively. The 
absorbance and the corresponding concentration of the drugs were plotted and regressed 
into a linear line with an intercept equal to zero as seen in Figures 2.11., 2.12. and 2.13., 
respectively. 
 
 
Figure 2.11. Absorbance as a function of Diclofenac concentration (µg/ml) in 
diluted AGJ solution with AGJ-to-water ratio of 1:5 and regressed into a linear line with 
an intercept equal to zero. 
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Figure 2.12. Absorbance as a function of 5-Fu concentration (µg/ml) in diluted 
AGJ solution with AGJ-to-water ratio of 1:5 and regressed into a linear line with an 
intercept equal to zero. 
 
 
Figure 2.13. Absorbance as a function of Metformin concentration (µg/ml) in 
diluted AGJ solution with AGJ-to-water ratio of 1:5 and regressed into a linear line with 
an intercept equal to zero. 
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2.2.10. Calibration curves of Diclofenac, 5-Fu and Metformin in 2% WG 2M NaOH 
aqueous solution 
The drug loaded WG fibers were hydrolyzed using a 2M aqueous NaOH solution 
at 50°C for 2 hours with continuous shaking. Dissolved WG solution was diluted with 
distilled water and the drug concentration in the solution was calculated by measuring the 
absorbance with a UV spectrometer at 275 nm, 284 nm and 248 nm using virgin WG 
fibers as control. The absorbance and the corresponding concentration of the drugs were 
plotted and regressed into a linear line with an intercept equal to zero as seen in Figures 
2.14., 2.15. and 2.16., respectively. 
 
Figure 2.14. Absorbance as a function of Diclofenac concentration (µg/ml) in 2% 
WG 2M NaOH aqueous solution and regressed into a linear line with an intercept equal 
to zero. 
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Figure 2.15. Absorbance as a function of 5-Fu concentration (µg/ml) in 2% WG 
2M NaOH aqueous solution and regressed into a linear line with an intercept equal to 
zero. 
 
Figure 2.16. Absorbance as a function of Metformin concentration (µg/ml) in 2% 
WG 2M NaOH aqueous solution and regressed into a linear line with an intercept equal 
to zero. 
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2.2.11. Calibration curves of Diclofenac, 5-Fu and Metformin in 2% SP 2M NaOH 
aqueous solution 
The drug loaded SP fibers were hydrolyzed using a 2M aqueous NaOH solution at 
50°C for 2 hours with continuous shaking. Dissolved SP solution was diluted with 
distilled water and the drug concentration in the solution was calculated by measuring the 
absorbance with a UV spectrometer at 275 nm, 284 nm and 248 nm using virgin SP 
fibers as control. The absorbance and the corresponding concentration of the drugs were 
plotted and regressed into a linear line with an intercept equal to zero as seen in Figures 
2.17., 2.18. and 2.19., respectively. 
 
Figure 2.17. Absorbance as a function of Diclofenac concentration (µg/ml) in 2% 
SP 2M NaOH aqueous solution and regressed into a linear line with an intercept equal to 
zero. 
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Figure 2.18. Absorbance as a function of 5-Fu concentration (µg/ml) in 2% SP 
2M NaOH aqueous solution and regressed into a linear line with an intercept equal to 
zero. 
 
Figure 2.19. Absorbance as a function of Metformin concentration (µg/ml) in 2% 
SP 2M NaOH aqueous solution and regressed into a linear line with an intercept equal to 
zero. 
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2.2.12. Determining the amount of drug loaded on the SA fibers  
The Diclofenac and 5-Fu loaded SA fibers were dissolved using formic acid and 
the absorbance of drug in the solution was measured with a UV spectrometer at 275 nm 
and 264 nm using virgin SA fibers as control. The Diclofenac and 5-Fu loading amounts 
on the SA fibers were calculated using calibration curves developed. The calibration 
curves for Diclofenac in 0.5 mg/ml SA formic acid solution had the relation of y = 0.034x 
(R
2 
= 0.999); Where y was absorbance and x was Diclofenac concentration in 0.5 mg/ml 
SA formic acid solution (µg/ml). The calibration curve for 5-Fu in 1.43 mg/ml SA formic 
acid solution had the relation of y = 0.044x (R
2 
= 0.999); Where y was absorbance and x 
was 5-Fu concentration in 1.43 mg/ml SA formic acid solution (µg/ml). Since formic acid 
had strong absorbance at the maximum absorbance wavelength of Metformin and it 
dissolved in water, the extraction with vaporizing method was used. Firstly, SA fibers 
were dissolved in formic acid at a liquor-to-solid ratio of 1 ml: 20 mg. The SA formic 
acid solution was mixed with distilled water with a SA solution-to-water ratio 1: 20. The 
mixtures were centrifuged and 6ml of each top clear layer was transferred to the vials. 
The vials were heated at 90°C for 6 hours to vaporize the solvents. After cooling down to 
the room temperature, 6 ml distilled water was added into the vials and was shaken for 3 
minutes. The absorbance of the solutions was measured at 232 nm. The calibration curve 
for Metformin in this method had the relation of y = 0.039x (R
2 
= 0.999); Where y was 
absorbance and x was Metformin concentration in SA fibers (µg/mg). 
2.2.13. Determining the amount of drug loaded on the WG fibers  
The drug loaded WG fibers were hydrolyzed using a 2M aqueous NaOH solution 
at 50°C for 2 hours with continuous shaking. Dissolved WG solution was diluted with 
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distilled water and the drug concentration in the solution was calculated by measuring the 
absorbance with a UV spectrometer at 275 nm, 284 nm and 248 nm using virgin WG 
fibers as control. The drug loading amount on the WG fibers were calculated using 
calibration curves developed previously. The calibration curves for Diclofenac in the 
0.952 mg/ml WG solution had the relation of y = 0.0386x (R
2 
= 0.999); Where y = 
absorbance and x = Diclofenac concentration in the 0.952 mg/ml WG solution with a unit 
of µg/ml. The calibration curve for 5-Fu in the 1.25 mg/ml WG solution had the relation 
of y = 0.0442x (R
2 
= 0.999); Where y = absorbance and x = Diclofenac concentration in 
the 1.25 mg/ml WG solution with a unit of µg/ml. The calibration curve for Metformin in 
the 1.25 mg/ml WG solution had the relation of y = 0.0346x (R
2 
= 0.999); Where y = 
absorbance and x = Metformin concentration in the 1.25 mg/ml WG solution with a unit 
of µg/mg. 
2.2.14. Determining the amount of drug loaded on the SP fibers  
The drug loaded SP fibers were hydrolyzed using a 2M aqueous NaOH solution at 
50°C for 2 hours with continuous shaking. Dissolved SP solution was diluted with 
distilled water and the drug concentration in the solution was calculated by measuring the 
absorbance with a UV spectrometer at 275 nm, 284 nm and 248 nm using virgin SP 
fibers as control. The drug loading amount on the SP fibers were calculated using 
calibration curves developed previously. The calibration curves for Diclofenac in the 
0.952 mg/ml SP 2M NaOH solution had the relation of y = 0.0085x (R
2 
= 0.999); Where 
y = absorbance and x = Diclofenac concentration in the 0.952 mg/ml SP 2M NaOH 
solution with a unit of µg/ml. The calibration curve for 5-Fu in the 1.25 mg/ml SP 2M 
NaOH solution had the relation of y = 0.0442x (R
2 
= 0.999); Where y = absorbance and x 
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= Diclofenac concentration in the 1.25 mg/ml SP 2M NaOH solution with a unit of 
µg/ml. The calibration curve for Metformin in the 1.25 mg/ml SP 2M NaOH solution had 
the relation of y = 0.0346x (R
2 
= 0.999); Where y = absorbance and x = Metformin 
concentration in the 1.25 mg/ml SP 2M NaOH solution with a unit of µg/mg. 
2.2.15. Drug release  
The drug release experiments were carried out in phosphate buffered saline (PBS) 
solution with pH = 7.4 in a shaking water bath maintained at 37.2°C and shaking at 120 
rpm. The conditions listed above are commonly used to mimic the environment in the 
human body.  Blank fibers without loading drugs were used as a control. About 10mg of 
drug loaded fibers were put into a centrifuge containing PBS solution with a PBS to fiber 
ratio of 1000:1. Precisely 0.5ml of PBS solution was removed at various time intervals 
and an equal amount of fresh PBS was added to maintain the same liquid to fiber ratio 
throughout the experiments. The collected solution containing the drug was diluted with 
5ml distilled water and the absorbance was measured. The amount of Diclofenac, 5-Fu 
and Metformin in the solution was calculated using the calibration curves for that 
particular drug that was developed previously. 
2.2.16. Diffusion coefficient and activation energy for diffusion  
The diffusion coefficients of the drugs through the fibers at 70, 80, 90 and 110°C 
were calculated using Equation (2) (Crank, 1975) and were obtained from a linear 
regression of CCt /  versus t
0.5
. 
5.02 )/(4/ rDtCCt     (2) 
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Where Ct is the drug concentration in the fibers at the loading time t, C∞ is the 
drug concentration in the fibers at the infinite time, D is the diffusion coefficient of the 
drug through fibers, r is the radius of the fibers, and t is the loading time.  
Example: Calculating diffusion coefficient: Plot CCt /  
and t
0.5
, then regress into a linear 
line with intercept set to 0 as seen in Figure 2.20. Substituting the slope into Equation (2) 
gives the following. 
 3.14m)/4) (14.08min (0.1726 = D 2-0.5    
/minm1.16 = D 2  
/min m10 1.16 = D 2-12  
 
 
Figure 2.20. Ct/C∞ as a function of t
0.5
 
The maximum diffusion coefficient and the activation energy for diffusion for the 
three drugs were calculated using Equation (3) (Stannett, 1968) and were obtained from 
the intercept and slope, respectively, of a linear regression of )ln( TD  versus T/1 . 
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Where DT is the diffusion coefficient at temperature T of the drug through fibers, 
D0 is a constant (maximum diffusion coefficient of a drug through a specific fiber), Ea is 
the activation energy for diffusion, R is the ideal gas constant, and T is the loading 
temperature. 
Activation energy for diffusion: Plot )ln( TD and T/1 and regress into a linear line 
with a slope equal to -1618.9 as seen in Figure 2.21. Substituting these values into 
Equation (3) gives the following. 
 J/mol 8.14(-1618.9)- = E a   
J/mol 13178 = E a  
kJ/mol 13.18 = E a  
 
Figure 2.21. Ln(DT) as a function of 1/T 
2.2.17. Affinity, sorption enthalpy and entropy  
For Diclofenac and Metformin, the activity of the drug in solution is calculated by 
Equation (4) (Tinoco et al., 2001) since they are completely ionized drugs.  
y = -1618.9x - 24.944
R² = 0.9578
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s
z
s
z
s DNaa ][][
1       (4) 
Where γ is the activity coefficient, as is the drug activity in the solution, z is the 
number of charges on the ion, [D]s is the drug concentration in the solution, and [Na
+
]s is 
the sodium ion concentration in the solution. The activity coefficients of Diclofenac and 
Metformin in the solution were calculated using Equation (5) (Tinoco et al., 2001). The 
concentration of 5-Fu in the solution was arbitrarily used as the activity in the solution 
because 5-Fu is not ionized.  

i
ii zcAz
5.022 )5.0(ln     (5) 
Where A is a constant approximately equal to 0.5 and 0.5 is used in this 
manuscript, c is the concentration, and i is the component i in the drug.  
Example: Activity coefficient (γ) and activity (a) for ionic drugs in water 
 The activity coefficient γ is calculated according to Equation (5). In the following 
sample equation, the concentration of Diclofenac cD
-
 is mol/L 101.092 -2 . Since the 
number of Diclofenac ions is equal to number of sodium ions, the sodium concentration 
cNa
+
 is mol/L 101.092 -2 . In addition, a Diclofenac ion carries one charge, and a sodium 
ion carried one charge in water, so both zNa
+
 and zD
-
 are 1. Substituting these values into 
Equation (5) gives the following. 
) ))1 mol/L101.092+1mol/L 10(1.092(0.51(-0.5 0.52 -22-22e = γ   
 0.964 = γ  
The activity of the Diclofenac in water aD
-
 is calculated according to Equation (4). 
Substituting the values above into Equation (4) gives the following. 
Lmol /(0.964))10(1.092 =a 22-2
D-
  
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mol/L 101.011 = a -4
D-
  
The activity of the drug on PLA fibers was calculated by Equation (6) 
(Vickerstaff, 1950) based on Langmuir sorption isotherm. Langmuir is selected because it 
has high R
2
 values and a unit slope for plot of )ln( fa  versus )ln( sa .  
)][]/([][ ffff DSDa     (6) 
Where af is the drug activity in the fibers, [D]f is the drug concentration in the 
fibers, and [S]f is the saturated drug concentration on the fibers.  
Activity for ionic drug fitting Langmuir isotherm in fibers   
Calculating the saturation concentration: Plot 1/[Ds] and 1/[Df] and regress into 
a linear line as seen in Figure 2.22. The intercept is equal to the inverse of saturation 
concentration. Substituting the value into the inverse gives the following. 
mol/kg 1/70 = [S]  
mol/kg 101.43 = [S]  -2  
 
Figure 2.22. 1/[Df] as a functionof 1/[Ds] 
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Activity (mol/kg) of drug in fibers: (assuming [Df] =8.31×10
-3
mol/kg) Substituting these 
values into Equation (10) gives the following. 
mol/kg) 108.31 - mol/kg 10 /(1.43mol/kg108.31  = a -3-2-3 f   
mol/kg 1.39 = a f  
Calculating V (L/kg): Plot 
faln  and saln  and regress into a linear line as seen in 
Figure 2.23. with a slope 0.533. Substituting the new 
faln  with faln /0.533 gives a new 
linear line with slope equal to 1.  
kgL /e = V  0.533  
kgL / 1.704 = V  
 
Figure 2.23. Ln(af) as a function of ln(as) 
Activity (as mol/L) of drug in fibers: Substituting V into as/V gives the following. 
L/kg  /1.704mol/kg 1.39 = (mol/L)a  s  
mol/L 0.816 = (mol/L)a  s  
y = 1.0007x + 10.036
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The apparent sorption affinities were calculated using Equation (7) (Tinoco et al., 
2001).  
)/ln( sf aaRT     (7) 
where -Δµ is the apparent sorption affinity, R is the ideal gas constant, and T is the 
loading temperature.  
Calculating the sorption affinity:  
 If as = 9.745×10
-5
mol/L and af = 0.816 mol/L at 90°C, Substituting these values 
into Equation (3) gives the following. 
mol/L))1045mol/L/(9.7 ln(0.816 K  363  mol) J/(K 8.314 = -5   
J/mol 26690 = Δ-   
kJ/mol 26.69 = Δ-   
 
The apparent sorption enthalpy was calculated according to Equation (8) (Tinoco 
et al., 2001) and was obtained by the slope of the linear regression of T/  versus T/1 . 
CTTH  //      (8) 
where ΔH is the apparent sorption enthalpy, and C is a constant.  
Calculating the sorption enthalpy (sorption heat): Plot Δµ/T and 1/T and regress into a 
linear line as seen in Figure 2.24. Then the slope is the sorption enthalpy.  
kJ/mol 9.24 = ΔH  
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Figure 2.24. Δµ/T as a function of 1/T 
The apparent sorption entropy was calculated using Equation (9) and was 
obtained from the slope of the linear regression of Δμ versus -T. 
STH      (9) 
where ΔS is the apparent sorption entropy.  
Calculating the sorption entropy:  
K)J/(mol39.122
1000343/)13.2185.20(
/)(


 THS 
 
2.2.18. Measurement of the size of Diclofenac, 5-Fu and Metformin by molecular 
modeling 
 The gradient-corrected Perdew-Burke-Ernzerh (PBE) exchange-correlation 
functional and the double-numerical polarized basis set (DNP), implemented in DMOL3 
software, were chosen for geometric optimization. 
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2.2.19. Statistics  
All the experiments were repeated at least three times. The data were reported 
with mean ± one standard deviation. To obtain equations to predict the initial burst and 
drug release after burst based on the affinity between drug and PLA fibers, drug loading 
concentration, activation energy for diffusion and time, linear regressions were 
performed. The linear regressions were performed on the initial burst or drug release after 
burst versus the affinity, drug loading concentration, RTEae
/ , 5.0
/
)(
RTEae

, t , t
0.5
 and their 
two-way interactions. 
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CHAPTER 3 RESULTS AND DISCUSSION 
3.1. Drug Release and Its Relationship with Kinetic and Thermodynamic 
Parameters of Drug Sorption onto PLA Fibers 
3.1.1. Diclofenac, 5-Fu and Metformin sorption rates on PLA fibers and their kinetic 
parameters  
The sorption rates of Diclofenac, 5-Fu and Metformin on PLA fibers and kinetic 
parameters of these three drugs on fibers are shown in Figures 3.1.1, 3.1.2 and 3.1.3 and 
Table 3.1.1, respectively. As seen in the figures, increasing temperatures increases the 
sorption rate which can be inferred from the initial slopes of the curves for all three 
drugs, and also this can be quantified by the diffusion coefficients as shown in Table 
3.1.1. As seen from the table, diffusion coefficients increase with the increasing 
temperatures for all three different drugs. This is mainly because of four reasons. First, at 
a higher temperature, drugs move faster in both bulk solution and the boundary layer. 
Increasing movement of drugs leads to the faster sorption rate. Second, with increasing 
the temperature, the boundary layer on the PLA fibers’ surface becomes thinner and then 
increases the rate for drugs to move onto the surface of fibers. Third, the size of holes on 
the PLA fibers increases with increasing the temperature and then facilitates the drugs to 
move inside of the PLA fibers. Since the loading temperatures used in this study are 
higher than the Tg (50-60 °C) of PLA, increasing the drug loading temperature increases 
the movement of PLA molecular chains and hence leads to the larger size of the holes on 
the fibers’ surface. Last, there are smaller aggregates of drugs at higher temperatures than 
those at lower temperatures, thus leading to fast movement of drugs into fibers.  
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Figure 3.1.1. Effect of temperatures on sorption rates of Diclofenac on PLA fibers in an 
aqueous solution with 5mg/g Diclofenac at pH 8.0 and 100:1 liquor-to-fibers ratio 
 
Figure 3.1.2. Effect of temperatures on sorption rates of 5-Fu on PLA fibers in an 
aqueous solution with 5mg/g 5-Fu at pH 8.0 and 100:1 liquor-to-fibers ratio 
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Figure 3.1.3. Effect of temperatures on sorption rates of Metformin on PLA fibers in an 
aqueous solution with 5mg/g Metformin at pH 6.3 and 100:1 liquor-to-fibers ratio 
Table 3.1.1. Kinetic parameters of Diclofenac, 5-Fu and Metformin onto PLA fibers  
 
Diclofenac 5-Fu Metformin 
70°C 80°C 90°C 110°C 70°C 80°C 90°C 110°C 70°C 80°C 90°C 110°C 
Diffusion 
coefficient 
(m
2
 · min
-1
*10
12
) 
0.314 
±0.042 
0.385 
±0.036 
0.432 
±0.054 
0.514 
±0.056 
0.730 
±0.036 
0.767 
±0.049  
0.860 
±0.047 
0.988 
±0.051 
1.420 
±0.076 
1.521 
±0.068 
1.629 
±0.084 
1.884 
±0.081 
ΔE for diffusion 
(kJ · mol
-1
) 
13.00 ± 1.68 8.58 ± 0.75 7.74 ± 0.26 
It also can be seen in Figures 3.1.1 to 3.1.3 that after achieving sorption 
equilibrium, higher temperature gives the higher drug sorption amount than lower loading 
temperature for these three drugs on PLA fibers within the temperatures studied. This is 
most likely because more accessible spaces have been created in the PLA fibers at higher 
temperatures and this leads to higher drug sorption. Higher temperatures can break 
stronger interactions among PLA polymer chains, resulting in more potential spaces for 
the drugs to be located in the fibers. These spaces lead to the relative high drug loading 
amount on PLA fibers. 
As shown in Figures 3.1.1 to 3.1.3 and Table 3.1.1, Metformin required the least 
time (high diffusion coefficients) to reach the sorption equilibrium, followed by 5-Fu and 
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then Diclofenac. This is probably because of the size of drugs and the affinity between 
the drug and PLA fibers. Metformin (with a diameter of 7.54 A) and 5-Fu (with a 
diameter of 5.42 A) are smaller than Diclofenac (with a diameter of 10.01 A), and 
Diclofenac has a large hydrophobic portion. The large hydrophobic tail leads Diclofenac 
to form aggregates in the solution. Both the size and the aggregation of Diclofenac limit 
its entrance into the PLA fibers. 5-Fu is a hydrophobic drug and it readily forms more 
aggregates than Metformin in the solution. In addition, affinity between drugs and PLA 
fibers influences the drug sorption rate. Increasing the affinity decreases the drug sorption 
rate in the PLA fibers because the sorbed drug molecule tightly interacts with PLA and 
thus blocks other drug molecules from moving inside of PLA fibers. As seen in Table 
3.1.2, 5-Fu has higher affinities than Metformin with PLA fibers. Hence, both the 
aggregation and higher affinities of 5-Fu lead to the slower sorption rates than Metformin 
on PLA fibers.  
The activation energies for diffusion for different drugs are listed in Table 3.1.1. 
As seen from the table, Diclofenac requires more energy than that of 5-Fu and 
Metformin. Higher activition energy for diffusion means that more energy is required to 
create an opening big enough for a drug to move into the fibers. Since the size of 
Diclofenac is larger than the other two drugs, the opening in the PLA fibers must be large 
enough in order to let Diclofenac move inside, and formation of this opening requires 
more energy. It also can be seen from the table that 5-Fu has a slight higher activiation 
engergy for diffusion than Metformin, and this is probably due to the fact 5-Fu can 
readily form aggregates than Metformin. 
43 
 
3.1.2. Isotherms and apparent thermodynamic parameters of Diclofenac, 5-Fu and 
Metformin on PLA fibers  
Isotherms of Diclofenac, 5-Fu and Metformin on PLA fibers and thermodynamic 
parameters of three drugs’ sorption on PLA fibers are shown in Figures 3.1.4, 3.1.5 and 
3.1.6 and Table 3.1.2, respectively. As seen in the figures, isotherms of three drugs on 
PLA fibers at different temperatures fit Langmuir isotherms well. It also can be seen in 
the figures that higher temperatures lead to high drug exhaustion for all three drugs. This 
is due to more accessible spaces in PLA fibers created at the higher temperature. Higher 
temperatures break more interactions among PLA polymer chains and create more 
accessible space for drugs to move inside of the fibers. Hence, high temperatures increase 
the exhaustion of drugs on PLA fibers within the temperatures studied. 
 
Figure 3.1.4. Isotherms of Diclofenac on PLA fibers with 100: 1 liquor-to-fibers ratio at 
different Diclofenac concentrations at specified temperatures 
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Figure 3.1.5. Isotherms of 5-Fu on PLA fibers with 100: 1 liquor-to-fibers ratio at 
different 5-Fu concentrations at specified temperatures 
 
Figure 3.1.6. Isotherms of Metformin on PLA fibers with 100: 1 liquor-to-fibers ratio at 
different Metformin concentrations at specified temperatures 
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Table 3.1.2. Apparent thermodynamic parameters of Diclofenac, 5-Fu and Metformin on 
PLA fibers 
 
Diclofenac 5-Fu Metformin 
70°C 80°C 90°C 110°C 70°C 80°C 90°C 110°C 70°C 80°C 90°C 110°C 
-Δµ (kJ · mol-1) 
21.13 
±0.76 
22.86 
±1.47 
24.02 
±1.37 
26.16 
±1.67 
9.22 
±0.55 
9.65 
±0.87 
10.05 
±0.79 
10.81 
±0.87 
6.17 
±0.45 
7.48 
±0.87 
8.44 
±0.30 
10.24 
±0.51 
ΔH (kJ · mol-1) 20.85±3.74 4.10±0.29 28.42±2.32 
ΔS (J · mol-1 · 
K
-1
) 
138.55 
±2.51 
139.65 
±4.70 
138.92 
±4.24 
137.06 
±4.87 
43.96 
±1.82 
43.93 
±2.78 
43.81 
±2.44 
43.47 
±2.54 
114.16 
±1.48 
114.70 
±2.78 
114.12 
±0.93 
112.71 
±1.49 
Compared with Diclofenac, 5-Fu and Metformin have lower exhaustion, as seen 
in Figures 3.1.4 to 3.1.6. This is because of the lower affinities between drugs (5-Fu and 
Metformin) and fibers than that of Diclofenac. As seen in Table 3.1.2, Diclofenac has the 
highest apparent affinity with PLA fibers, followed by 5-Fu and then Metformin. This is 
due to the interactions between the drugs and PLA fibers. Since Diclofenac has a big 
hydrophobic tail which can tightly interact with PLA via van der Waals’ force. In 
addition, Diclofenac has functional groups -COO
-
 and –NH- which can form ion-dipole, 
dipole-dipole interactions or hydrogen bonds with =CO or –COO- in PLA molecules. 
Since PLA is a hydrophobic polymer, it can form strong van der Waals’ force with 5-Fu 
which is more hydrophobic than Metformin. The strong van der Waals’ force leads to 
higher affinities of 5-Fu on PLA than that of Metformin. As seen from Table 3.1.2, the 
entropy changes during the sorption process for both Diclofenac and Metformin are much 
larger than that of 5-Fu. This is due to the higher water solubility of both Diclofenac and 
Metformin. In the solution, both ionized groups are surrounded by water molecules. After 
the drugs are sorbed, the water molecules are released and then increase the sorption 
entropy. 
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3.1.3. Diclofenac, 5-Fu and Metformin release in vitro  
Diclofenac, 5-Fu and Metformin release in vitro from drug loaded PLA fibers are 
shown in Figures 3.1.7, 3.1.8 and 3.1.9, respectively. As seen in the figures, all three 
drugs loaded on PLA fibers have initial bursts at the beginning of the release and 
followed with the constant drug release. The initial burst has a reverse relationship with 
the loading temperatures as seen in the figures. This is probably due to the temperature 
effect on the opening spaces in PLA fibers. Increasing the loading temperature increases 
the amount of opening spaces inside of the PLA fibers and then more drugs located in 
these opening spaces after the drug loading as indicated by the increasing affinity. Hence, 
the higher loading temperature leads to the lower initial burst at the release temperature. 
However, there is no significant change from 90 to 110°C. This is probably due to the 
fact that PLA has been hydrolyzed more at 110°C, leading to the fast release.  
 
Figure 3.1.7. Diclofenac release from PLA fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm for Diclofenac loaded with the dissolution method and the 
sorption method loaded at 70, 80, 90 and 110°C 
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Figure 3.1.8. 5-Fu release from PLA fibers in PBS (pH 7.4) at 37.2±0.1°C with shaking 
speed at 120 rpm for 5-Fu loaded at 70, 80, 90 and 110°C 
 
Figure 3.1.9. Metformin release from PLA fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm for Metformin loaded at 70, 80, 90 and 110°C 
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It also can be seen from Figure 3.1.7 that PLA fibers with higher amounts of 
loaded drug have higher initial bursts than those of PLA fibers with lower drug loading 
concentrations. This is probably due to stronger interactions between the drug and the 
fibers at lower drug loading concentrations. In the PLA fibers, there are various sites the 
drug can occupy, and these sites have different affinities with the drug. At the lower drug 
loading concentration, drugs mainly occupy the sites with the strongest interaction with 
PLA fibers, and lead to lower initial burst than the high drug loading concentration. 
When the amount of drug loaded on the fibers is higher, more drugs occupy sites in the 
fibers where they form weaker interactions with PLA fibers because most of the stronger 
interaction sites are occupied by other drugs. Drugs that form weaker interactions with 
PLA fibers are released more quickly as indicated by the higher initial burst when a 
larger amount of drug is loaded on PLA fibers. Although 5-Fu and Metformin have lower 
concentrations than Diclofenac, 5-Fu and Metformin have higher initial bursts than that 
of Diclofenac from PLA fibers and this is because of lower affinities between these two 
drugs (5-Fu and Metformin) and PLA fibers. It also can be seen in the figure that the 
dissolution method has the similar initial burst with the sorption method at the loading 
temperature of 90 and 110°C. 
It can be seen from Figures 3.1.7 to 3.1.9 that Diclofenac has slower drug release 
after burst than 5-Fu and Metformin, and this is because the higher activation energy for 
diffusion. The activiation energy for diffusion, which is the barrier for a drug to diffuse, 
influences the drug release rate. The higher the activiation energy for diffusion, the more 
energy the drug needs in order to overcome the barrier and diffuse out of the fibers. As 
seen in Table 3.1.1, the activiation energy for diffusion of Diclofenac on PLA fibers is 
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about 1.5 times that of 5-Fu and Metformin. Therefore, it is logical for Diclofenac to have 
a smaller initial burst and slower release after burst than 5-Fu and Metformin. 
3.1.4. Prediction of initial burst and drug release after burst  
It has been found that initial burst has a linear relationship with drug loading 
concentration and the interaction between affinity and drug loading concentration for 
three drugs used in this study. This linear regression gives equation (10) (R
2 
= 0.838): 
CACIB  3.1376.3806%    (10) 
where %IB is initial burst (drug release within the first hour), C is the drug 
loading concentration (mol · kg
-1
), and A is the affinity (kJ · mol
-1
) between drug and 
PLA fibers. A linear regression of drug release after burst versus the square root of time 
and the square root of interaction between RTEae
/ and time, has been developed. This 
linear regression gives equation (11) (R
2
 = 0.954): 
5.05.0/5.0 )(5.48.0% tetDR RTEa      (11) 
where %DR is drug release percentage minus initial burst, t is the release time 
(min), Ea is the activation energy for diffusion (J · mol
-1
), R is the ideal gas constant 
(8.314 J · K
-1
 · mol
-1
) and T is the release temperature (310.2 K). 
Comparisons between experimental data and theoretical data are shown in Figure 
3.1.10 (a) and (b). As seen in the figures, prediction of the drug release after initial bursts 
fit the experimental data better than that of the initial bursts as indicated by higher R
2
. It 
can be seen from Figure 3.1.10 (a) that the predictions of initial bursts of all three drugs 
at lower loading temperatures are lower than the experimental data, and this is probably 
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due to the fact that more drugs located on the surface or near the surface of PLA fibers 
after drug loading. Since drugs are readily formed aggregates at lower temperatures, more 
drugs in solution may interact with the drug on the surface of the fibers to form 
aggregates, thus leading to higher intial bursts than predictions. Increasing release time 
increases the difference between the predictions of drug release after initial burst and 
experimental data as seen in Figure 3.1.10 (b). This is probably due to the hydrolysis of 
the PLA during the release process. PLA fibers were hydrolyzed during the release 
process and led to more drugs released from the fibers, resulting the difference between 
the prediction and experimental data.    
 
(a) 
51 
 
 
(b) 
Figure 3.1.10. (a) Comparison between experimental and theoretical initial bursts (IB) 
from PLA drug loaded fibers using the sorption method. (b) Comparison between 
experimental and theoretical drug release after initial bursts (DR) from PLA drug loaded 
fibers using the sorption method. D1 to D5 represent drug release from PLA fibers with 
5.74, 5.57, 5.14, 5.46 and 11.01 mg/g Diclofenac loaded at 70, 80, 90, 110 and 110°C, 
respectively; F1 to F5 represent drug release of PLA fibers with 0.61, 0.67, 0.68, 0.63 and 
1.13 mg/g 5-Fu loaded at 70, 80, 90, 110 and 110°C; M1 to M5, drug release of PLA 
fibers with 0.81, 0.83, 0.86, 0.91 and 1.92 mg/g Metformin loaded at 70, 80, 90, 110 and 
110°C 
The high R
2
 values of equation (10) and (11) indicate that there are strong linear 
relationships between drug release and kinetic and thermodynamic parameters. These 
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equations can be used to predict initial burst and drug release after burst for drugs loaded 
on PLA fibers with the sorption method. 
3.1.5. Conclusions  
The relationship between drug release and kinetic and thermodynamic parameters 
of drug sorption onto PLA fibers has been discussed. It has been found that increasing 
loading temperature increases the diffusion coefficient of drugs and increases the drug 
sorption on PLA fibers within the temperatures studied. Loading drugs onto PLA fibers 
via the sorption method at higher temperatures results in low initial bursts and constant 
drug release. Decreasing drug loading concentration decreases the initial burst. It also has 
been found that Diclofenac has lower initial bursts and a more constant release rate from 
PLA fibers than 5-Fu and Metformin. A general linear relationship has been established 
using the initial burst and drug release after burst as dependant variables, and the drug 
loading concentration, affinity between drug and PLA fibers, square root of RTEae
/  and 
square root of time as independent variables. In addition, it has been found that the 
sorption method has a similar drug release profile with the dissolution method. Our study 
shows that high affinity, low drug loading concentration, and high activation energy for 
diffusion result in low initial burst and constant drug release.  
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3.2. Drug Release and Its Relationship with Kinetic and Thermodynamic 
Parameters of Drug Sorption onto SA Fibers 
3.2.1. Sorption rates and kinetic parameters of Diclofenac, 5-Fu and Metformin on 
SA fibers  
Sorption rates and kinetic parameters of Diclofenac, 5-Fu and Metformin on SA 
fibers at different temperatures are shown in Figures 3.2.1, 3.2.2 and 3.2.3 and Table 
3.2.1, respectively. As seen from the figures, increasing temperature increases drug 
sorption rate which is reflected in the initial slope of the sorption rate curves and this can 
be quantified by the diffusion coefficients as shown in Table 3.2.1. As seen from the 
table, diffusion coefficients increase with the increasing temperatures for all three 
different drugs. This is mainly because of four reasons. First, at a higher temperature, 
drugs move faster in both bulk solution and the boundary layer. Increasing movement of 
drugs leads to the faster sorption rate. Second, with increasing the temperature, the 
boundary layer on the SA fibers’ surface becomes thinner and then increases the rate for 
drugs to move onto the surface of fibers. Third, the size of holes on the SA fibers 
increases with increasing the temperature and then facilitates the drugs to move inside of 
the fibers. Since the loading temperatures used in this study are higher than the Tg (50-60 
°C) of SA with DS 2.3, increasing the drug loading temperature increases the movement 
of SA molecular chains and hence leads to the larger size of the holes on the fibers’ 
surface. Fourth, there are smaller aggregates of drugs at higher temperatures than those at 
lower temperatures, thus leading to fast movement of drugs into fibers.  
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Figure 3.2.1. Sorption rates of Diclofenac on SA fibers at 70, 80, and 90°C with initial 
Diclofenac concentration of 5 mg/ml in 0.5% aqueous sodium chloride solution. 
 
Figure 3.2.2. Sorption rates of 5-Fu on SA fibers at 70, 80, and 90°C with initial 5-Fu 
concentration of 5 mg/ml. 
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Figure 3.2.3. Sorption rates of Metformin on SA fibers at 70, 80, and 90°C with initial 
Metformin concentration of 5 mg/ml. 
Table 3.2.1. Kinetic parameters of drug sorption onto SA fibers at different temperatures. 
 
Diclofenac 5-Fu Metformin 
70°C 80°C 90°C 70°C 80°C 90°C 70°C 80°C 90°C 
Diffusion coefficient 
*10
12 
(m
2
 · min
-1
) 
0.576 
±0.001 
0.711 
±0.000 
0.805 
±0.000 
2.805 
±0.001 
2.953 
±0.003 
3.421 
±0.001 
1.712 
±0.008 
1.890 
±0.018 
2.136 
±0.000 
Ea (kJ · mol
-1
) 17.42±2.32 10.23±3.01 11.42±0.90 
As seen in Table 3.2.1, 5-Fu has the highest diffusion coefficients followed by 
Metformin and then Diclofenac. This is due to drug size and the affinity between drug 
and SA fibers. Metformin (with a diameter of 7.54 A) and 5-Fu (with a diameter of 5.42 
A) are smaller than Diclofenac (with a diameter of 10.01 A). The larger size of drug, the 
more difficult for it to move into the SA fibers. A drug with large size moves more 
slowly in the solution and is also more hindered when moving through the openings in 
the SA fibers than a drug of much smaller size. In addition, affinity between drug and SA 
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fibers influences the diffusion coefficients. Increasing affinity decreases the sorption rate 
because the sorbed drug molecule is tightly interacting with SA and thus blocks other 
drug molecules from moving inside of the SA fibers. As seen in Table 3.2.2, Diclofenac 
has the highest affinities, followed with Metformin and 5-Fu. The diffusion coefficients 
of Metformin are smaller than those of 5-Fu probably because Metformin has higher 
affinities than 5-Fu on SA fibers. 
Figures 3.2.1 to 3.2.3 show that increasing the drug loading temperature increases 
the drug exhaustion. This occurs probably because more accessible space is created at 
higher temperatures for drugs to be sorbed in SA fibers. The differences among 5-Fu 
loading amounts on SA fibers at the three temperatures studied are small compared with 
that of Diclofenac on SA fibers as seen in the figures. This is probably due to the 
combined effects of temperature on accessible space and sorption enthalpy. 
 Diclofenac has the largest activition energy for diffusion, followed by Metformin 
and 5-Fu as seen in Table 3.2.1. Higher activition energy for diffusion means that more 
energy is required to create an opening big enough for Diclofenac to move into the fibers. 
Since the size of Diclofenac is larger than the other two drugs, the opening in the SA 
fibers must be large enough in order to let Diclofenac move inside, and formation of this 
opening requires more energy. 
3.2.2. Isotherms and apparent thermodynamic parameters of Diclofenac, 5-Fu and 
Metformin sorption on SA fibers  
Isotherms of Diclofenac, 5-Fu and Metformin and thermodynamic parameters on 
SA fibers at different temperatures are shown in Figures 3.2.4, 3.2.5 and 3.2.6 and Table 
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3.2.2. As seen in the figures, increasing temperature increases drug sorption, and about 
12% of Diclofenac by weight of SA can be loaded on SA fibers using the sorption 
method at 90°C. This is probably because SA fibers create more accessible space for drug 
at higher temperatures (above the Tg). The differences in loading amount at the three 
temperatures studied for 5-Fu are smaller compared to that of Diclofenac and Metformin. 
This is most likely due to the combined effects of accessible space in the SA fiber and 
sorption enthalpy. High temperature increases accessible space in the SA fibers, which 
results in an increase in drug sorption. When sorption enthalpy is usually exothermic, it 
decreases drug sorption with increasing temperature. For 5-Fu on SA fibers, sorption 
enthalpy is probably more negtive than that of Diclofenac and Metformin. The opposite 
effects of accessible space and sorption enthalpy on drug sorption lead to small 
differences in 5-Fu sorption on SA fibers among three temperatures. 
 
Figure 3.2.4. Isotherms of Diclofenac on SA fibers in 0.5% aqueous sodium chloride 
solution, drug solution to fibers ratio 100: 1, and 120 minutes equilibration time at 70, 80, 
and 90°C. 
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Figure 3.2.5. Isotherms of 5-Fu on SA fibers at drug solution to fibers ratio 100: 1, and 90 
minutes equilibration time at 70, 80, and 90°C. 
 
Figure 3.2.6. Isotherms of Metformin on SA fibers at drug solution to fibers ratio 100: 1 
and 120 minutes equilibration time at 70, 80, and 90°C. 
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Table 3.2.2. Apparent thermodynamic parameters of drug sorption onto SA fibers at 
different temperatures. 
 
Diclofenac 5-Fu Metformin 
70°C 80°C 90°C 70°C 80°C 90°C 70°C 80°C 90°C 
-Δµ (kJ · mol-1) 
26.81 
±2.26 
29.95 
±1.57 
31.47 
±1.57 
6.35 
±0.21 
6.93 
±0.28 
7.48 
±0.58 
13.70 
±1.50 
15.36 
±1.78 
19.97 
±1.18 
ΔH (kJ · mol-1) 51.91±1.80 12.71±0.21 78.74±2.26 
ΔS(J · mol-1 · K-1) 
229.50 
±6.59 
231.90 
±4.45 
229.70 
±4.32 
55.57 
±0.61 
55.64 
±0.79 
55.62 
±1.60 
269.50 
±4.37 
266.57 
±5.04 
271.93 
±3.25 
 Isotherms of 5-Fu and Metformin on SA fibers at different temperatures are 
shown in Figures 3.2.5 and 3.2.6, respectively. As seen in Figure 3.2.5, the differences in 
loading amount at the three temperatures studied for 5-Fu are smaller compared to that of 
Diclofenac and Metformin. This is most likely due to the combined effects of accessible 
space in the SA fiber and sorption enthalpy. High temperature increases accessible space 
in the SA fibers, which results in an increase in drug sorption. When sorption enthalpy is 
usually exothermic, it decreases drug sorption with increasing temperature. For 5-Fu on 
SA fibers, sorption enthalpy is probably more negtive than that of Diclofenac and 
Metformin. The opposite effects of accessible space and sorption enthalpy on drug 
sorption lead to small differences in 5-Fu sorption on SA fibers among three temperatures. 
Metformin isotherms in Figure 3.2.6 are similar to those of Diclofenac on SA fibers and 
the reasons are also similar. However, a drawback for both 5-Fu and Metformin loading 
using the sorption method is that the drug loading amount is low, less than 1.2 % by 
weight of SA. This is due to either the small interaction with SA fibers or high water 
solubility.  
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 Apparent thermodynamic parameters of durg sorption on SA fibers are listed in 
Table 3.2.2. As seen from the table, Diclofenac has the highest sorption affinities 
followed by Metformin and 5-Fu on SA fibers. This is caused by the different 
interactions between drugs and SA fibers. As seen in Figure 2.1, Diclofenac has a big 
hydrophobic tail which can form strong Van der Waals forces and also has hydrophobic 
interactions with SA molecules. In addition, amine and carboxylic groups in Diclofenac 
can form hydrogen bonding with ester, ether, and hydroxyl groups in SA. These 
interactions give Diclofenac high affinities with SA fibers. Metformin has higher 
affinities than 5-Fu with SA fibers because it forms stronger hydrogen bonds and has 
greater flexibility. Additionally, the hydrogens on the primary amine in Metformin are 
relatively flexible and can facilitate the amine forming a hydrogen bond with oxygen in 
SA.  
 As seen in Table 3.2.2, Metformin and Diclofenac have higher apparent 
enthalpies than 5-Fu. This is most likely a result of the sorption enthalpy of 5-Fu on SA 
being more negtive than that of Metformin and Diclofenac. Metformin and Diclofenac 
also have higher drug sorption entropies than that of 5-Fu as seen in Table 3.2.2. This is 
because more water molecules are released from Metformin and Diclofenac during drug 
sorption onto the SA fibers. Both Metformin and Diclofenac carry charges which attract 
many water molecules around them. Once Metformin and Diclofenac are sorbed by SA 
fibers, the water molecules are released, which increases the entropy. 
3.2.3. Diclofenac, 5-Fu and Metformin release in vitro 
Diclofenac release from drug loaded SA fibers are shown in Figure 3.2.7. As seen 
in the figure, all four conditions have an initial burst from SA fibers. Increasing drug 
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loading temperature decreases this initial burst. This is because increasing temperature 
increases affinity between Diclofenac and SA, and more drugs become located in 
unreadily accessible spaces. The higher the affinity between Diclofenac and SA, the less 
readily drug releases from the fibers. In addition, once a drug is located in an unreadily 
accessible space in the SA fibers at high drug loading temperature, the drug will not 
readily move out at the release temperature. It also can be seen from Figure 3.2.7 that SA 
fibers with higher amounts of loaded drug have higher initial bursts than those of SA 
fibers with lower drug loading concentrations. This is probably due to stronger 
interactions between the drug and the fibers at lower drug loading concentrations. In the 
SA fibers, there are various sites the drug can occupy, and these sites have different 
affinities with drug. At lower drug loading concentration, drugs mainly occupy the sites 
with the strongest interaction with SA fibers, and lead to lower initial burst than high 
drug loading concentration. When the amount of drug loaded on the fiber is higher, more 
drugs occupy sites in the fiber where they form weaker interactions with SA fiber 
because most of the stronger interaction sites are occupied by other drugs. Drugs that 
form weaker interactions with SA fiber are released more quickly as indicated by the 
higher initial burst when a larger amount of drug is loaded on SA fibers. 
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Figure 3.2.7. Diclofenac release from SA fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm for Diclofenac loaded at 70, 80, and 90°C at 60 or 120 mg/g 
initial concentration in SA fibers. 
 
Figure 3.2.8. 5-Fu release from SA fibers in PBS (pH 7.4) at 37.2±0.1°C with shaking 
speed at 120 rpm for 5-Fu loaded at 70, 80, and 90°C at 5.5 or 11 mg/g initial 
concentration in SA fibers. 
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Figure 3.2.9. Metformin release from SA fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm for Metformin loaded at 70, 80, and 90°C at 1 or 4 mg/g initial 
concentration in SA fibers. 
 5-Fu and Metformin release from SA fibers, after having been loaded at different 
temperatures, are  shown in Figures 3.2.8 and 3.2.9. As seen in the figures, all drug 
release curves have an initial burst, and SA fibers with drug loaded at higher 
temperatures have slower drug release. When compared with Diclofenac, 5-Fu and 
Metformin loaded at 90°C, both have higher initial bursts and faster release after burst. 
This is probably because of lower affinities between these drugs (5-Fu and Metformin) 
and SA fibers, and lower activiation energy for diffusion than Diclofenac. Low affinity 
between drug and SA allows the drug to be easily released from the fibers. In addition, 
activiation energy for diffusion, which is the barrier for a drug to diffuse, also influences 
drug release rate. The higher the activiation energy for diffusion, the more energy the 
drug needs in order to overcome the barrier and diffuse out of the fibers. As seen in Table 
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3.2.1, the activiation energy for diffusion of Diclofenac on SA fibers is more than 1.5 
times that of 5-Fu and Metformin. Therefore, it is logical for Diclofenac to have a smaller 
initial burst and slower release after burst than 5-Fu and Metformin when loaded at 90°C. 
As seen in Figure 3.2.8, the differences in the release of 5-Fu from SA fibers are 
smaller compared to those of Diclofenac and Metformin. This difference is probably 
caused by low affinities between 5-Fu and SA fibers, small differences among the 
affinities at different loading temperatures, and the small activation energy for diffusion 
of 5-Fu. It can be seen in Table 3.2.2 that the affinities at different drug loading 
temperatures between 5-Fu and SA fibers are small and also the differences among them 
are small. Small affinities indicate the interaction between 5-Fu and SA fibers is weak 
and the drug can be readily released. The small differences among the affinities at 
different loading temperatures leads to small differences in drug release. It also can be 
seen from Table 3.2.1 that 5-Fu has the smallest activation energy for diffusion. This 
indicates that 5-Fu can easily diffuse out of the SA fibers. The release rate of Metformin 
from SA fibers is between those of Diclofenac and 5-Fu, as seen in Figures 3.2.7, 3.2.8 
and 3.2.9. This is because both the activation energy for diffusion and the affinity of 
Metformin are between those of Diclofenac and 5-Fu, as is seen in Table 3.2.1 and Table 
3.2.2.  
3.2.4. Prediction of initial burst and drug release after burst 
It has been found that initial burst has a linear relationship with drug loading 
concentration and the interaction between affinity and drug loading concentration for 
three drugs used in this study. This linear regression gives equation (12) (R
2 
= 0.710): 
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CACIB *77.1287.40222.27%                                  (12) 
where %IB is initial burst (drug release within the first hour), C is the drug 
loading concentration (mol · kg
-1
), and A is the affinity (kJ · mol
-1
) between drug and SA 
fibers. A linear regression of drug release after burst versus the square root of time and 
the square root of interaction between RTEae
/  and time, has been developed. This linear 
regression gives equation (13) (R
2
 = 0.788): 
5.05.0/5.0 )(6.73.18.2% tetDR
RTEa     (13) 
where %DR is drug release percentage minus initial burst, t is the release time 
(min), Ea is the activation energy for diffusion (J · mol
-1
), R is the ideal gas constant 
(8.314 J ·  K
-1
 · mol
-1
) and T is the release temperature (310.2 K). 
The high R
2
 values of equation (12) and (13) indicate that there are strong linear 
relationship between drug release and kinetic and thermodynamic parameters. These 
equations can be used to predict initial burst and drug release after burst for drugs loaded 
on SA fibers with the sorption method. 
3.2.5. Conclusions 
 The relationship between drug release and kinetic and thermodynamic parameters 
of drug sorption onto SA fibers has been discussed. Using the sorption method, up to 
12% of Diclofenac by weight of SA can be loaded onto fibers while only 1.2% and 
0.35% of 5-Fu and Metformin, respectively, can be loaded onto the fibers. Increasing 
loading temperature increases the diffusion coefficient of drugs and increases drug 
sorption on SA fibers within the temperatures studied. Diclofenac has a more constant 
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release rate from SA fibers than 5-Fu and Metformin. Loading drugs onto SA fibers via 
the sorption method at higher temperatures results in a more constant drug release rate. 
Decreasing drug loading concentration decreases the initial burst. A general linear 
relationship has been established using initial burst and drug release after burst as 
dependant variables, and drug loading concentration, affinity between drug and SA 
fibers, square root of e
(-Ea/RT)
 and square root of time as independent variables. Our study 
shows that high affinity, low drug loading concentration, and high activation energy for 
diffusion result in lower initial burst and more constant drug release.  
3.3. Drug Release and Its Relationship with Kinetic and Thermodynamic 
Parameters of Drug Sorption onto WG Fibers 
3.3. 1. Sorption rates and kinetic parameters of Diclofenac, 5-Fu and Metformin on 
WG fibers 
 Sorption rates and kinetic parameters of Diclofenac, 5-Fu and Metformin on WG 
fibers at different temperatures are shown in Figures 3.3.1, 3.3.2 and 3.3.3 and Table 
3.3.1, respectively. As seen from the figures, higher temperature leads to higher drug 
sorption rate reflected by the slope of the sorption rate curves. The sorption rate can be 
quantified as the diffusion coefficient in Table 3.3.1. Diffusion coefficients increase with 
increasing temperatures for all three different drugs because of three reasons. First, at a 
higher temperature, drugs moved faster in both bulk solution and the boundary layer 
leading to a faster sorption rate. Second, with increasing the temperature, the boundary 
layer on the surface of WG fibers became thinner resulting in an increasing rate for drugs 
to move onto the surface of fibers. Third, there were smaller aggregates of drugs at higher 
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temperatures than those at lower temperatures, which facilitated the drugs through the 
fiber surface, thus leading to the fast movement of drugs into fibers. 
 
Figure 3.3.1. Sorption rates of Diclofenac on WG fibers at 50, 70, and 90°C with initial 
Diclofenac concentration of 5 mg/ml at pH 3.0. 
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Figure 3.3.2. Sorption rates of 5-Fu on WG fibers at 50, 70, and 90°C with initial 5-Fu 
concentration of 5 mg/ml at pH 10.0. 
 
 
Figure 3.3.3. Sorption rates of Metformin on WG fibers at 50, 70, and 90°C with initial 
Metformin concentration of 5 mg/ml. 
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Table 3.3.1. Kinetic parameters of drug sorption onto WG fibers at different 
temperatures. 
 
Diclofenac 5-Fu Metformin 
70°C 80°C 90°C 70°C 80°C 90°C 70°C 80°C 90°C 
Diffusion coefficient 
*10
12 
(m
2
 
 
· min
-1
) 
0.786 
±0.031 
1.129 
±0.004 
1.485 
±0.054 
5.468 
±0.054 
6.851 
±0.038 
7.632 
±0.275 
2.021 
±0.054 
3.032 
±0.019 
4.000 
±0.004 
ΔE for diffusion 
(kJ
 
· mol
-1
) 
15.54±0.71 8.17±1.38 16.68±1.25 
 It also can be seen from Figures 3.3.1 to 3.3.3 and Table 3.3.1, drug sorption rates 
for both 5-Fu and Metformin are higher than that of Diclofenac on WG fibers probably 
because of the size of the drugs. Metformin (with a diameter of 7.54 A) and 5-Fu (with a 
diameter of 5.42 A) are smaller than Diclofenac (with a diameter of 10.01 A). Increasing 
the size of drugs increases the difficulty to go through the openings in the WG fibers, 
leading to the slower drug sorption rate at the same drug loading temperature. 
Figures 3.3.1 and 3.3.3 show that higher temperatures give higher drug 
equilibrium exhaustion for Diclofenac and Metformin. This is probably due to more 
accessible space created at higher temperatures for drugs to be sorbed in WG fibers. 
Higher temperature can break stronger interactions among WG molecular chains and 
hence leads to more sorption of Diclofenac and Metformin. As shown from Figure 3.3.2, 
higher drug loading temperature leads to lower drug exhaustion for 5-Fu. This is probably 
because the sorption of 5-Fu on WG fibers is exothermic within the temperatures studied. 
The space effect on 5-Fu sorption onto WG fibers is smaller than the effect of sorption 
enthalpy. Diclofenac has the largest activation energy for diffusion, followed by 5-Fu and 
Metformin as seen in Table 3.3.1. Higher activation energy for diffusion means that more 
energy is required to let drugs to move into the fibers. Since the size of Diclofenac is 
large compared to the other two drugs, the opening in WG fibers must be large enough in 
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order to let Diclofenac move inside, and the formation of this opening requires more 
energy. 
3.3.2. Isotherms and apparent thermodynamic parameters of Diclofenac, 5-Fu and 
Metformin sorption on WG fibers 
Isotherms of Diclofenac, 5-Fu and Metformin on WG fibers at different 
temperatures are shown in Figures 3.3.4, 3.3.5 and 3.3.6, respectively. As seen from 
Figures 3.3.4 and 3.3.6, higher temperature leads to higher drug sorption for Diclofenac 
and Metformin on WG fibers. This is probably because WG fibers create more accessible 
space at higher temperatures. Higher temperature can break stronger interactions among 
WG molecular chains leading to more sorption of Diclofenac and Metformin.  
 
Figure 3.3.4. Isotherms of Diclofenac on WG fibers at pH 3.0, drug solution to fibers 
ratio 100: 1, and 60 minutes equilibration time at 50, 70, and 90°C. 
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Figure 3.3.5. Isotherms of 5-Fu on WG fibers at pH 10.0 with drug solution to fibers ratio 
100: 1, and 60 minutes equilibration time at 50, 70 and 90°C. 
 
Figure 3.3.6. Isotherms of Metformin on WG fibers at drug solution to fibers ratio 100: 1 
and 60 minutes equilibration time at 50, 70, and 90°C. 
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Table 3.3.2. Apparent thermodynamic parameters of drug sorption onto WG fibers at 
different temperatures. 
 
Diclofenac 5-Fu Metformin 
50°C 70°C 90°C 50°C 70°C 90°C 50°C 70°C 90°C 
-Δµ (kJ · mol
-1
) 
37.87 
±1.83 
42.28 
±2.29 
46.18 
±4.45 
9.85 
±0.70 
10.69 
±0.86 
11.42 
±0.23 
20.83 
±1.51 
25.41 
±2.48 
29.20 
±1.85 
ΔH (kJ
 
· mol
-1
) 29.48±2.54 -2.86±0.50 46.86±3.94 
ΔS(J
 
· mol
-1 
· K
-1
) 
208.51 
±5.66 
209.21 
±6.68 
208.43 
±12.26 
21.64 
±2.17 
22.83 
±2.51 
23.58 
±0.63 
210.37 
±4.67 
211.46 
±7.23 
210.25 
±1.85 
 As seen in Figure 3.3.5, lower temperature gives higher 5-Fu exhausion on WG 
fibers. This is probably because the sorption of 5-Fu on WG fibers is exothermic, 
meaning that drug exhausion decreases with increasing temperature. Although higher 
temperature may create more space in WG fibers for 5-Fu, the space effect for 5-Fu is 
smaller compared to sorption enthalpy. A drawback for both 5-Fu and Metformin loading 
using sorption method is that the drug loading amount is low, less than 8 mg/g by weight 
of SP. This is due to the small interactions between the drugs and WG fibers.  
 Thermodynamic parameters of durg sorption on WG fibers are listed in Table 
3.3.2. As seen from the table, Diclofenac and Metformin have similar sorption affinities 
followed by 5-Fu on WG fibers. This is due to the different forces between drugs and 
WG fibers. As seen in Figure 2.1, Diclofenac and Metformin has a negative charge and a 
positive charge, which can form strong interactions with amine and carboxylic groups in 
WG via the ionic force at dyeing conditions, respectively. In addition, amine and 
carboxylic groups in Diclofenac can form hydrogen bonding with amine, hydroxyl and 
carbonyl groups in WG. These interactions give Diclofenac high affinities with WG 
fibers. Metformin has more atoms which can form hydrogen bonding with WG than 5-Fu. 
In addition, the hydrogens on primary amine in Metformin are less rigid than that in 5-Fu, 
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leading to easy formation of hydrogen bonding with oxygen elements in WG, resulting in 
higher affinities with WG fibers than 5-Fu.  
 As depicted in Table 3.3.2, Metformin and Diclofenac have positive sorption 
enthalpies, while 5-Fu has a negtive sorption enthalpy on WG fibers. This is because the 
sorption of Metformin and Diclofenac on WG fibers are endothermic while the sorption 
of 5-Fu on WG is exothermic within the temperatures studied. Metformin and Diclofenac 
have higher drug sorption entropies than that of 5-Fu as seen in Table 3.3.2. This is 
because more water molecules are released from Metformin, Diclofenac and WG during 
the drug sorption onto the WG fibers. Since Metformin and Diclofenac carried charges 
which attracted many water molecules around them, once Metformin and Diclofenac 
were sorbed by WG fibers, the water molecules were released, which increased the 
sorption entropy. Metformin can form more hydrogen bonding with WG than Diclofenac, 
leading to more water molecules released from the WG fibers, resulting in a higher 
entropy than Diclofenac. 
3.3.3. Diclofenac, 5-Fu and Metformin release in PBS 
Diclofenac, 5-Fu and Metformin release in PBS from drug loaded WG fibers are 
shown in Figures 3.3.7, 3.3.8 and 3.3.9, respectively. As seen in Figures 3.3.7 and 3.3.9, 
Diclofenac and Metformin have high initial bursts for all conditions studied. This is 
probably because the interactions between Diclofenac/Metformin and WG fibers are 
mainly ionic force and the drugs are exchanged out of the fibers by salts in PBS. It can be 
seen from the figure that increasing drug loading temperature decreases the initial burst. 
This is because increasing the temperature increases the affinity between Diclofenac and 
WG, and more drugs become located in sites with stronger interactions with WG. The 
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higher the affinity between Diclofenac and WG, the less readily drug releases from the 
fibers. It also can be seen from Figures 3.3.7 to 3.3.9 that WG fibers with higher amounts 
of loaded drug have higher initial bursts than those of WG fibers with lower drug loading 
concentrations. This is probably due to stronger interactions between the drug and the 
fibers at lower drug concentrations. In WG fibers, there are various sites the drug can 
occupy, and these sites have different affinities with the drug. At the lower drug loading 
concentration, drugs mainly occupy the sites with the strongest interaction with WG 
fibers, and lead to lower initial bursts than the high drug loading concentration. When the 
amount of drug loaded on the fibers is higher, more drugs occupy sites in the fibers where 
they form weaker interactions with WG fibers because most of the stronger interaction 
sites are occupied by other drugs. Drugs that form weaker interactions with WG fiber are 
released more quickly as indicated by the higher initial burst when a larger amount of 
drugs are loaded on WG fiber. In addition, it can be seen from the figure that Diclofenac 
release from WG fibers using the sorption method at 90°C has a lower initial burst and 
more constant release than that using the dissolution method because of the high affinity 
between the drug and WG fibers. 
  
75 
 
 
Figure 3.3.7. Diclofenac release from WG fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 
Figure 3.3.8. 5-Fu release from WG fibers in PBS (pH 7.4) at 37.2±0.1°C with shaking 
speed at 120 rpm. 
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Figure 3.3.9. Metformin release from WG fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 The initial bursts of 5-Fu from WG fibers are smaller compared to those of 
Diclofenac and Metformin. This is probably caused by the different forces between the 
drug and WG fibers. The force between 5-Fu and WG are mainly van der Waals force 
which has smaller effect on salt exchange compared with the ionic force, and thus leading 
to lower 5-Fu initial bursts.  
3.3.4. Diclofenac, 5-Fu and Metformin release in AGJ 
Diclofenac, 5-Fu and Metformin release from drug loaded WG fibers in AGJ are 
shown in Figures 3.3.10, 3.3.11 and 3.3.12, respectively. As seen from Figure 3.3.10, the 
dissolution method has a similar initial burst with 50°C but higher than 90°C of the 
sorption method. This is probably due to the lower affinity between drugs and WG fibers 
for the dissolution method. Since the drugs could not completely dissolve in the spinning 
solution, the drugs were physically entrapped in the solidified WG fibers after the fiber 
fabrication, resulting in lower affinity between the drugs and fibers. Within the sorption 
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method, increasing temperature decreases the initial burst of Diclofenac and Metformin 
as seen in Figures 3.3.10 and 3.3.12, while increasing temperature decreases the initial 
burst of 5-Fu as observed in Figure 3.3.11. This is because the affinity between drugs and 
WG fibers increases with the increasing loading temperature for Diclofenac and 
Metformin, and decreases with the increasing loading temperature for 5-Fu as shown in 
Table 3.3.2. The higher affinity leads to the less readily drug releases from the fibers. It 
also can be seen from Figures 3.3.10, 3.3.11 and 3.3.12 that WG fibers with higher drug 
loading concentration have higher initial bursts than that with lower drug loading 
concentration. This is because of the high percentage of sites with the higher affinity 
occupied at the lower drug concentration, which is same to the drug release in PBS. 
Compared with the Diclofenac release from WG fibers in PBS, Diclofenac release in 
AGJ were much slower and more constant. This is because Diclofenac, which carries a 
negative charge, is attracted by the protonized WG fibers in AGJ. The strong interaction 
between Diclofenac and protonized WG fibers leads to the low initial burst and constant 
drug release.  
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Figure 3.3.10. Diclofenac release from WG fibers in AGJ (pH 1.2) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 
Figure 3.3.11. 5-Fu release from WG fibers in AGJ (pH 1.2) at 37.2±0.1°C with shaking 
speed at 120 rpm. 
79 
 
 
Figure 3.3.12. Metformin release from WG fibers in AGJ (pH 1.2) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
  As seen in Figures 3.3.10, 3.3.11 and 3.3.12, 5-Fu has the highest initial bursts in 
AGJ, followed by Metformin and Diclofenac. This is due to the low affinity of 5-Fu on 
WG fibers as seen in Table 3.3.2. The weak interactions between 5-Fu and fibers leads to 
the high initial burst.  
3.3.5. Prediction of initial burst and drug release after burst 
It has been found that initial bursts in PBS have linear relationship with the drug 
loading concentration and the interaction between the affinity and the drug loading 
concentration for three drugs used in this study. Also the initial burst in AGJ has linear 
relationship with the drug loading concentration, the interaction between the affinity and 
the drug loading concentration and 5.0
/
)(
RTEae

. These linear regressions give equation 
(14) (R
2 
= 0.632) and equation (15) (R
2 
= 0.617): 
CACIB  1.1064.54171.21% 1     (14) 
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5.0/
2 )(2.1376.222.11196.4%
RTEaeCACIB
   (15) 
where %IB1 is the initial burst in PBS, %IB2 is the initial burst in AGJ, C is the 
drug loading concentration (mol kg
-1
), A is the affinity (kJ mol
-1
) between the drug and 
WG fibers, Ea is the activation energy for diffusion (J mol
-1
), R is the ideal gas constant 
(8.314 J K
-1
 mol
-1
) and T is the release temperature (310.2 K).  
A linear regression of the drug release after burst in PBS versus the square root of 
time and the square root of interaction between RTEae
/  and time, and a linear regression 
of drug release after burst in AGJ versus the affinity, the square root of time and the 
square root of interaction between RTEae
/  and time, have been developed. These linear 
regressions give equation (16) (R
2
 = 0.721) and equation (17) ( R
2
 = 0.815): 
5.05.0/5.0
1 )(7.129.07.5% tetDR
RTEa      (16) 
5.05.0/5.0
2 )(5103.0% tetADR
RTEa      (17) 
where %DR1 is the drug release percentage minus the initial burst in PBS, %DR2 
is the drug release percentage minus the initial burst in AGJ, t is the release time (hour), 
Ea is the activation energy for diffusion (J mol
-1
), R is the ideal gas constant (8.314 J K
-1
 
mol
-1
), A is the affinity (kJ mol
-1
) between the drug and WG fibers and T is the release 
temperature (310.2 K). 
The high R
2
 values of four equations indicate that there are strong relationship 
between drug release and kinetic and thermodynamic parameters. These equations can be 
used to predict initial burst and drug release after bursts for drugs loaded on WG fibers 
with the sorption method. 
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3.3.6. Conclusions 
The relationship between drug release and kinetic and thermodynamic parameters 
of drug sorption onto WG fibers has been discussed. Increasing loading temperature 
increases the diffusion coefficient of drugs and increases Diclofenac and Metformin 
sorption on WG fibers within the temperatures studied. Nevertheless, increasing loading 
temperature decreases 5-Fu sorption on WG fibers within the temperatures studied. 
Diclofenac has less constant release rates from WG fibers in PBS than those in AGJ. 
Diclofenac has more constant drug release from WG fibers than those of 5-Fu and 
Metformin in AGJ. Loading drugs onto WG fibers by sorption at higher temperature 
results in a more constant drug release rate. Decreasing drug loading concentration 
decreases the initial burst.  
The study also showed that Diclofenac loaded on WG fibers using the sorption 
method at a high temperature has the lower initial burst and more constant subsequent 
drug release than that using the dissolution method. General linear relationships have 
been established on the initial burst and drug release after burst, respectively, as 
dependant variables, and drug loading concentration, affinity between drug and WG 
fibers, square root of RTEae
/  and square root of time as independent variables. Our study 
shows that high affinity (specially with van der Waals force), low drug loading 
concentration, and high activation energy for diffusion result in lower initial burst and 
more constant drug release. 
82 
 
3.4. Drug Release and Its Relationship with Kinetic and Thermodynamic 
Parameters of Drug Sorption onto SP Fibers 
3.4.1. Sorption rates and kinetic parameters of Diclofenac, 5-Fu and Metformin on 
SP fibers 
Sorption rates and kinetic parameters of Diclofenac, 5-Fu and Metformin on SP 
fibers at different loading temperatures are shown in Figures 3.4.1, 3.4.2 and 3.4.3 and 
Table 3.4.1, respectively. As seen from the figures, higher temperature leads to higher 
drug sorption rate reflected by the slope of the sorption rate curves. The sorption rate can 
be quantified as the diffusion coefficient in Table 3.4.1. Diffusion coefficients increase 
with increasing temperatures for all three different drugs because of three reasons. First, 
at a higher temperature, drugs moved faster in both bulk solution and the boundary layer 
leading to a faster sorption rate. Second, with increasing the temperature, the boundary 
layer on the surface of SP fibers became thinner resulting in an increasing rate for drugs 
to move onto the surface of fibers. Third, there were smaller aggregates of drugs at higher 
temperatures than those at lower temperatures, which facilitated the drugs through the 
fiber surface, thus leading to the fast movement of drugs into fibers.  
83 
 
 
Figure 3.4.1. Sorption rates of Diclofenac on SP fibers at 50, 70, and 90°C with initial 
Diclofenac concentration of 5 mg/ml at pH 3.0. 
 
 
Figure 3.4.2. Sorption rates of 5-Fu on SP fibers at 50, 70, and 90°C with initial 5-Fu 
concentration of 5 mg/ml. 
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Figure 3.4.3. Sorption rates of Metformin on SP fibers at 50, 70, and 90°C with initial 
Metformin concentration of 5 mg/ml at pH 6.3. 
Table 3.4.1. Kinetic parameters of drug sorption onto SP fibers at different temperatures. 
 
Diclofenac 5-Fu Metformin 
70°C 80°C 90°C 70°C 80°C 90°C 70°C 80°C 90°C 
Diffusion 
coefficient *10
12
 
(m
2
 · min
-1
) 
1.688 
±0.008 
2.596 
±0.004 
4.044 
±0.009 
2.534 
±0.000 
3.207 
±0.005 
4.460 
±0.006 
2.713 
±0.009 
4.022 
±0.003 
5.186 
±0.012 
Ea (kJ · mol
-1
) 21.26±0.89 13.93±1.79 15.84±1.43 
It also can be seen from Figures 3.4.1 to 3.4.3 and Table 3.4.1, drug sorption rates 
for both 5-Fu and Metformin are higher than that of Diclofenac on SP fibers probably 
because of the size of the drugs. Metformin (with a diameter of 7.54 A) and 5-Fu (with a 
diameter of 5.42 A) are smaller than Diclofenac (with a diameter of 10.01 A). Increasing 
the size of drugs increases the difficulty to go through the openings in the SP fibers, 
leading to the slower drug sorption rate at the same drug loading temperature. Compared 
with Diclofenac sorption onto polylactic acid (PLA) and starch acetate (SA) fibers, rates 
of Diclofenac sorption onto SP and WG fibers are faster because of the larger opening on 
the fiber surface and stronger forces between the drug and fibers. SP and WG are more 
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hydrophilic than PLA and SA. Increasing hydrophilicity increases the swell of SP and 
WG leading to the larger opening and wider channels in the fibers, resulting in faster drug 
sorption rates. Furthermore, the strong forces between Diclofenac and SP/WG increase 
the movement of the drug onto fibers, although the drugs tightly interacted with protein 
fibers take some spaces of the channels, the remaining spaces are wide enough for 
Diclofenac to go through. 
Figures 3.4.1 and 3.4.3 show that higher temperatures give higher drug 
equilibrium exhaustion for Diclofenac and Metformin. This is probably due to more 
accessible space created at higher temperatures for drugs to be sorbed in SP fibers. 
Higher temperature can break stronger interactions among SP molecular chains and 
hence leads to more sorption of Diclofenac and Metformin. As shown from Figure 3.4.2, 
higher drug loading temperature leads to lower drug exhaustion for 5-Fu. This is probably 
because the sorption of 5-Fu on SP fibers is exothermic within the temperatures studied. 
The space effect on 5-Fu sorption onto SP fibers is smaller than the effect of sorption 
enthalpy.  
Diclofenac has the largest activition energy for diffusion, followed by 5-Fu and 
Metformin as seen in Table 3.4.1. Higher activition energy for diffusion means that more 
energy is required to let drugs to move into the fibers. Since the size of Diclofenac is 
large compared to the other two drugs, the opening in SP fibers must be large enough in 
order to let Diclofenac move inside, and the formation of this opening requires more 
energy. 
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3.4.2. Isotherms and thermodynamic parameters of Diclofenac, 5-Fu and Metformin 
sorption on SP fibers 
Isotherms of Diclofenac, 5-Fu and Metformin on SP fibers at different 
temperatures are shown in Figures 3.4.4, 3.4.5 and 3.4.6, respectively. As seen from 
Figures 3.4.4 and 3.4.6, higher temperature leads to higher drug sorption for Diclofenac 
and Metformin on SP fibers. This is probably because SP fibers create more accessible 
space at higher temperatures. Higher temperature can break stronger interactions among 
SP molecular chains leading to more sorption of Diclofenac and Metformin.  
 
 
Figure 3.4.4. Isotherms of Diclofenac on SP fibers at pH 3.0, drug solution to fibers ratio 
100: 1, and 60 minutes equilibration time at 50, 70, and 90°C. 
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Figure 3.4.5. Isotherms of 5-Fu on SP fibers at drug solution to fibers ratio 100: 1, and 60 
minutes equilibration time at 50, 70 and 90°C. 
 
Figure 3.4.6. Isotherms of Metformin on SP fibers at drug solution to fibers ratio 100: 1 
and 60 minutes equilibration time at 50, 70, and 90°C. 
 As seen in Figure 3.4.5, lower temperature gives higher 5-Fu exhausion on SP 
fibers. This is probably because the sorption of 5-Fu on SP fibers is exothermic, meaning 
that drug exhausion decreases with increasing temperature. Although higher temperature 
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may create more space in SP fibers for 5-Fu, the space effect for 5-Fu is smaller 
compared to sorption enthalpy. A drawback for both 5-Fu and Metformin loading using 
sorption method is that the drug loading amount is low, less than 8 mg/g by weight of SP. 
This is due to the small interactions between the drugs and SP fibers.  
 Thermodynamic parameters of durg sorption on SP fibers are listed in Table 3.4.2. 
As seen from the table, Diclofenac and Metformin have similar sorption affinities 
followed by 5-Fu on SP fibers. This is due to the different forces between drugs and SP 
fibers. As seen in Figure 2.1, Diclofenac and Metformin has a negative charge and a 
positive charge, which can form strong interactions with amine and carboxylic groups in 
SP via the ionic force at dyeing conditions, respectively. In addition, amine and 
carboxylic groups in Diclofenac can form hydrogen bonding with amine, hydroxyl and 
carbonyl groups in SP. These interactions give Diclofenac high affinities with SP fibers. 
Metformin has more atoms which can form hydrogen bonding with SP than 5-Fu. In 
addition, the hydrogens on primary amine in Metformin are less rigid than that in 5-Fu, 
leading to easy formation of hydrogen bonding with oxygen elements in SP, resulting in 
higher affinities with SP fibers than 5-Fu.  
Table 3.4.2. Thermodynamic parameters of drug sorption onto SP fibers at different 
temperatures. 
 
Diclofenac 5-Fu Metformin 
50°C 70°C 90°C 50°C 70°C 90°C 50°C 70°C 90°C 
-Δµ (kJ · mol
-1
) 
25.17 
±0.92 
27.53 
±0.90 
29.60 
±2.12 
12.02 
±0.66 
12.34 
±0.86 
12.66 
±0.41 
24.48 
±0.79 
27.21 
±0.84 
30.73 
±1.05 
ΔH (kJ · mol
-1
) 10.62±1.46 -8.23±0.82 25.88±3.95 
ΔS (J · mol
-1
 · K
-1
) 
110.80 
±2.85 
111.22 
±2.62 
111.80 
±5.84 
11.74 
±1.61 
11.99 
±2.80 
12.21 
±3.50 
155.91 
±2.44 
154.78 
±2.45 
155.95 
±2.89 
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 As depicted in Table 3.4.2, Metformin and Diclofenac have positive sorption 
enthalpies, while 5-Fu has a negtive sorption enthalpy on SP fibers. This is because the 
sorption of Metformin and Diclofenac on SP fibers are endothermic while the sorption of 
5-Fu on SP is exothermic within the temperatures studied. Metformin and Diclofenac 
have higher drug sorption entropies than that of 5-Fu as seen in Table 3.4.2. This is 
because more water molecules are released from Metformin, Diclofenac and SP during 
the drug sorption onto the SP fibers. Since Metformin and Diclofenac carried charges 
which attracted many water molecules around them, once Metformin and Diclofenac 
were sorbed by SP fibers, the water molecules were released, which increased the 
sorption entropy. Metformin can form more hydrogen bonding with SP than Diclofenac, 
leading to more water molecules released from the SP fibers, resulting in a higher entropy 
than Diclofenac. 
3.4.3. Diclofenac, 5-Fu and Metformin release in PBS 
Diclofenac, 5-Fu and Metformin release in PBS from drug loaded SP fibers are 
shown in Figures 3.4.7, 3.4.8 and 3.4.9, respectively. As seen in the figures, Diclofenac 
and Metformin have high initial bursts for all the conditions. This is probably because the 
interactions between drugs and SP fibers are mainly ionic force and SP are readily swell 
in PBS. Ionic force can be readily broken by the salt exchange in PBS, while the swell of 
SP increases the drug release rates. The initial bursts of 5-Fu are lower than those of 
Diclofenac and Metformin due to the van der Waals forces between the 5-Fu and SP 
fibers. The van der Waals forces have a few effects on the salt exchange compared with 
the ionic force, leading to lower initial bursts. It also can be seen from the figures that 
increasing the drug loading temperature for Diclofenac and Metformin and decreasing the 
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drug loading temperature for 5-Fu decreases the initial bursts. This is most likely because 
increasing the temperature for Diclofenac and Metformin and decreasing the temperature 
for 5-Fu increases the affinities between drugs and SP as seen in Table 3.4.2, leading to 
more drugs located in sites with stronger interactions with SP. The figures also show that 
SP fibers with higher amounts of loaded drug have higher initial bursts than those of SP 
fibers with lower drug loading amounts. This is probably due to stronger interactions 
between the drug and the fibers at lower drug concentrations. In SP fibers, there are 
various sites the drug can occupy, and these sites have different affinities with the drug. 
At the lower drug loading concentration, drugs mainly occupy the sites with the strongest 
interaction with SP fibers, leading to lower initial bursts than the high drug loading 
concentration. When the amount of drug loaded on the fibers is higher, more drugs 
occupy sites in the fibers where they form weaker interactions with SP fibers because 
most of the stronger interaction sites are occupied by other drugs. Drugs that form weaker 
interactions with SP fibers are released more quickly as indicated by the higher initial 
burst when a larger amount of drugs are loaded on SP fibers. In addition, it has been 
found from Figure 3.4.7 that Diclofenac release from SP fibers using the sorption method 
at 90°C has a lower initial burst and more constant release than that using the dissolution 
method because of the higher affinity between the drug and SP fibers. 
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Figure 3.4.7. Diclofenac release from SP fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 
 
Figure 3.4.8. 5-Fu release from SP fibers in PBS (pH 7.4) at 37.2±0.1°C with shaking 
speed at 120 rpm. 
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Figure 3.4.9. Metformin release from SP fibers in PBS (pH 7.4) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 Compared with drug release rates in PBS from the drug loaded PLA, SA and WG 
fibers using the sorption and the dissolution drug loading methods, SP has higher initial 
bursts and less constant subsequent release than PLA and SA, and silimar release profiles 
with WG. This is most likely because of the swell of the fibers, and the swell can be 
reflected by the moisture regains. The moisture regain of PLA is 0.48% which is lower 
than 4.5% of SA, 10.8% of WG and 12.0% of SP at 21°C and 65%RH. PLA has the 
lowest intial burst and most constant drug release, followed by SA, WG and SP. 
Increasing the swell of the fibers increases the openings and channels in the fibers, 
resulting in a quick drug release rate.   
3.4.4. Diclofenac, 5-Fu and Metformin release in AGJ 
Diclofenac, 5-Fu and Metformin release from drug loaded SP fibers in AGJ are 
shown in Figures 3.4.10, 3.4.11 and 3.4.12, respectively. As seen from Figure 3.4.10, the 
dissolution method has a similar initial burst with 50°C but higher than 90°C of the 
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sorption method. This is probably due to the lower affinity between drugs and SP fibers 
for the dissolution method. Since the drugs could not completely dissolve in the spinning 
solution, the drugs were physically entrapped in the solidified SP fibers after the fiber 
fabrication, resulting in lower affinity between the drugs and fibers. Within the sorption 
method, increasing temperature decreases the initial burst of Diclofenac and Metformin 
as seen in Figures 3.4.10 and 3.4.12, while increasing temperature decreases the initial 
burst of 5-Fu as observed in Figure 3.4.11. This is because the affinity between drugs and 
SP fibers increases with the increasing loading temperature for Diclofenac and 
Metformin, and decreases with the increasing loading temperature for 5-Fu as shown in 
Table 3.4.2. The higher affinity leads to the less readily drug releases from the fibers. It 
also can be seen from Figures 3.4.10, 3.4.11 and 3.4.12 that SP fibers with higher drug 
loading concentration have higher initial bursts than that with lower drug loading 
concentration. This is because of the high percentage of sites with the higher affinity 
occupied at the lower drug concentration, which is same to the drug release in PBS. 
Compared with the Diclofenac release from SP fibers in PBS, Diclofenac release in AGJ 
were much slower and more constant. This is because Diclofenac, which carries a 
negative charge, is attracted by the protonized SP fibers in AGJ. The strong interaction 
between Diclofenac and protonized SP fibers leads to the low initial burst and constant 
drug release.  
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Figure 3.4.10. Diclofenac release from SP fibers in AGJ (pH 1.2) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 
Figure 3.4.11. 5-Fu release from SP fibers in AGJ (pH 1.2) at 37.2±0.1°C with shaking 
speed at 120 rpm. 
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Figure 3.4.12. Metformin release from SP fibers in AGJ (pH 1.2) at 37.2±0.1°C with 
shaking speed at 120 rpm. 
 As seen in Figures 3.4.10, 3.4.11 and 3.4.12, 5-Fu has the highest initial bursts in 
AGJ, followed by Metformin and Diclofenac. This is due to the low affinity of 5-Fu on 
SP fibers as seen in Table 3.4.2. The weak interactions between 5-Fu and fibers leads to 
the high initial burst.  
3.4.5. Prediction of initial burst and drug release after burst 
It has been found that initial bursts in PBS and in AGJ have linear relationship 
with the drug loading concentration, the interaction between the affinity and the drug 
loading concentration and 5.0
/
)(
RTEae

for three drugs used in this study. These linear 
regressions give equation (18) (R
2 
= 0.920) and equation (19) (R
2 
= 0.941): 
5.0/
1 )(5.10801.30978%
RTEaeCACIB
   (18) 
5.0/
2 )(8813.45.93%
RTEaeCACIB
    (19) 
where %IB1 is the initial burst in PBS, %IB2 is the initial burst in AGJ, C is the 
drug loading concentration (mol · kg
-1
), A is the affinity (kJ · mol
-1
) between the drug and 
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SP fibers, Ea is the activation energy for diffusion (J · mol
-1
), R is the ideal gas constant 
(8.314 J · K
-1
 · mol
-1
) and T is the release temperature (310.2 K).  
A linear regression of the drug release after burst in PBS against the affinity, 
squar root of time and square root of RTEae
/ , and a linear regression of drug release after 
burst in AGJ against the affinity, squar root of time and square root of interaction 
between RTEae
/  and time, have been developed. These linear regressions give equation 
(20) (R
2
 = 0.701) and equation (21) (R
2
 = 0.948): 
5.0/5.0
1 )(8.43739.0%
RTEaetADR
    (20) 
5.05.0/5.0
2 )(6.2337.15.0% tetADR
RTEa     (21) 
where %DR1 is the drug release percentage minus the initial burst in PBS, %DR2 
is the drug release percentage minus the initial burst in AGJ, t is the release time (hour), 
Ea is the activation energy for diffusion (J · mol
-1
), R is the ideal gas constant (8.314 J · K
-
1
 · mol
-1
), A is the affinity (kJ · mol
-1
) between the drug and SP fibers and T is the release 
temperature (310.2 K). 
The high R
2
 values of four equations indicate that there are strong relationship 
between drug release and kinetic and thermodynamic parameters. These equations can be 
used to predict initial burst and drug release after bursts for drugs loaded on SP fibers 
with the sorption method. 
3.4.6. Conclusions 
The quantitative relationship between drug release and kinetic and 
thermodynamic parameters of drug sorption onto SP fibers has been discussed. Increasing 
loading temperature increases the diffusion coefficient of drugs and increases Diclofenac 
and Metformin sorption on SP fibers within the temperatures studied. While increasing 
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loading temperature decreases 5-Fu sorption on SP fibers within the temperatures studied. 
It also has been found that Diclofenac has less constant release rates from SP fibers in 
PBS than those in AGJ. Diclofenac has more constant drug release from SP fibers than 
those of 5-Fu and Metformin in AGJ. Decreasing drug loading concentration decreases 
initial burst from drug loaded fibers.  
The study also showed that Diclofenac loaded on SP fibers using the sorption 
method at a high temperature has the lower initial burst and more constant subsequent 
drug release than that using the dissolution method. General linear relationships have 
been established on the initial burst and subsequent drug release as dependant variables, 
and the drug loading concentration, affinity between drug and SP fibers, square root of 
RTEae
/  and square root of time as independent variables, respectively. Our study shows 
that high affinity (specially with van der Waals forces), low moisture regain and low drug 
loading concentration result in lower initial burst and more constant drug release. 
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IMPLICATION 
 This study has established the quantitative relationship between drug release and 
kinetic and thermodynamic parameters of drug sorption onto PLA, SA, WG and SP 
fibers. The drug release rates from the drug loaded fibers with the sorption loading 
method can be predicted using the equations developed in this research. Furthermore, the 
selection of drugs on particular fibers to achieve more constant drug release has been 
analyzed. Additionally, with the physical parameters calculated, the sorption rates and 
drug sorption amount onto the fibers can be predicted within the temperature range 
studied. 
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OVERALL CONCLUSIONS 
The quantitative relationships between drug release and kinetic and 
thermodynamic parameters of drug sorption onto PLA, SA, WG and SP fibers have been 
discussed using Diclofenac, 5-Fu and Metformin as model drugs. The study showed that 
increasing loading temperature increased the diffusion coefficient of drugs. Diffusion 
coefficients of drug onto PLA fibers were the smallest, followed by SA, WG and SP. It 
has also been found that increasing loading temperature increases Diclofenac and 
Metformin sorption amount onto WG and SP fibers and increases sorption amount of all 
three drugs onto PLA and SA fibers within the temperatures studied. Nevertheless, 
increasing loading temperature decreases 5-Fu sorption on WG and SP fibers within the 
temperatures studied.  
Drug release from drug loaded PLA fibers in PBS had the lowest initial bursts and 
the most constant release, followed by SA, WG and SP fibers. Diclofenac and Metformin 
release from WG and SP fibers in PBS had higher initial burst and quick subsequent 
release. It also has been found that Diclofenac has more constant drug release from 
WG/SP fibers than those of 5-Fu and Metformin in AGJ. In addition, it has been found 
that decreasing drug loading concentration decreased initial bursts.  
The study showed that Diclofenac loaded on PLA, SA, WG and SP fibers using 
the sorption method at a high temperature has the lower initial burst and more constant 
subsequent drug release than that using the dissolution method. General linear 
relationships have been established on the initial burst and subsequent drug release as 
dependant variables, and the drug loading concentration, affinity between drug and fibers, 
square root of 
RTEae
/
 and square root of time as independent variables, respectively. Our 
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study shows that high affinity (specially with van der Waals forces), low swelling of 
polymers, low drug loading concentration and high activation energy for diffusion result 
in lower initial burst and more constant drug release. 
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RECOMMENDATIONS FOR FUTURE RESEARCH 
First, the drug loading amount on PLA fibers is low because of the low affinities 
between PLA and the drugs used in the study. The drugs with relatively high affinity on 
PLA fibers should have larger structure and be more planar than Diclofenac. Therefore, 
select a drug which has a chemical structure met qualifications mentioned above is 
recommended for the future work. Second, the drug release in PBS from plant proteins 
without crosslinking was fast due to the ionic force and the swell of the fibers. 
Crosslinking of plant proteins decreases the swell of the fibers and then improves the 
drug release profiles. Last, since the mechanical properties of the biofibers used in this 
study may be changed during the drug loading method, it is necessary to study the 
mechanical properties of the fibers after high temperature drug loading. The following 
specific recommendations are proposed for future research work regarding the utilization 
of plant proteins in biofibers in medical field: 
 Select a drug which has high affinity with PLA fibers 
 Select a medically compatible crosslinker   
 Optimize the conditions for crosslinking plant proteins  
 Examine the drug release profiles from the drug loaded plant protein fibers 
 Study the mechanical properties of biofibers after high temperature drug loading  
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APPENDIX 
APPENDIX – A 
Data for effect of temperatures on sorption rates of Diclofenac, 5-Fu and Metformin on 
PLA fibers (DCF=Drug concentration on fibers, R=Repetition, D=Diclofenac, 
M=Metformin, DLT=Drug loading temperature) 
Drug DLT (°C) Time (min) DCF R1(mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
D 70 240 3.34 3.53 3.44 
D 70 180 3.69 3.29 3.49 
D 70 150 3.00 3.10 3.05 
D 70 120 2.72 2.96 2.84 
D 70 90 2.85 2.54 2.70 
D 70 60 2.49 2.31 2.40 
D 70 30 1.97 1.79 1.88 
D 70 15 1.71 1.43 1.57 
D 70 10 1.16 1.41 1.28 
D 70 5 1.01 1.00 1.00 
D 70 3 1.01 0.89 0.75 
D 70 1 0.61 0.79 0.60 
D 80 240 4.82 5.03 4.93 
D 80 180 4.88 4.71 4.80 
D 80 150 4.18 4.35 4.27 
D 80 120 3.73 4.20 3.97 
D 80 90 3.79 4.33 4.06 
D 80 60 3.80 3.75 3.78 
D 80 30 3.16 2.94 3.05 
D 80 15 2.32 2.16 2.24 
D 80 10 1.65 1.50 1.58 
D 80 5 1.08 1.11 1.10 
D 80 3 0.86 0.90 0.88 
D 80 1 0.69 0.54 0.61 
D 90 180 5.52 5.26 5.39 
D 90 150 5.60 4.77 5.18 
D 90 120 4.78 4.85 4.82 
D 90 90 4.23 4.61 4.42 
D 90 60 4.19 4.34 4.16 
D 90 30 4.19 3.69 3.64 
D 90 15 3.43 3.07 3.05 
D 90 10 2.63 2.45 2.50 
D 90 5 1.73 1.46 1.60 
D 90 3 1.09 0.94 0.91 
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Drug T (°C) Time (min) DCF R1(mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
D 90 1 0.72 0.59 0.68 
D 110 180 10.33 10.97 10.60 
D 110 150 6.89 7.42 7.15 
D 110 120 6.55 6.99 6.77 
D 110 90 6.32 6.94 6.63 
D 110 60 6.46 6.17 6.32 
D 110 30 4.59 5.45 5.02 
D 110 15 2.97 3.30 3.13 
D 110 10 2.11 2.01 2.06 
D 110 5 1.34 1.15 1.24 
D 110 3 0.72 0.96 0.84 
D 110 1 0.72 0.67 0.69 
5-Fu 70 150 0.49 0.57 0.53 
5-Fu 70 120 0.55 0.47 0.51 
5-Fu 70 90 0.50 0.49 0.49 
5-Fu 70 60 0.43 0.48 0.46 
5-Fu 70 30 0.41 0.36 0.38 
5-Fu 70 15 0.22 0.30 0.26 
5-Fu 70 10 0.18 0.22 0.20 
5-Fu 70 5 0.11 0.15 0.13 
5-Fu 70 3 0.09 0.12 0.11 
5-Fu 70 1 0.08 0.10 0.09 
5-Fu 80 150 0.54 0.56 0.55 
5-Fu 80 120 0.45 0.58 0.52 
5-Fu 80 90 0.55 0.50 0.52 
5-Fu 80 60 0.46 0.48 0.47 
5-Fu 80 30 0.39 0.40 0.40 
5-Fu 80 15 0.33 0.31 0.32 
5-Fu 80 10 0.29 0.23 0.26 
5-Fu 80 5 0.27 0.14 0.21 
5-Fu 80 1 0.14 0.10 0.12 
5-Fu 90 150 0.57 0.53 0.57 
5-Fu 90 120 0.56 0.54 0.55 
5-Fu 90 90 0.58 0.55 0.56 
5-Fu 90 60 0.55 0.51 0.53 
5-Fu 90 30 0.51 0.47 0.49 
5-Fu 90 15 0.51 0.45 0.38 
5-Fu 90 10 0.44 0.49 0.30 
5-Fu 90 3 0.37 0.48 0.15 
5-Fu 90 1 0.12 0.10 0.12 
5-Fu 110 150 0.75 0.85 0.80 
5-Fu 110 120 0.81 0.81 0.81 
5-Fu 110 90 0.81 0.70 0.75 
5-Fu 110 60 0.71 0.60 0.66 
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Drug T (°C) Time (min) DCF R1(mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
5-Fu 110 30 0.54 0.50 0.52 
5-Fu 110 15 0.33 0.44 0.39 
5-Fu 110 10 0.29 0.35 0.32 
5-Fu 110 5 0.25 0.29 0.27 
5-Fu 110 3 0.23 0.23 0.23 
5-Fu 110 1 0.15 0.12 0.14 
M 70 180 0.42 0.45 0.43 
M 70 150 0.40 0.38 0.39 
M 70 120 0.40 0.44 0.42 
M 70 90 0.35 0.40 0.38 
M 70 60 0.43 0.35 0.39 
M 70 30 0.43 0.36 0.40 
M 70 10 0.27 0.38 0.33 
M 70 5 0.21 0.32 0.26 
M 70 3 0.19 0.22 0.20 
M 70 1 0.14 0.12 0.13 
M 80 180 0.42 0.55 0.49 
M 80 150 0.42 0.50 0.46 
M 80 120 0.42 0.51 0.46 
M 80 90 0.43 0.44 0.44 
M 80 60 0.38 0.45 0.41 
M 80 30 0.39 0.41 0.40 
M 80 10 0.24 0.35 0.30 
M 80 5 0.25 0.37 0.31 
M 80 3 0.28 0.27 0.27 
M 80 1 0.21 0.09 0.15 
M 90 180 0.43 0.52 0.47 
M 90 150 0.36 0.47 0.42 
M 90 120 0.45 0.46 0.45 
M 90 90 0.38 0.46 0.42 
M 90 60 0.43 0.39 0.41 
M 90 30 0.43 0.41 0.42 
M 90 10 0.33 0.41 0.37 
M 90 5 0.36 0.36 0.36 
M 90 3 0.25 0.14 0.19 
M 90 1 0.18 0.25 0.22 
M 110 180 1.02 1.17 1.10 
M 110 150 0.90 0.93 0.91 
M 110 120 0.80 0.95 0.87 
M 110 90 0.89 1.00 0.95 
M 110 60 0.87 0.93 0.90 
M 110 30 1.02 0.89 0.95 
M 110 10 0.86 0.81 0.84 
M 110 5 0.60 0.42 0.51 
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Drug T (°C) Time (min) DCF R1(mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
M 110 3 0.52 0.37 0.44 
M 110 1 0.40 0.33 0.37 
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APPENDIX – B 
Data for isotherms of Diclofenac, 5-Fu and Metformin on PLA fibers (DCF=Drug 
concentration on fibers, DCS=Drug concentration in solution, R=Repetition, 
D=Diclofenac, M=Metformin, DLT=Drug loading temperature) 
Drug 
DLT 
(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
D 70 1.17 1.17 1.16 0.10 0.13 0.12 
D 70 1.38 1.36 1.36 0.13 0.14 0.13 
D 70 3.50 3.44 3.44 0.15 0.21 0.18 
D 70 4.88 4.89 4.83 0.24 0.26 0.25 
D 70 5.67 5.76 5.65 0.37 0.33 0.35 
D 70 7.43 7.34 7.31 0.47 0.44 0.45 
D 70 9.42 9.30 9.27 0.50 0.40 0.45 
D 70 10.09 9.74 9.82 0.62 0.47 0.54 
D 70 12.57 12.65 12.48 0.67 0.67 0.66 
D 70 15.26 15.32 15.14 1.29 0.92 1.09 
D 80 1.13 1.11 1.11 0.12 0.14 0.13 
D 80 1.33 1.28 1.29 0.17 0.22 0.19 
D 80 3.42 3.38 3.37 0.37 0.40 0.38 
D 80 4.93 4.89 4.86 0.33 0.44 0.38 
D 80 5.75 5.65 5.64 0.44 0.42 0.43 
D 80 7.42 7.32 7.30 0.49 0.62 0.55 
D 80 9.50 9.16 9.23 0.52 0.63 0.57 
D 80 9.90 9.72 9.71 0.57 0.65 0.60 
D 80 12.59 12.54 12.44 0.64 0.76 0.69 
D 80 15.32 15.35 15.18 0.70 0.73 0.71 
D 90 1.00 0.97 1.01 1.56 1.51 1.57 
D 90 2.90 2.81 2.93 3.92 3.80 3.96 
D 90 3.40 3.30 3.44 4.19 4.06 4.23 
D 90 5.52 5.35 5.57 5.48 5.31 5.53 
D 90 6.07 5.89 6.13 5.99 5.81 6.05 
D 90 6.78 6.57 6.84 6.19 6.00 6.25 
D 90 7.83 7.59 7.90 6.98 6.77 7.05 
D 90 9.48 9.19 9.57 7.60 7.37 7.67 
D 110 0.61 0.64 0.62 1.34 1.10 1.21 
D 110 1.09 1.10 1.08 1.96 2.15 2.04 
D 110 2.70 2.71 2.68 4.21 3.21 3.67 
D 110 5.39 5.32 5.30 5.55 6.89 6.16 
D 110 8.06 8.03 7.96 8.23 6.55 7.32 
D 110 10.73 10.72 10.62 9.19 8.37 8.69 
D 110 15.91 15.97 15.78 11.24 9.23 10.14 
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Drug 110 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
D 70 20.81 21.01 20.70 12.01 10.77 11.27 
5-Fu 70 0.14 0.13 0.14 0.02 0.02 0.02 
5-Fu 70 0.40 0.39 0.41 0.09 0.09 0.09 
5-Fu 70 0.70 0.68 0.71 0.07 0.06 0.07 
5-Fu 70 1.46 1.41 1.47 0.11 0.10 0.11 
5-Fu 70 2.22 2.15 2.24 0.27 0.26 0.28 
5-Fu 70 3.69 3.58 3.73 0.29 0.28 0.30 
5-Fu 80 8.73 8.47 8.81 0.70 0.67 0.72 
5-Fu 80 0.14 0.13 0.13 0.02 0.05 0.03 
5-Fu 80 0.20 0.20 0.19 0.21 0.01 0.11 
5-Fu 80 0.40 0.40 0.39 0.04 0.05 0.05 
5-Fu 80 0.35 0.35 0.35 0.06 0.07 0.07 
5-Fu 80 0.70 0.70 0.69 0.13 0.08 0.11 
5-Fu 80 1.47 1.46 1.45 0.32 0.13 0.22 
5-Fu 80 2.25 2.25 2.22 0.21 0.18 0.19 
5-Fu 80 3.63 3.74 3.65 0.37 0.28 0.32 
5-Fu 80 6.61 6.65 6.56 0.84 0.50 0.67 
5-Fu 90 8.77 8.76 8.68 0.89 0.70 0.79 
5-Fu 90 0.14 0.15 0.14 0.04 0.04 0.04 
5-Fu 90 0.40 0.40 0.39 0.07 0.08 0.08 
5-Fu 90 1.49 1.46 1.46 0.21 0.22 0.23 
5-Fu 90 2.23 2.25 2.21 0.31 0.32 0.34 
5-Fu 90 3.68 3.72 3.66 0.42 0.44 0.46 
5-Fu 90 6.67 6.54 6.54 0.64 0.66 0.70 
5-Fu 110 8.78 8.79 8.70 0.75 0.77 0.82 
5-Fu 110 0.48 0.49 0.48 0.02 0.04 0.03 
5-Fu 110 0.85 0.82 0.83 0.12 0.08 0.10 
5-Fu 110 2.43 2.43 2.41 0.37 0.21 0.29 
5-Fu 110 4.94 4.95 4.89 0.83 0.71 0.77 
5-Fu 110 7.90 8.22 7.98 1.12 0.95 1.02 
5-Fu 110 10.20 10.09 10.05 1.14 1.12 1.12 
5-Fu 110 12.43 12.29 12.24 1.37 1.66 1.50 
5-Fu 70 14.34 13.91 13.99 1.49 1.78 1.62 
M 70 0.10 0.12 0.11 0.02 0.05 0.03 
M 70 0.48 0.48 0.48 0.02 0.06 0.04 
M 70 1.02 1.03 1.01 0.06 0.07 0.06 
M 70 2.62 2.61 2.59 0.14 0.22 0.18 
M 70 4.87 4.91 4.84 0.28 0.35 0.31 
M 70 7.47 7.63 7.47 0.40 0.49 0.44 
M 70 10.11 10.15 10.03 0.55 0.57 0.56 
M 80 13.67 13.71 13.55 0.93 0.90 0.91 
M 80 0.11 0.11 0.11 0.07 0.01 0.04 
M 80 0.47 0.48 0.47 0.04 0.05 0.05 
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Drug 80 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
M 80 1.00 1.01 1.00 0.09 0.12 0.11 
M 80 2.62 2.64 2.61 0.19 0.31 0.24 
M 80 4.90 4.92 4.86 0.37 0.36 0.36 
M 80 7.55 7.56 7.48 0.56 0.68 0.61 
M 90 10.25 10.16 10.10 0.67 0.84 0.75 
M 90 12.10 12.09 11.98 0.98 1.32 1.14 
M 90 0.11 0.10 0.10 0.03 0.03 0.03 
M 90 0.48 0.48 0.48 0.08 0.06 0.07 
M 90 1.03 1.02 1.02 0.11 0.09 0.10 
M 90 2.65 2.65 2.63 0.24 0.25 0.24 
M 90 4.93 4.94 4.89 0.49 0.43 0.45 
M 90 7.64 7.68 7.58 0.66 0.57 0.61 
M 90 10.24 10.09 10.07 0.88 0.82 0.84 
M 110 12.15 12.28 12.10 0.86 1.02 0.93 
M 110 13.84 13.93 13.75 1.00 1.11 1.05 
M 110 0.60 0.79 0.69 0.08 0.14 0.11 
M 110 1.44 1.08 1.25 0.13 0.31 0.22 
M 110 2.57 2.60 2.56 0.27 0.56 0.41 
M 110 4.89 5.09 4.94 1.10 0.90 0.99 
M 110 7.54 7.46 7.42 1.41 1.11 1.25 
M 110 10.00 10.18 9.99 1.26 1.80 1.51 
M 70 14.08 14.31 14.05 1.72 2.18 1.93 
M 70 17.17 17.93 17.38 2.37 2.70 2.51 
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APPENDIX – C 
Data for Diclofenac, 5-Fu and Metformin release from PLA fibers in PBS and 
comparison between experimental initial bursts (EIB), subsequent drug release (EDR) 
and theoretical initial bursts (TIB), subsequent drug release (TDR) from PLA drug loaded 
fibers using the sorption method, repectively. (DLT=Drug loading temperature, 
DRP=Drug release percentage, R=Repetition, D=Diclofenac, M=Metformin, EDR=DRP-
EIB) 
Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
D 70 1 25.9% 31.5% 30.9% 28.4% 15.7% 
D 70 2 28.5% 32.6% 32.0% 1.1% 1.6% 
D 70 4 29.1% 31.7% 31.0% 2.1% 2.3% 
D 70 7 29.6% 36.0% 35.2% 3.4% 3.0% 
D 70 12 29.9% 33.0% 32.4% 2.6% 3.8% 
D 70 23 31.9% 33.2% 32.6% 3.4% 5.4% 
D 70 47 33.8% 37.0% 36.3% 7.7% 7.8% 
D 70 71 37.7% 39.1% 38.3% 10.5% 9.5% 
D 70 95 39.8% 46.7% 45.8% 13.9% 11.0% 
D 70 119 42.0% 43.8% 42.9% 14.3% 12.3% 
D 70 143 42.3% 44.0% 43.1% 14.6% 13.5% 
D 70 167 46.1% 45.9% 45.0% 17.2% 14.6% 
D 70 191 46.4% 46.0% 45.1% 18.0% 15.6% 
D 70 215 44.7% 47.7% 46.8% 17.8% 16.6% 
D 70 239 48.1% 45.7% 44.8% 18.5% 17.5% 
D 70 263 49.9% 49.0% 48.0% 21.0% 18.4% 
D 70 287 51.7% 50.6% 49.5% 22.7% 19.2% 
D 70 311 51.7% 48.4% 47.4% 21.6% 20.0% 
D 70 335 53.3% 49.6% 48.6% 23.0% 20.7% 
D 70 359 53.0% 50.8% 49.8% 23.5% 21.4% 
D 70 383 54.5% 53.9% 52.8% 25.8% 22.1% 
D 70 407 54.1% 59.0% 57.8% 28.1% 22.8% 
D 70 431 55.3% 55.2% 54.1% 26.8% 23.5% 
D 70 455 56.6% 58.3% 57.1% 29.0% 24.1% 
D 70 479 57.8% 61.5% 60.3% 31.2% 24.8% 
D 70 503 60.9% 59.4% 58.2% 31.7% 25.4% 
D 70 527 58.7% 60.6% 59.4% 31.2% 26.0% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
D 70 551 63.4% 63.6% 62.4% 35.1% 26.6% 
D 70 575 63.0% 65.0% 63.7% 35.6% 27.1% 
D 70 599 64.3% 66.4% 65.1% 36.9% 27.7% 
D 70 623 65.5% 66.0% 64.6% 37.3% 28.2% 
D 70 647 66.8% 67.2% 65.8% 38.6% 28.8% 
D 70 671 66.2% 66.5% 65.2% 37.9% 29.3% 
D 70 695 69.1% 69.4% 68.0% 40.9% 29.8% 
D 70 719 68.5% 68.8% 67.4% 40.2% 30.3% 
D 70 743 69.6% 69.8% 68.4% 41.3% 30.8% 
D 80 1 12.0% 17.2% 13.8% 14.3% 10.1% 
D 80 2 16.7% 13.7% 13.4% 0.6% 2.3% 
D 80 4 16.5% 11.4% 14.6% 2.1% 3.0% 
D 80 7 14.4% 17.4% 17.5% 0.5% 3.8% 
D 80 12 13.8% 11.9% 18.8% 0.9% 5.4% 
D 80 23 12.9% 12.6% 20.1% 4.6% 7.8% 
D 80 47 18.7% 16.7% 21.5% 5.2% 9.5% 
D 80 71 18.2% 17.7% 22.8% 8.7% 11.0% 
D 80 95 21.0% 22.1% 25.9% 8.3% 12.3% 
D 80 119 20.5% 21.8% 25.7% 8.3% 13.5% 
D 80 143 21.5% 21.2% 25.3% 12.8% 14.6% 
D 80 167 26.0% 25.7% 29.9% 12.0% 15.6% 
D 80 191 23.9% 23.6% 31.4% 12.6% 16.6% 
D 80 215 24.9% 24.6% 31.2% 15.4% 17.5% 
D 80 239 27.7% 25.6% 36.0% 17.8% 18.4% 
D 80 263 30.6% 28.3% 37.7% 18.7% 19.2% 
D 80 287 30.2% 29.5% 39.4% 18.3% 20.0% 
D 80 311 26.3% 34.1% 37.6% 20.1% 20.7% 
D 80 335 27.0% 37.3% 38.9% 21.9% 21.4% 
D 80 359 31.1% 37.3% 40.3% 20.9% 22.1% 
D 80 383 30.4% 35.3% 39.9% 21.9% 22.8% 
D 80 407 29.5% 36.5% 42.8% 23.6% 23.5% 
D 80 431 31.9% 37.7% 44.1% 27.0% 24.1% 
D 80 455 36.2% 42.3% 45.5% 27.2% 24.8% 
D 80 479 35.7% 42.1% 46.8% 28.4% 25.4% 
D 80 503 36.8% 43.4% 48.2% 28.0% 26.0% 
D 80 527 37.8% 41.3% 47.8% 29.6% 26.6% 
D 80 551 38.8% 44.0% 49.0% 31.9% 27.1% 
D 80 575 41.6% 45.2% 51.9% 32.0% 27.7% 
D 80 599 42.8% 44.7% 51.5% 34.8% 28.2% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
D 80 623 44.0% 49.1% 54.4% 33.8% 28.8% 
D 80 647 43.5% 47.0% 54.0% 34.9% 29.3% 
D 80 671 44.5% 48.0% 55.2% 37.7% 29.8% 
D 80 695 47.2% 52.5% 56.3% 38.9% 30.3% 
D 80 719 48.4% 53.8% 57.5% 39.6% 30.8% 
D 90 1 5.4% 3.6% 7.1% 5.4% 7.8% 
D 90 2 5.9% 7.5% 7.8% 0.0% 1.1% 
D 90 4 4.7% 4.6% 6.7% 0.1% 2.3% 
D 90 7 6.8% 8.5% 7.2% 2.2% 3.0% 
D 90 12 7.3% 5.7% 7.7% 1.6% 3.8% 
D 90 23 6.1% 7.8% 10.0% 2.6% 5.4% 
D 90 47 10.0% 11.9% 10.7% 5.5% 7.8% 
D 90 71 10.7% 14.6% 13.1% 7.5% 9.5% 
D 90 95 11.5% 12.1% 14.0% 7.2% 11.0% 
D 90 119 14.0% 16.4% 16.6% 10.3% 12.3% 
D 90 143 13.1% 17.4% 15.8% 10.1% 13.5% 
D 90 167 17.4% 18.5% 18.5% 12.8% 14.6% 
D 90 191 22.0% 21.4% 21.3% 16.2% 15.6% 
D 90 215 19.9% 19.0% 22.4% 15.1% 16.6% 
D 90 239 22.7% 23.5% 25.4% 18.5% 17.5% 
D 90 263 24.0% 23.0% 26.7% 19.2% 18.4% 
D 90 287 27.0% 25.8% 28.1% 21.6% 19.2% 
D 90 311 24.9% 25.3% 29.4% 21.2% 20.0% 
D 90 335 29.5% 26.3% 29.0% 22.9% 20.7% 
D 90 359 31.0% 27.4% 28.4% 23.6% 21.4% 
D 90 383 30.6% 28.5% 27.6% 23.5% 22.1% 
D 90 407 31.8% 29.5% 28.5% 24.6% 22.8% 
D 90 431 33.1% 30.6% 31.1% 26.2% 23.5% 
D 90 455 36.1% 33.5% 33.9% 29.1% 24.1% 
D 90 479 37.6% 34.7% 35.1% 30.4% 24.8% 
D 90 503 39.0% 34.2% 34.4% 30.5% 25.4% 
D 90 527 40.4% 33.5% 37.2% 31.7% 26.0% 
D 90 551 41.9% 36.1% 38.4% 33.4% 26.6% 
D 90 575 43.3% 37.2% 39.6% 34.7% 27.1% 
D 90 599 42.9% 36.5% 40.8% 34.7% 27.7% 
D 90 623 44.2% 40.9% 42.0% 37.0% 28.2% 
D 90 647 45.4% 40.4% 41.3% 37.0% 28.8% 
D 90 671 46.7% 39.7% 42.4% 37.5% 29.3% 
D 90 695 46.1% 40.6% 43.4% 38.0% 29.8% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
D 90 719 49.0% 41.5% 44.4% 39.6% 30.3% 
D 90 743 50.2% 42.3% 45.4% 40.6% 30.8% 
D 110 1 6.1% 7.1% 6.8% 5.6% 3.7% 
D 110 2 6.7% 7.8% 7.4% 0.3% 2.3% 
D 110 4 7.3% 9.5% 8.6% 0.1% 3.0% 
D 110 7 6.9% 8.3% 7.7% 1.1% 3.8% 
D 110 12 9.4% 9.9% 9.9% 1.6% 5.4% 
D 110 23 10.1% 10.6% 10.6% 5.2% 7.8% 
D 110 47 11.8% 13.3% 12.8% 4.9% 9.5% 
D 110 71 12.6% 14.2% 13.7% 5.6% 11.0% 
D 110 95 13.4% 14.1% 14.0% 4.3% 12.3% 
D 110 119 13.2% 12.8% 13.3% 5.8% 13.5% 
D 110 143 13.9% 14.5% 14.4% 7.4% 14.6% 
D 110 167 15.6% 16.2% 16.2% 6.1% 15.6% 
D 110 191 15.3% 17.0% 16.5% 5.5% 16.6% 
D 110 215 15.0% 15.7% 15.7% 5.9% 17.5% 
D 110 239 16.6% 17.3% 17.3% 8.3% 18.4% 
D 110 263 17.3% 17.0% 17.5% 5.9% 19.2% 
D 110 287 19.0% 17.6% 18.7% 8.2% 20.0% 
D 110 311 19.8% 18.2% 19.4% 6.7% 20.7% 
D 110 335 18.6% 18.8% 19.0% 8.0% 21.4% 
D 110 359 18.1% 18.3% 18.6% 9.4% 22.1% 
D 110 383 19.7% 18.8% 19.6% 10.9% 22.8% 
D 110 407 20.3% 21.4% 21.2% 12.5% 23.5% 
D 110 431 23.9% 21.0% 22.9% 10.1% 24.1% 
D 110 455 20.7% 24.7% 23.2% 9.5% 24.8% 
D 110 479 22.2% 21.5% 22.3% 10.8% 25.4% 
D 110 503 22.8% 23.0% 23.4% 11.2% 26.0% 
D 110 527 23.4% 26.7% 25.5% 12.6% 26.6% 
D 110 551 24.0% 22.5% 23.7% 12.1% 27.1% 
D 110 575 24.6% 23.9% 24.7% 14.5% 27.7% 
5-Fu 70 1 29.9% 14.9% 14.9% 19.9% 12.7% 
5-Fu 70 2 26.6% 23.8% 23.8% 0.8% 3.3% 
5-Fu 70 4 28.0% 11.0% 18.4% 1.5% 4.4% 
5-Fu 70 7 30.1% 11.7% 19.8% 4.5% 5.6% 
5-Fu 70 12 32.2% 19.8% 21.3% 6.2% 7.9% 
5-Fu 70 23 34.3% 21.3% 22.7% 7.8% 11.3% 
5-Fu 70 47 36.4% 22.7% 24.1% 11.9% 13.9% 
5-Fu 70 71 38.6% 31.5% 25.5% 13.8% 16.1% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
5-Fu 70 95 40.7% 33.6% 26.9% 15.7% 18.0% 
5-Fu 70 119 42.8% 35.7% 28.3% 20.1% 19.8% 
5-Fu 70 143 44.9% 37.8% 37.1% 19.7% 21.3% 
5-Fu 70 167 47.0% 32.5% 39.3% 24.0% 22.8% 
5-Fu 70 191 49.1% 41.4% 41.4% 26.1% 24.2% 
5-Fu 70 215 51.2% 43.5% 43.5% 27.9% 25.5% 
5-Fu 70 239 49.1% 45.6% 48.8% 29.9% 26.8% 
5-Fu 70 263 50.6% 47.7% 51.1% 31.9% 28.0% 
5-Fu 70 287 52.1% 49.8% 53.4% 33.8% 29.1% 
5-Fu 70 311 53.6% 51.9% 55.6% 34.5% 30.2% 
5-Fu 70 335 55.1% 54.0% 54.0% 33.7% 31.3% 
5-Fu 70 359 56.6% 52.1% 52.1% 34.1% 32.3% 
5-Fu 70 383 58.2% 50.1% 53.6% 34.2% 33.3% 
5-Fu 70 407 55.7% 55.1% 51.5% 34.4% 34.3% 
5-Fu 70 431 57.1% 52.9% 52.9% 38.3% 35.2% 
5-Fu 70 455 58.5% 54.3% 61.7% 39.9% 36.2% 
5-Fu 70 479 59.9% 55.7% 63.8% 39.1% 37.0% 
5-Fu 70 503 61.3% 57.1% 58.5% 40.5% 37.9% 
5-Fu 70 527 62.7% 58.5% 59.9% 41.9% 38.8% 
5-Fu 70 551 64.1% 59.9% 61.3% 43.3% 39.6% 
5-Fu 70 575 65.5% 61.3% 62.7% 44.7% 40.4% 
5-Fu 70 599 66.9% 62.7% 64.1% 46.1% 41.2% 
5-Fu 70 623 68.3% 64.1% 65.5% 46.3% 42.0% 
5-Fu 70 647 69.7% 61.8% 66.9% 47.5% 42.8% 
5-Fu 70 671 71.1% 62.8% 68.3% 47.6% 43.6% 
5-Fu 70 695 72.5% 60.2% 69.7% 48.8% 44.3% 
5-Fu 70 719 74.0% 60.9% 71.1% 48.7% 45.0% 
5-Fu 80 1 19.6% 19.6% 19.6% 19.6% 12.3% 
5-Fu 80 2 28.0% 21.4% 18.1% 2.6% 3.3% 
5-Fu 80 4 17.4% 10.2% 8.4% 2.9% 4.4% 
5-Fu 80 7 25.1% 10.8% 14.6% 3.2% 5.6% 
5-Fu 80 12 20.4% 24.5% 15.7% 4.2% 7.9% 
5-Fu 80 23 28.2% 26.4% 16.7% 3.6% 11.3% 
5-Fu 80 47 23.5% 28.2% 17.8% 7.1% 13.9% 
5-Fu 80 71 31.3% 30.0% 18.9% 6.6% 16.1% 
5-Fu 80 95 26.6% 31.9% 20.0% 7.9% 18.0% 
5-Fu 80 119 34.3% 27.2% 21.0% 13.4% 19.8% 
5-Fu 80 143 36.2% 35.0% 27.8% 13.0% 21.3% 
5-Fu 80 167 31.5% 36.8% 29.4% 14.5% 22.8% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
5-Fu 80 191 32.7% 38.6% 31.0% 18.3% 24.2% 
5-Fu 80 215 40.5% 40.5% 32.6% 20.0% 25.5% 
5-Fu 80 239 42.3% 42.3% 34.2% 21.8% 26.8% 
5-Fu 80 263 44.2% 44.2% 35.8% 23.6% 28.0% 
5-Fu 80 287 46.0% 46.0% 37.4% 25.3% 29.1% 
5-Fu 80 311 47.9% 47.9% 39.0% 27.1% 30.2% 
5-Fu 80 335 49.7% 49.7% 40.6% 31.0% 31.3% 
5-Fu 80 359 58.1% 51.6% 42.3% 29.8% 32.3% 
5-Fu 80 383 50.8% 53.4% 43.9% 31.4% 33.3% 
5-Fu 80 407 52.3% 55.2% 45.5% 33.1% 34.3% 
5-Fu 80 431 53.8% 57.1% 47.1% 34.7% 35.2% 
5-Fu 80 455 55.4% 58.9% 48.7% 34.2% 36.2% 
5-Fu 80 479 56.9% 54.3% 50.3% 35.7% 37.0% 
5-Fu 80 503 58.4% 55.5% 51.9% 37.1% 37.9% 
5-Fu 80 527 60.0% 56.7% 53.5% 38.6% 38.8% 
5-Fu 80 551 61.5% 57.9% 55.1% 40.1% 39.6% 
5-Fu 80 575 63.1% 59.2% 56.7% 39.6% 40.4% 
5-Fu 80 599 64.6% 60.4% 52.6% 40.9% 41.2% 
5-Fu 80 623 66.1% 61.6% 53.7% 42.2% 42.0% 
5-Fu 80 647 67.7% 62.9% 54.8% 43.5% 42.8% 
5-Fu 80 671 69.2% 64.1% 55.9% 43.7% 43.6% 
5-Fu 80 695 70.7% 62.1% 56.9% 44.8% 44.3% 
5-Fu 80 719 72.3% 63.0% 58.0% 46.0% 45.0% 
5-Fu 90 1 14.2% 10.7% 14.2% 13.0% 11.9% 
5-Fu 90 2 15.5% 11.7% 19.1% 1.0% 3.3% 
5-Fu 90 4 13.3% 9.1% 13.7% 1.1% 4.4% 
5-Fu 90 7 14.3% 13.3% 14.7% 2.1% 5.6% 
5-Fu 90 12 15.3% 14.3% 15.7% 4.3% 7.9% 
5-Fu 90 23 19.9% 15.3% 16.7% 7.8% 11.3% 
5-Fu 90 47 24.8% 16.3% 21.2% 9.1% 13.9% 
5-Fu 90 71 26.4% 17.3% 22.6% 10.4% 16.1% 
5-Fu 90 95 28.1% 18.3% 23.9% 11.8% 18.0% 
5-Fu 90 119 29.8% 19.3% 25.2% 13.1% 19.8% 
5-Fu 90 143 31.5% 20.3% 26.6% 14.4% 21.3% 
5-Fu 90 167 33.1% 21.3% 27.9% 17.0% 22.8% 
5-Fu 90 191 34.8% 25.9% 29.2% 18.4% 24.2% 
5-Fu 90 215 36.5% 27.2% 30.6% 19.9% 25.5% 
5-Fu 90 239 38.1% 28.6% 31.9% 21.3% 26.8% 
5-Fu 90 263 39.8% 29.9% 33.3% 23.9% 28.0% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
5-Fu 90 287 41.5% 31.2% 38.1% 24.3% 29.1% 
5-Fu 90 311 36.1% 36.1% 39.8% 25.8% 30.2% 
5-Fu 90 335 37.1% 37.8% 41.5% 27.2% 31.3% 
5-Fu 90 359 38.1% 39.5% 43.2% 29.8% 32.3% 
5-Fu 90 383 39.1% 41.2% 48.4% 27.9% 33.3% 
5-Fu 90 407 40.1% 35.7% 46.8% 29.1% 34.3% 
5-Fu 90 431 41.1% 36.7% 48.5% 30.3% 35.2% 
5-Fu 90 455 42.1% 37.7% 50.2% 31.5% 36.2% 
5-Fu 90 479 43.1% 38.7% 51.8% 32.8% 37.0% 
5-Fu 90 503 44.1% 39.7% 53.5% 34.0% 37.9% 
5-Fu 90 527 45.1% 40.7% 55.2% 34.0% 38.8% 
5-Fu 90 551 46.1% 41.7% 53.3% 35.1% 39.6% 
5-Fu 90 575 47.1% 42.7% 54.6% 36.3% 40.4% 
5-Fu 90 599 48.1% 43.7% 56.0% 37.4% 41.2% 
5-Fu 90 623 49.1% 44.7% 57.3% 38.5% 42.0% 
5-Fu 90 647 50.1% 45.8% 58.7% 38.4% 42.8% 
5-Fu 90 671 51.1% 46.8% 56.4% 39.4% 43.6% 
5-Fu 90 695 52.1% 47.8% 57.5% 40.4% 44.3% 
5-Fu 90 719 53.1% 48.8% 58.5% 42.0% 45.0% 
5-Fu 110 1 13.7% 5.8% 10.2% 12.1% 11.6% 
5-Fu 110 2 15.0% 6.4% 11.2% 3.2% 3.3% 
5-Fu 110 4 23.2% 6.9% 15.8% 4.3% 4.4% 
5-Fu 110 7 18.3% 7.5% 13.6% 5.0% 5.6% 
5-Fu 110 12 19.7% 13.9% 17.6% 5.3% 7.9% 
5-Fu 110 23 21.0% 9.2% 15.8% 8.0% 11.3% 
5-Fu 110 47 25.7% 9.8% 18.6% 10.3% 13.9% 
5-Fu 110 71 24.0% 16.1% 21.1% 11.5% 16.1% 
5-Fu 110 95 25.3% 17.3% 22.3% 12.7% 18.0% 
5-Fu 110 119 26.6% 18.4% 23.6% 15.4% 19.8% 
5-Fu 110 143 27.9% 22.4% 26.4% 15.3% 21.3% 
5-Fu 110 167 29.3% 20.9% 26.3% 16.6% 22.8% 
5-Fu 110 191 30.6% 22.1% 27.6% 18.3% 24.2% 
5-Fu 110 215 38.8% 17.4% 29.5% 18.6% 25.5% 
5-Fu 110 239 27.1% 29.6% 29.7% 19.7% 26.8% 
5-Fu 110 263 27.7% 31.3% 31.0% 21.4% 28.0% 
5-Fu 110 287 35.2% 27.1% 32.7% 22.1% 29.1% 
5-Fu 110 311 29.7% 34.1% 33.5% 20.9% 30.2% 
5-Fu 110 335 37.2% 24.1% 32.2% 21.9% 31.3% 
5-Fu 110 359 38.5% 24.7% 33.2% 22.3% 32.3% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
5-Fu 110 383 33.0% 31.1% 33.6% 26.1% 33.3% 
5-Fu 110 407 33.7% 38.0% 37.6% 26.1% 34.3% 
5-Fu 110 431 37.8% 33.9% 37.6% 27.1% 35.2% 
5-Fu 110 455 38.8% 35.0% 38.7% 26.5% 36.2% 
5-Fu 110 479 36.3% 36.1% 38.0% 27.4% 37.0% 
5-Fu 110 503 37.0% 37.3% 39.0% 27.8% 37.9% 
5-Fu 110 527 30.8% 44.2% 39.4% 29.1% 38.8% 
5-Fu 110 551 37.7% 40.1% 40.8% 33.9% 39.6% 
5-Fu 110 575 52.0% 35.4% 45.9% 35.2% 40.4% 
M 70 1 22.2% 33.3% 13.3% 23.0% 15.2% 
M 70 2 24.3% 38.7% 16.8% 8.9% 3.6% 
M 70 4 28.6% 42.0% 24.9% 10.0% 4.8% 
M 70 7 28.7% 43.2% 27.0% 10.2% 6.1% 
M 70 12 30.8% 41.9% 26.9% 16.9% 8.7% 
M 70 23 32.9% 51.3% 35.5% 18.8% 12.4% 
M 70 47 37.2% 50.2% 38.0% 21.4% 15.3% 
M 70 71 39.5% 50.9% 42.7% 23.2% 17.6% 
M 70 95 39.6% 53.6% 45.4% 25.0% 19.7% 
M 70 119 41.7% 56.3% 45.9% 26.7% 21.6% 
M 70 143 43.8% 59.0% 46.2% 28.3% 23.4% 
M 70 167 48.1% 61.7% 44.1% 29.9% 25.0% 
M 70 191 48.2% 64.5% 46.0% 32.9% 26.5% 
M 70 215 52.5% 67.2% 47.8% 34.4% 28.0% 
M 70 239 52.6% 69.9% 49.7% 36.7% 29.4% 
M 70 263 54.7% 72.6% 51.6% 38.2% 30.7% 
M 70 287 56.8% 73.1% 53.5% 40.3% 31.9% 
M 70 311 58.8% 75.6% 55.4% 41.7% 33.1% 
M 70 335 60.9% 75.9% 57.3% 45.3% 34.3% 
M 70 359 65.3% 80.5% 59.1% 45.3% 35.4% 
M 70 383 63.1% 80.7% 61.0% 47.3% 36.5% 
M 70 407 65.0% 83.0% 62.9% 48.6% 37.6% 
M 70 431 66.9% 83.1% 64.8% 49.8% 38.6% 
M 70 455 68.8% 85.2% 64.4% 52.5% 39.6% 
M 70 479 70.6% 89.5% 66.1% 52.2% 40.6% 
M 70 503 72.5% 91.8% 61.1% 51.7% 41.6% 
M 70 527 74.4% 87.5% 62.2% 53.3% 42.5% 
M 70 551 76.3% 89.1% 63.2% 54.8% 43.4% 
M 70 575 78.2% 90.8% 64.3% 54.1% 44.3% 
M 70 599 80.1% 85.8% 65.3% 55.4% 45.2% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
M 70 623 81.9% 86.9% 66.4% 56.8% 46.0% 
M 70 647 83.8% 87.9% 67.4% 58.1% 46.9% 
M 70 671 85.7% 89.0% 68.5% 59.4% 47.7% 
M 70 695 87.6% 90.0% 69.5% 60.0% 48.5% 
M 70 719 87.3% 91.1% 70.5% 60.5% 49.3% 
M 80 1 10.9% 26.2% 30.5% 22.5% 14.3% 
M 80 2 22.8% 28.6% 33.2% 8.2% 3.6% 
M 80 4 24.9% 33.3% 33.9% 9.2% 4.8% 
M 80 7 26.9% 33.8% 34.4% 11.5% 6.1% 
M 80 12 26.8% 38.4% 36.9% 15.3% 8.7% 
M 80 23 30.8% 41.1% 41.5% 16.3% 12.4% 
M 80 47 30.7% 43.8% 42.0% 19.3% 15.3% 
M 80 71 34.8% 46.4% 44.5% 21.0% 17.6% 
M 80 95 36.8% 49.1% 44.7% 21.9% 19.7% 
M 80 119 34.5% 51.8% 47.0% 23.3% 21.6% 
M 80 143 36.1% 54.4% 47.1% 25.5% 23.4% 
M 80 167 37.8% 57.1% 49.1% 24.7% 25.0% 
M 80 191 39.4% 55.4% 46.8% 26.5% 26.5% 
M 80 215 41.1% 51.1% 55.0% 28.4% 28.0% 
M 80 239 42.7% 52.8% 57.3% 30.2% 29.4% 
M 80 263 44.4% 54.4% 59.5% 31.3% 30.7% 
M 80 287 46.0% 56.1% 59.6% 33.1% 31.9% 
M 80 311 47.6% 57.7% 61.7% 34.9% 33.1% 
M 80 335 49.3% 59.3% 63.7% 36.0% 34.3% 
M 80 359 50.9% 61.0% 63.6% 37.7% 35.4% 
M 80 383 52.6% 62.6% 65.4% 39.4% 36.5% 
M 80 407 54.2% 64.3% 67.3% 41.8% 37.6% 
M 80 431 55.9% 65.9% 71.3% 44.3% 38.6% 
M 80 455 57.5% 67.6% 75.5% 44.7% 39.6% 
M 80 479 59.1% 69.2% 73.4% 46.4% 40.6% 
M 80 503 60.8% 70.8% 75.3% 48.1% 41.6% 
M 80 527 62.4% 72.5% 77.1% 48.4% 42.5% 
M 80 551 64.1% 69.8% 79.0% 50.0% 43.4% 
M 80 575 65.7% 71.0% 80.8% 50.1% 44.3% 
M 80 599 67.4% 72.2% 78.3% 51.5% 45.2% 
M 80 623 69.0% 73.5% 79.8% 53.0% 46.0% 
M 80 647 70.6% 74.7% 81.2% 53.0% 46.9% 
M 80 671 67.9% 75.9% 82.6% 54.3% 47.7% 
M 80 695 69.2% 77.2% 84.1% 54.8% 48.5% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
M 80 719 70.4% 78.4% 83.3% 56.1% 49.3% 
M 90 1 20.1% 16.1% 18.1% 18.1% 13.6% 
M 90 2 20.0% 17.6% 21.8% 3.4% 3.6% 
M 90 4 21.7% 19.1% 23.7% 5.8% 4.8% 
M 90 7 23.4% 22.6% 25.6% 7.5% 6.1% 
M 90 12 27.1% 24.3% 25.5% 9.3% 8.7% 
M 90 23 27.0% 26.0% 29.2% 11.7% 12.4% 
M 90 47 32.7% 27.7% 29.0% 12.9% 15.3% 
M 90 71 32.8% 29.4% 30.7% 14.7% 17.6% 
M 90 95 32.6% 31.1% 34.5% 17.1% 19.7% 
M 90 119 36.3% 32.8% 36.3% 19.6% 21.6% 
M 90 143 38.2% 34.5% 40.2% 22.2% 23.4% 
M 90 167 42.1% 36.2% 42.3% 23.4% 25.0% 
M 90 191 42.2% 37.9% 44.4% 25.3% 26.5% 
M 90 215 42.1% 39.6% 48.5% 26.6% 28.0% 
M 90 239 43.8% 41.3% 48.8% 25.7% 29.4% 
M 90 263 41.5% 39.0% 50.8% 27.3% 30.7% 
M 90 287 42.8% 40.3% 52.9% 28.2% 31.9% 
M 90 311 44.1% 41.7% 53.0% 28.4% 33.1% 
M 90 335 45.5% 43.0% 50.9% 29.7% 34.3% 
M 90 359 46.8% 44.3% 52.4% 32.5% 35.4% 
M 90 383 48.1% 49.7% 53.9% 33.3% 36.5% 
M 90 407 49.4% 49.4% 55.4% 34.1% 37.6% 
M 90 431 50.7% 48.9% 56.9% 35.5% 38.6% 
M 90 455 52.1% 50.2% 58.4% 36.9% 39.6% 
M 90 479 53.4% 51.5% 59.9% 38.3% 40.6% 
M 90 503 54.7% 52.8% 61.5% 41.0% 41.6% 
M 90 527 56.0% 58.2% 63.0% 41.8% 42.5% 
M 90 551 57.4% 57.9% 64.5% 43.3% 43.4% 
M 90 575 58.7% 59.4% 66.0% 44.7% 44.3% 
M 90 599 60.0% 60.9% 67.5% 46.8% 45.2% 
M 90 623 61.3% 64.4% 69.0% 47.7% 46.0% 
M 90 647 62.7% 64.1% 70.5% 47.8% 46.9% 
M 90 671 64.0% 65.6% 68.0% 48.5% 47.7% 
M 90 695 65.3% 65.1% 69.2% 49.7% 48.5% 
M 90 719 66.6% 66.4% 70.3% 51.0% 49.3% 
M 110 1 12.5% 12.2% 14.2% 12.2% 12.3% 
M 110 2 12.9% 17.2% 15.8% 2.7% 3.6% 
M 110 4 14.1% 15.0% 17.4% 6.7% 4.8% 
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Drug 
DLT 
(°C) 
Time 
(hour) 
DRP R1 
(%) 
DRP R2 
(%) 
DRP R3 
(%) 
EDR 
(%) 
TDR 
(%) 
M 110 7 17.8% 19.0% 22.1% 8.2% 6.1% 
M 110 12 19.2% 20.4% 23.8% 8.7% 8.7% 
M 110 23 18.2% 21.0% 25.4% 11.0% 12.4% 
M 110 47 16.9% 23.3% 30.5% 12.5% 15.3% 
M 110 71 22.7% 24.7% 29.1% 13.0% 17.6% 
M 110 95 21.7% 25.2% 30.7% 14.4% 19.7% 
M 110 119 22.9% 26.6% 32.4% 14.8% 21.6% 
M 110 143 21.6% 27.0% 34.0% 16.1% 23.4% 
M 110 167 22.6% 28.3% 35.7% 20.2% 25.0% 
M 110 191 26.0% 32.4% 40.8% 18.0% 26.5% 
M 110 215 22.3% 30.2% 39.4% 21.0% 28.0% 
M 110 239 27.9% 33.3% 41.0% 21.4% 29.4% 
M 110 263 26.6% 33.7% 42.7% 20.8% 30.7% 
M 110 287 27.6% 33.1% 40.9% 22.9% 31.9% 
M 110 311 26.1% 35.1% 45.7% 23.1% 33.1% 
M 110 335 29.2% 35.4% 43.9% 23.3% 34.3% 
M 110 359 27.7% 35.5% 45.2% 27.1% 35.4% 
M 110 383 30.9% 39.3% 50.0% 25.5% 36.5% 
M 110 407 29.4% 37.8% 48.2% 24.7% 37.6% 
M 110 431 30.1% 36.9% 46.1% 28.3% 38.6% 
M 110 455 33.2% 40.5% 50.5% 28.9% 39.6% 
M 110 479 35.4% 41.2% 50.1% 27.6% 40.6% 
M 110 503 32.8% 39.9% 49.6% 29.4% 41.6% 
M 110 527 36.0% 41.6% 50.6% 29.4% 42.5% 
M 110 551 36.9% 41.6% 49.9% 31.1% 43.4% 
M 110 575 37.9% 43.4% 52.4% 35.8% 44.3% 
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APPENDIX – D 
Data to perform linear regression of initial burst from PLA fibers in PBS with kinetic and 
thermodynamic parameters (T=Temperature, IB=Initial burst, C=Concentration, 
A×C=Interaction of affinity and concentration) 
Drug T (°C) IB (%) C (mol/kg) A×C 
D 70 28.4% 1.73E-02 3.65E-01 
D 80 14.3% 1.73E-02 4.06E-01 
D 90 5.4% 1.73E-02 4.22E-01 
D 110 5.6% 1.73E-02 4.52E-01 
D 110 6.6% 3.46E-02 9.05E-01 
5-Fu 70 19.9% 5.00E-03 4.61E-02 
5-Fu 80 19.6% 5.00E-03 4.92E-02 
5-Fu 90 13.0% 5.00E-03 5.17E-02 
5-Fu 110 12.1% 5.00E-03 5.40E-02 
5-Fu 110 12.1% 8.69E-03 9.39E-02 
M 70 23.0% 5.13E-03 3.17E-02 
M 80 22.5% 5.13E-03 3.84E-02 
M 90 18.1% 5.13E-03 4.33E-02 
M 110 12.2% 5.13E-03 5.26E-02 
M 110 19.8% 1.16E-02 1.19E-01 
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APPENDIX – E 
Data to perform linear regression of initial burst from PLA fibers in PBS with kinetic and 
thermodynamic parameters (DRP=Drug release percentage, SRT=Square root of time, 
SRIAT=Square root of interaction of affinity and time) 
DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
0.10% 1.00 0.07 16.96% 13.82 2.62 
2.10% 1.41 0.10 18.41% 14.66 2.78 
1.06% 2.00 0.15 19.86% 15.46 2.93 
3.36% 2.65 0.19 21.31% 16.22 3.07 
2.58% 3.46 0.26 23.94% 16.94 3.21 
3.35% 4.80 0.35 24.32% 17.64 3.34 
7.72% 6.86 0.51 25.77% 18.30 3.47 
10.47% 8.43 0.62 27.22% 18.95 3.59 
13.89% 9.75 0.72 29.85% 19.57 3.71 
14.34% 10.91 0.80 27.86% 20.17 3.82 
14.62% 11.96 0.88 29.08% 20.76 3.93 
17.19% 12.92 0.95 30.31% 21.33 4.04 
17.97% 13.82 1.02 31.53% 21.89 4.14 
17.77% 14.66 1.08 32.76% 22.43 4.25 
18.52% 15.46 1.14 33.99% 22.96 4.35 
21.04% 16.22 1.20 34.03% 23.47 4.44 
22.72% 16.94 1.25 35.14% 23.98 4.54 
21.62% 17.64 1.30 36.26% 24.47 4.63 
23.03% 18.30 1.35 37.37% 24.96 4.73 
23.52% 18.95 1.40 38.49% 25.44 4.82 
25.78% 19.57 1.44 38.42% 25.90 4.90 
28.12% 20.17 1.49 39.42% 26.36 4.99 
26.83% 20.76 1.53 40.42% 26.81 5.08 
28.99% 21.33 1.57 41.98% 27.26 5.16 
31.24% 21.89 1.61 5.31% 2.00 0.38 
31.73% 22.43 1.65 3.16% 2.65 0.50 
31.20% 22.96 1.69 7.02% 3.39 0.64 
35.12% 23.47 1.73 5.33% 4.80 0.91 
35.61% 23.98 1.77 7.99% 6.86 1.30 
36.93% 24.47 1.80 10.30% 8.43 1.60 
37.33% 24.96 1.84 11.52% 9.75 1.85 
38.57% 25.44 1.87 12.75% 10.91 2.07 
37.95% 25.90 1.91 15.43% 11.96 2.26 
40.86% 26.36 1.94 15.34% 12.92 2.45 
40.24% 26.81 1.98 16.57% 13.82 2.62 
41.30% 27.26 2.01 18.31% 14.66 2.78 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
0.63% 2.00 0.15 18.56% 15.46 2.93 
2.11% 2.65 0.19 19.73% 16.22 3.07 
0.48% 3.39 0.25 21.42% 16.94 3.21 
0.87% 4.80 0.35 22.13% 17.64 3.34 
4.63% 6.86 0.51 20.91% 18.30 3.47 
5.24% 8.43 0.62 21.86% 18.95 3.59 
8.66% 9.75 0.72 22.29% 19.57 3.71 
8.29% 10.91 0.80 26.09% 20.17 3.82 
8.33% 11.96 0.88 26.07% 20.76 3.93 
12.84% 12.92 0.95 27.13% 21.33 4.04 
11.95% 13.82 1.02 26.48% 21.89 4.14 
12.56% 14.66 1.08 27.37% 22.43 4.25 
15.41% 15.46 1.14 27.76% 22.96 4.35 
17.85% 16.22 1.20 29.11% 23.47 4.44 
18.68% 16.94 1.25 33.94% 23.98 4.54 
18.31% 17.64 1.30 35.22% 24.47 4.63 
20.07% 18.30 1.35 10.11% 2.00 0.38 
21.87% 18.95 1.40 7.24% 2.65 0.50 
20.87% 19.57 1.44 12.69% 3.39 0.64 
21.94% 20.17 1.49 9.82% 4.80 0.91 
23.58% 20.76 1.53 15.27% 6.86 1.30 
27.00% 21.33 1.57 16.68% 8.43 1.60 
27.20% 21.89 1.61 18.09% 9.75 1.85 
28.44% 22.43 1.65 19.50% 10.91 2.07 
27.96% 22.96 1.69 20.91% 11.96 2.26 
29.60% 23.47 1.73 19.89% 12.92 2.45 
31.88% 23.98 1.77 21.63% 13.82 2.62 
31.97% 24.47 1.80 24.90% 14.66 2.78 
34.81% 24.96 1.84 22.02% 15.46 2.93 
33.82% 25.44 1.87 27.48% 16.22 3.07 
34.89% 25.90 1.91 26.46% 16.94 3.21 
37.68% 26.36 1.94 25.78% 17.64 3.34 
38.91% 26.81 1.98 28.81% 18.30 3.47 
39.58% 27.26 2.01 27.84% 18.95 3.59 
0.00% 1.00 0.07 31.04% 19.57 3.71 
0.13% 2.00 0.15 30.35% 20.17 3.82 
2.16% 2.65 0.19 30.96% 20.76 3.93 
1.56% 3.39 0.25 30.04% 21.33 4.04 
2.61% 4.80 0.35 30.70% 21.89 4.14 
5.52% 6.86 0.51 33.66% 22.43 4.25 
7.46% 8.43 0.62 37.02% 22.96 4.35 
7.15% 9.75 0.72 33.91% 23.47 4.44 
10.29% 10.91 0.80 37.28% 23.98 4.54 
10.08% 11.96 0.88 37.24% 24.47 4.63 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
12.75% 12.92 0.95 8.91% 2.00 0.45 
16.18% 13.82 1.02 10.01% 2.65 0.59 
15.09% 14.66 1.08 10.23% 3.39 0.76 
18.51% 15.46 1.14 16.90% 4.80 1.08 
19.20% 16.22 1.20 18.81% 6.86 1.54 
21.61% 16.94 1.25 21.40% 8.43 1.89 
21.16% 17.64 1.30 23.24% 9.75 2.19 
22.93% 18.30 1.35 25.01% 10.91 2.45 
23.56% 18.95 1.40 26.71% 11.96 2.68 
23.53% 19.57 1.44 28.34% 12.92 2.90 
24.58% 20.17 1.49 29.90% 13.82 3.10 
26.23% 20.76 1.53 32.87% 14.66 3.29 
29.13% 21.33 1.57 34.43% 15.46 3.47 
30.41% 21.89 1.61 36.67% 16.22 3.64 
30.51% 22.43 1.65 38.16% 16.94 3.80 
31.68% 22.96 1.69 40.32% 17.64 3.96 
33.44% 23.47 1.73 41.74% 18.30 4.11 
34.66% 23.98 1.77 45.32% 18.95 4.25 
34.70% 24.47 1.80 45.33% 19.57 4.39 
36.99% 24.96 1.84 47.35% 20.17 4.53 
37.02% 25.44 1.87 48.63% 20.76 4.66 
37.54% 25.90 1.91 49.84% 21.33 4.79 
37.99% 26.36 1.94 52.47% 21.89 4.91 
39.58% 26.81 1.98 52.20% 22.43 5.04 
40.63% 27.26 2.01 51.72% 22.96 5.15 
0.26% 2.00 0.15 53.25% 23.47 5.27 
0.06% 2.65 0.19 54.79% 23.98 5.38 
1.15% 3.39 0.25 54.10% 24.47 5.49 
1.64% 4.80 0.35 55.43% 24.96 5.60 
5.17% 6.86 0.51 56.75% 25.44 5.71 
4.94% 8.43 0.62 58.08% 25.90 5.82 
5.63% 9.75 0.72 59.40% 26.36 5.92 
4.29% 10.91 0.80 59.99% 26.81 6.02 
5.79% 11.96 0.88 60.50% 27.26 6.12 
7.39% 12.92 0.95 8.15% 2.00 0.45 
6.05% 13.82 1.02 9.16% 2.65 0.59 
5.53% 14.66 1.08 11.49% 3.39 0.76 
5.92% 15.46 1.14 15.27% 4.80 1.08 
8.34% 16.22 1.20 16.28% 6.86 1.54 
5.89% 16.94 1.25 19.34% 8.43 1.89 
8.21% 17.64 1.30 21.01% 9.75 2.19 
6.67% 18.30 1.35 21.88% 10.91 2.45 
7.98% 18.95 1.40 23.35% 11.96 2.68 
9.39% 19.57 1.44 25.47% 12.92 2.90 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
10.89% 20.17 1.49 24.68% 13.82 3.10 
12.49% 20.76 1.53 26.53% 14.66 3.29 
10.14% 21.33 1.57 28.38% 15.46 3.47 
9.52% 21.89 1.61 30.23% 16.22 3.64 
10.83% 22.43 1.65 31.35% 16.94 3.80 
11.22% 22.96 1.69 33.13% 17.64 3.96 
12.63% 23.47 1.73 34.91% 18.30 4.11 
12.10% 23.98 1.77 35.96% 18.95 4.25 
14.52% 24.47 1.80 37.67% 19.57 4.39 
1.79% 2.00 0.15 39.38% 20.17 4.53 
0.96% 2.65 0.19 41.82% 20.76 4.66 
3.03% 3.39 0.25 44.33% 21.33 4.79 
3.72% 4.80 0.35 44.72% 21.89 4.91 
5.94% 6.86 0.51 46.44% 22.43 5.04 
6.78% 8.43 0.62 48.15% 22.96 5.15 
7.11% 9.75 0.72 48.41% 23.47 5.27 
6.37% 10.91 0.80 49.98% 23.98 5.38 
7.53% 11.96 0.88 50.10% 24.47 5.49 
9.24% 12.92 0.95 51.54% 24.96 5.60 
9.52% 13.82 1.02 52.98% 25.44 5.71 
8.73% 14.66 1.08 52.96% 25.90 5.82 
10.34% 15.46 1.14 54.26% 26.36 5.92 
10.52% 16.22 1.20 54.83% 26.81 6.02 
11.68% 16.94 1.25 56.07% 27.26 6.12 
12.37% 17.64 1.30 3.40% 2.00 0.45 
12.04% 18.30 1.35 5.78% 2.65 0.59 
11.61% 18.95 1.40 7.54% 3.39 0.76 
12.62% 19.57 1.44 9.31% 4.80 1.08 
14.18% 20.17 1.49 11.74% 6.86 1.54 
15.84% 20.76 1.53 12.90% 8.43 1.89 
16.07% 21.33 1.57 14.66% 9.75 2.19 
15.23% 21.89 1.61 17.10% 10.91 2.45 
16.29% 22.43 1.65 19.60% 11.96 2.68 
18.41% 22.96 1.69 22.16% 12.92 2.90 
16.60% 23.47 1.73 23.44% 13.82 3.10 
17.61% 23.98 1.77 25.33% 14.66 3.29 
18.15% 24.47 1.80 26.56% 15.46 3.47 
0.76% 2.00 0.38 25.71% 16.22 3.64 
1.47% 2.65 0.50 27.28% 16.94 3.80 
4.54% 3.39 0.64 28.19% 17.64 3.96 
6.18% 4.80 0.91 28.36% 18.30 4.11 
7.82% 6.86 1.30 29.75% 18.95 4.25 
11.95% 8.43 1.60 32.48% 19.57 4.39 
13.82% 9.75 1.85 33.32% 20.17 4.53 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
15.69% 10.91 2.07 34.10% 20.76 4.66 
20.06% 11.96 2.26 35.49% 21.33 4.79 
19.68% 12.92 2.45 36.87% 21.89 4.91 
24.04% 13.82 2.62 38.26% 22.43 5.04 
26.15% 14.66 2.78 40.99% 22.96 5.15 
27.94% 15.46 2.93 41.83% 23.47 5.27 
29.90% 16.22 3.07 43.28% 23.98 5.38 
31.86% 16.94 3.21 44.73% 24.47 5.49 
33.82% 17.64 3.34 46.85% 24.96 5.60 
34.49% 18.30 3.47 47.69% 25.44 5.71 
33.74% 18.95 3.59 47.80% 25.90 5.82 
34.05% 19.57 3.71 48.46% 26.36 5.92 
34.20% 20.17 3.82 49.72% 26.81 6.02 
34.38% 20.76 3.93 50.98% 27.26 6.12 
38.27% 21.33 4.04 2.73% 2.00 0.45 
39.91% 21.89 4.14 6.74% 2.65 0.59 
39.06% 22.43 4.25 8.20% 3.39 0.76 
40.47% 22.96 4.35 8.72% 4.80 1.08 
41.87% 23.47 4.44 11.02% 6.86 1.54 
43.28% 23.98 4.54 12.48% 8.43 1.89 
44.68% 24.47 4.63 13.00% 9.75 2.19 
46.09% 24.96 4.73 14.37% 10.91 2.45 
46.25% 25.44 4.82 14.79% 11.96 2.68 
47.54% 25.90 4.90 16.07% 12.92 2.90 
47.58% 26.36 4.99 20.17% 13.82 3.10 
48.75% 26.81 5.08 17.95% 14.66 3.29 
48.68% 27.26 5.16 21.02% 15.46 3.47 
2.60% 2.00 0.38 21.44% 16.22 3.64 
2.94% 2.65 0.50 20.84% 16.94 3.80 
3.22% 3.39 0.64 22.87% 17.64 3.96 
4.17% 4.80 0.91 23.11% 18.30 4.11 
3.58% 6.86 1.30 23.27% 18.95 4.25 
7.14% 8.43 1.60 27.09% 19.57 4.39 
6.55% 9.75 1.85 25.54% 20.17 4.53 
7.94% 10.91 2.07 24.66% 20.76 4.66 
13.39% 11.96 2.26 28.31% 21.33 4.79 
12.98% 12.92 2.45 28.93% 21.89 4.91 
14.54% 13.82 2.62 27.63% 22.43 5.04 
18.28% 14.66 2.78 29.39% 22.96 5.15 
20.04% 15.46 2.93 29.36% 23.47 5.27 
21.81% 16.22 3.07 31.12% 23.98 5.38 
23.57% 16.94 3.21 35.79% 24.47 5.49 
25.34% 17.64 3.34 6.10% 2.00 0.45 
27.10% 18.30 3.47 6.37% 2.65 0.59 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
31.05% 18.95 3.59 9.70% 3.39 0.76 
29.75% 19.57 3.71 9.92% 4.80 1.08 
31.42% 20.17 3.82 10.47% 6.86 1.54 
33.08% 20.76 3.93 14.14% 8.43 1.89 
34.74% 21.33 4.04 12.86% 9.75 2.19 
34.23% 21.89 4.14 14.51% 10.91 2.45 
35.69% 22.43 4.25 16.85% 11.96 2.68 
37.14% 22.96 4.35 20.61% 12.92 2.90 
38.60% 23.47 4.44 19.80% 13.82 3.10 
40.06% 23.98 4.54 21.45% 14.66 3.29 
39.62% 24.47 4.63 22.16% 15.46 3.47 
40.90% 24.96 4.73 23.72% 16.22 3.64 
42.18% 25.44 4.82 26.91% 16.94 3.80 
43.46% 25.90 4.90 26.06% 17.64 3.96 
43.65% 26.36 4.99 26.17% 18.30 4.11 
44.83% 26.81 5.08 27.51% 18.95 4.25 
46.01% 27.26 5.16 27.48% 19.57 4.39 
0.99% 2.00 0.38 26.81% 20.17 4.53 
1.09% 2.65 0.50 30.92% 20.76 4.66 
2.09% 3.39 0.64 32.40% 21.33 4.79 
4.28% 4.80 0.91 30.75% 21.89 4.91 
7.76% 6.86 1.30 30.18% 22.43 5.04 
9.09% 8.43 1.60 31.75% 22.96 5.15 
10.43% 9.75 1.85 32.03% 23.47 5.27 
11.77% 10.91 2.07 34.29% 23.98 5.38 
13.11% 11.96 2.26 32.58% 24.47 5.49 
14.44% 12.92 2.45 
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APPENDIX – F 
Data for sorption rates of Diclofenac, 5-Fu and Metformin on SA fibers (DLT=Drug 
loading temperature, DCF=Drug concentration on fibers, R=Repetition) 
Drug DLT(°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
D 70 240 52.00 50.00 51.51 
D 70 180 45.59 48.65 47.59 
D 70 150 43.76 42.59 43.61 
D 70 120 45.88 37.59 42.15 
D 70 90 38.47 37.00 38.11 
D 70 60 30.18 26.41 28.58 
D 70 30 15.53 14.88 15.36 
D 70 15 7.94 6.41 7.25 
D 70 10 6.65 4.88 5.82 
D 70 5 3.29 3.47 3.42 
D 70 3 3.01 2.65 2.85 
D 70 1 2.47 3.00 2.76 
D 80 240 92.24 97.88 94.11 
D 80 180 80.35 92.06 85.34 
D 80 150 78.29 76.88 76.81 
D 80 120 75.06 67.47 70.55 
D 80 90 66.53 66.47 65.84 
D 80 60 45.18 51.94 48.07 
D 80 30 31.65 36.18 33.57 
D 80 15 17.65 21.35 19.31 
D 80 10 14.29 16.12 15.05 
D 80 5 8.59 8.47 8.44 
D 80 3 5.35 6.24 5.74 
D 80 1 3.29 3.53 3.38 
D 90 240 106.04 105.89 103.84 
D 90 180 91.63 100.96 94.37 
D 90 150 94.44 90.19 90.47 
D 90 120 92.37 85.95 87.38 
D 90 90 69.25 75.69 71.02 
D 90 60 62.00 63.56 61.53 
D 90 30 52.09 42.52 46.36 
D 90 15 28.08 25.88 26.44 
D 90 10 21.54 18.00 19.38 
D 90 5 11.29 9.07 9.97 
D 90 3 8.07 6.66 7.22 
D 90 1 1.81 1.66 1.70 
5-Fu 70 240 2.60 2.73 2.69 
5-Fu 70 180 2.49 2.90 2.72 
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Drug DLT(°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
5-Fu 70 150 2.92 2.84 2.91 
5-Fu 70 120 2.71 2.73 2.75 
5-Fu 70 90 2.76 2.66 2.74 
5-Fu 70 60 2.62 2.87 2.77 
5-Fu 70 30 2.51 2.43 2.49 
5-Fu 70 15 2.25 2.25 2.27 
5-Fu 70 10 1.95 1.81 1.90 
5-Fu 70 5 1.69 1.33 1.53 
5-Fu 70 3 1.12 1.14 1.14 
5-Fu 70 1 0.61 0.61 0.62 
5-Fu 80 240 3.16 3.16 3.19 
5-Fu 80 180 2.94 2.86 2.92 
5-Fu 80 150 3.05 3.60 3.36 
5-Fu 80 120 3.01 3.08 3.08 
5-Fu 80 90 2.81 4.13 3.50 
5-Fu 80 60 2.76 3.75 3.29 
5-Fu 80 30 2.39 3.09 2.77 
5-Fu 80 15 2.59 2.49 2.56 
5-Fu 80 10 2.55 3.03 2.82 
5-Fu 80 5 1.66 1.79 1.74 
5-Fu 80 3 1.89 2.03 1.98 
5-Fu 80 1 0.63 0.56 0.60 
5-Fu 90 240 4.21 4.49 4.31 
5-Fu 90 180 3.89 5.04 4.42 
5-Fu 90 150 3.97 3.94 3.91 
5-Fu 90 120 4.41 4.61 4.47 
5-Fu 90 90 3.89 3.92 3.87 
5-Fu 90 60 3.27 3.41 3.31 
5-Fu 90 30 3.21 3.30 3.22 
5-Fu 90 15 4.03 3.00 3.48 
5-Fu 90 10 2.24 2.54 2.36 
5-Fu 90 5 1.92 1.98 1.93 
5-Fu 90 3 1.33 1.36 1.33 
5-Fu 90 1 0.82 0.71 0.76 
M 70 240 0.18 0.13 0.16 
M 70 180 0.13 0.16 0.15 
M 70 150 0.13 0.16 0.15 
M 70 120 0.16 0.13 0.15 
M 70 90 0.13 0.16 0.15 
M 70 60 0.14 0.16 0.15 
M 70 30 0.11 0.13 0.12 
M 70 15 0.08 0.13 0.11 
M 70 10 0.08 0.08 0.08 
M 70 5 0.08 0.05 0.07 
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Drug DLT(°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
M 70 3 0.05 0.05 0.05 
M 70 1 0.03 0.05 0.04 
M 80 240 0.79 0.68 0.72 
M 80 180 0.68 0.63 0.64 
M 80 150 0.53 0.58 0.54 
M 80 120 0.42 0.53 0.46 
M 80 90 0.42 0.42 0.41 
M 80 60 0.37 0.37 0.36 
M 80 30 0.32 0.37 0.34 
M 80 15 0.26 0.37 0.31 
M 80 10 0.26 0.32 0.28 
M 80 5 0.21 0.26 0.23 
M 80 3 0.16 0.21 0.18 
M 80 1 0.11 0.16 0.13 
M 90 240 2.14 2.12 2.09 
M 90 180 1.64 1.72 1.65 
M 90 150 1.46 1.57 1.48 
M 90 120 1.51 1.33 1.39 
M 90 90 1.09 1.07 1.06 
M 90 60 0.83 0.75 0.77 
M 90 30 0.57 0.46 0.50 
M 90 15 0.33 0.38 0.35 
M 90 10 0.28 0.25 0.26 
M 90 5 0.22 0.14 0.18 
M 90 3 0.20 0.09 0.14 
M 90 1 0.04 0.04 0.04 
  
140 
 
APPENDIX – G 
Data for isotherms of Diclofenac, 5-Fu and Metformin on SA fibers (DCF=Drug 
concentration on fibers, DCS=Drug concentration in solution, R=Repetition, 
D=Diclofenac, M=Metformin, DLT=Drug loading temperature) 
Drug 
DLT
(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
D 70 0.03 0.03 0.03 26.82 26.76 27.41 
D 70 0.53 0.57 0.54 36.34 37.82 35.59 
D 70 1.75 1.81 1.76 42.37 44.29 41.29 
D 70 4.37 4.34 4.31 51.77 51.00 53.59 
D 70 5.65 5.68 5.61 52.24 52.35 53.18 
D 70 6.82 6.84 6.76 57.59 59.94 56.41 
D 70 8.02 7.98 7.92 59.37 61.65 58.29 
D 70 9.21 9.32 9.17 62.78 64.76 62.06 
D 80 0.03 0.02 0.05 25.30 24.71 26.41 
D 80 0.45 0.47 0.45 43.24 44.41 42.94 
D 80 1.65 1.65 1.69 48.25 52.06 45.41 
D 80 4.06 4.07 4.12 61.06 60.47 62.88 
D 80 5.40 5.44 5.47 63.51 64.24 64.06 
D 80 6.53 6.53 6.66 67.87 69.12 68.00 
D 80 7.52 7.51 7.69 70.32 74.35 67.71 
D 80 8.68 8.77 8.78 80.57 77.12 85.65 
D 90 0.06 0.07 0.06 26.88 31.82 29.06 
D 90 0.15 0.15 0.16 60.06 65.41 62.11 
D 90 1.03 1.06 1.01 80.53 77.47 78.21 
D 90 3.15 3.18 3.18 89.76 103.00 95.42 
D 90 4.32 4.29 4.44 96.94 107.29 101.10 
D 90 5.62 5.71 5.64 107.06 109.53 107.21 
D 90 6.17 6.72 5.76 106.47 128.71 116.41 
D 90 7.50 7.63 7.52 125.12 110.00 116.38 
5-Fu 70 0.65 0.65 0.64 2.53 3.07 2.04 
5-Fu 70 1.37 1.39 1.37 3.34 4.25 2.50 
5-Fu 70 2.73 2.76 2.72 3.69 3.48 3.96 
5-Fu 70 5.67 5.67 5.62 6.75 6.90 6.73 
5-Fu 70 6.98 7.11 6.98 8.21 7.64 8.94 
5-Fu 70 8.34 8.40 8.29 8.12 8.77 7.64 
5-Fu 70 9.54 9.71 9.53 9.47 9.72 9.40 
5-Fu 70 10.99 11.05 10.91 10.79 10.99 10.80 
5-Fu 80 0.63 0.65 0.64 1.81 1.86 1.80 
5-Fu 80 1.34 1.36 1.34 2.90 3.31 2.55 
5-Fu 80 2.69 2.71 2.68 3.89 4.06 3.80 
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Drug 
DLT
(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
5-Fu 80 5.64 5.69 5.61 6.61 7.11 6.24 
5-Fu 80 6.91 6.92 6.85 7.68 8.27 7.24 
5-Fu 80 8.16 8.19 8.10 8.66 8.03 9.47 
5-Fu 80 9.46 9.51 9.39 8.81 8.97 8.83 
5-Fu 80 10.82 10.90 10.75 10.91 11.03 11.03 
5-Fu 90 0.63 0.63 0.64 2.13 2.32 1.99 
5-Fu 90 1.32 1.32 1.35 2.73 3.33 2.20 
5-Fu 90 2.66 2.69 2.68 4.13 3.66 4.68 
5-Fu 90 5.56 5.60 5.64 7.03 8.24 5.97 
5-Fu 90 6.78 6.80 6.90 7.32 7.46 7.32 
5-Fu 90 8.05 8.14 8.11 8.28 7.99 8.73 
5-Fu 90 9.23 9.45 9.20 9.58 11.20 8.16 
5-Fu 90 10.57 10.49 10.86 12.32 12.14 12.76 
M 70 0.17 0.17 0.17 0.01 0.01 0.01 
M 70 0.57 0.57 0.59 0.05 0.03 0.03 
M 70 1.74 1.76 1.77 0.08 0.07 0.07 
M 70 3.97 4.02 3.99 0.11 0.09 0.10 
M 70 7.11 7.15 7.22 0.22 0.20 0.21 
M 70 9.84 9.94 9.94 0.30 0.32 0.31 
M 70 12.10 12.26 12.18 0.36 0.37 0.36 
M 70 17.63 17.87 17.75 0.49 0.54 0.51 
M 80 0.16 0.17 0.17 0.01 0.03 0.01 
M 80 0.57 0.58 0.57 0.01 0.01 0.01 
M 80 1.73 1.74 1.72 0.07 0.07 0.08 
M 80 3.78 3.94 3.82 0.17 0.16 0.18 
M 80 7.20 6.98 7.02 0.33 0.34 0.32 
M 80 9.90 9.71 9.70 0.42 0.42 0.43 
M 80 12.16 12.14 12.03 0.51 0.57 0.47 
M 80 17.64 17.68 17.48 0.68 0.70 0.67 
M 90 0.17 0.17 0.17 0.09 0.08 0.11 
M 90 0.58 0.59 0.58 0.53 0.63 0.45 
M 90 1.75 1.77 1.76 0.95 1.08 0.84 
M 90 3.98 3.99 4.05 1.60 1.74 1.50 
M 90 7.11 7.13 7.24 2.18 2.00 2.39 
M 90 9.90 9.94 10.07 2.40 2.26 2.58 
M 90 11.99 11.99 12.24 3.00 2.89 3.16 
M 90 17.55 17.68 17.77 3.14 3.18 3.16 
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APPENDIX – H 
Data for Diclofenac, 5-Fu and Metformin release from SA fibers in PBS (DLT=Drug 
loading temperature, DRP=Drug release percentage, R=Repetition, D=Diclofenac, 
M=Metformin) 
Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 70 0 0.0% 0.0% 0.0% 
D 70 1 46.4% 41.6% 43.6% 
D 70 5 50.0% 44.8% 46.9% 
D 70 10 52.3% 46.3% 48.8% 
D 70 24 54.0% 49.6% 51.3% 
D 70 47 58.8% 53.6% 55.6% 
D 70 72 60.0% 54.6% 56.7% 
D 70 96 59.4% 54.9% 56.6% 
D 70 120 62.2% 55.2% 58.1% 
D 70 144 61.4% 56.0% 58.1% 
D 70 168 61.7% 57.3% 58.9% 
D 70 192 61.2% 56.1% 58.1% 
D 70 216 61.9% 56.6% 58.7% 
D 70 240 62.5% 57.7% 59.5% 
D 70 264 61.9% 56.9% 58.8% 
D 70 288 63.5% 57.9% 60.1% 
D 70 312 63.4% 59.4% 60.7% 
D 70 336 63.1% 58.4% 60.1% 
D 70 360 62.7% 58.6% 60.0% 
D 70 384 63.5% 59.3% 60.8% 
D 70 408 63.6% 58.8% 60.6% 
D 70 432 63.1% 58.7% 60.3% 
D 70 456 64.9% 59.3% 61.5% 
D 70 480 64.3% 59.8% 61.4% 
D 70 504 63.6% 59.6% 61.0% 
D 70 528 64.1% 59.4% 61.1% 
D 70 552 63.9% 59.8% 61.2% 
D 70 576 64.8% 60.1% 61.9% 
D 70 600 64.0% 59.2% 61.0% 
D 70 624 64.2% 59.4% 61.2% 
D 70 648 63.9% 59.6% 61.1% 
D 70 672 64.0% 59.7% 61.2% 
D 70 696 64.2% 59.8% 61.4% 
D 70 720 64.3% 59.9% 61.5% 
D 70 744 64.4% 59.3% 61.2% 
D 70 768 63.8% 59.3% 61.0% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 70 792 64.4% 60.5% 61.8% 
D 70 816 64.4% 59.3% 61.2% 
D 70 840 63.7% 59.8% 61.2% 
D 70 864 64.9% 60.3% 62.0% 
D 70 888 64.8% 60.2% 61.9% 
D 70 912 64.7% 60.1% 61.8% 
D 70 936 64.0% 59.9% 61.3% 
D 80 0 0.0% 0.0% 0.0% 
D 80 1 32.4% 29.9% 34.2% 
D 80 5 36.2% 33.9% 37.7% 
D 80 10 40.0% 37.9% 41.4% 
D 80 24 42.8% 40.8% 43.8% 
D 80 47 48.3% 46.3% 49.4% 
D 80 72 50.7% 48.9% 51.5% 
D 80 96 51.8% 49.6% 52.9% 
D 80 120 52.9% 50.9% 53.8% 
D 80 144 54.5% 52.2% 55.8% 
D 80 168 56.2% 54.1% 57.1% 
D 80 192 56.3% 54.1% 57.3% 
D 80 216 57.2% 55.3% 57.9% 
D 80 240 58.3% 56.4% 59.1% 
D 80 264 58.3% 56.3% 59.0% 
D 80 288 59.3% 58.6% 58.9% 
D 80 312 60.7% 59.0% 61.1% 
D 80 336 61.4% 59.4% 62.1% 
D 80 360 61.1% 59.1% 61.9% 
D 80 384 63.2% 61.7% 63.4% 
D 80 408 62.6% 60.8% 63.1% 
D 80 432 62.1% 60.4% 62.7% 
D 80 456 63.7% 62.3% 64.0% 
D 80 480 64.2% 62.4% 64.7% 
D 80 504 64.5% 62.4% 65.4% 
D 80 528 64.2% 62.4% 64.8% 
D 80 552 63.9% 62.3% 64.1% 
D 80 576 65.3% 63.4% 65.8% 
D 80 600 65.1% 63.3% 65.7% 
D 80 624 65.0% 63.1% 65.6% 
D 80 648 65.0% 63.4% 65.3% 
D 80 672 65.3% 63.1% 66.3% 
D 80 696 65.3% 63.4% 66.0% 
D 80 720 66.5% 64.2% 67.5% 
D 80 744 65.8% 63.9% 66.5% 
D 80 768 65.7% 64.0% 66.1% 
D 80 792 66.5% 64.8% 66.9% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 80 816 66.3% 64.3% 67.0% 
D 80 840 66.1% 63.8% 67.1% 
D 80 864 67.4% 65.0% 68.4% 
D 80 888 67.2% 65.1% 67.9% 
D 80 912 67.5% 65.7% 68.0% 
D 80 936 66.9% 65.1% 67.4% 
D 90 0 0.0% 0.0% 0.0% 
D 90 1 3.1% 3.1% 3.0% 
D 90 5 4.4% 5.0% 4.6% 
D 90 10 5.9% 6.5% 6.1% 
D 90 24 9.8% 8.6% 9.0% 
D 90 47 10.3% 11.5% 10.6% 
D 90 72 11.9% 13.2% 12.3% 
D 90 96 13.0% 14.4% 13.4% 
D 90 120 13.6% 15.6% 14.3% 
D 90 144 13.5% 16.2% 14.6% 
D 90 168 15.9% 18.1% 16.6% 
D 90 192 15.9% 18.2% 16.7% 
D 90 216 17.0% 19.4% 17.9% 
D 90 240 17.6% 20.1% 18.5% 
D 90 264 17.6% 20.8% 18.9% 
D 90 288 18.8% 21.5% 19.8% 
D 90 312 19.4% 22.8% 20.7% 
D 90 336 20.0% 23.6% 21.4% 
D 90 360 21.2% 24.3% 22.3% 
D 90 384 21.9% 25.6% 23.3% 
D 90 408 21.9% 25.8% 23.3% 
D 90 432 21.9% 25.9% 23.4% 
D 90 456 23.7% 26.6% 24.6% 
D 90 480 23.7% 26.6% 24.7% 
D 90 504 23.7% 27.3% 25.0% 
D 90 528 24.3% 28.0% 25.6% 
D 90 552 24.2% 28.0% 25.6% 
D 90 576 25.4% 29.3% 26.8% 
D 90 600 25.3% 29.3% 26.8% 
D 90 624 25.9% 29.3% 27.1% 
D 90 648 26.4% 29.9% 27.6% 
D 90 672 27.0% 30.5% 28.2% 
D 90 696 26.9% 30.5% 28.1% 
D 90 720 28.0% 31.7% 29.3% 
D 90 744 28.0% 31.7% 29.2% 
D 90 768 28.5% 31.7% 29.5% 
D 90 792 29.0% 32.2% 30.0% 
D 90 816 28.9% 32.8% 30.2% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 90 840 29.4% 33.3% 30.7% 
D 90 864 29.8% 34.4% 31.5% 
D 90 888 29.7% 34.4% 31.4% 
D 90 912 30.8% 34.3% 31.9% 
D 90 936 30.6% 34.2% 31.8% 
5-Fu 70 0 0.0% 0.0% 0.0% 
5-Fu 70 1 0.6% 62.3% 70.0% 
5-Fu 70 5 0.7% 73.1% 76.1% 
5-Fu 70 10 0.8% 79.2% 77.1% 
5-Fu 70 24 0.8% 80.2% 77.9% 
5-Fu 70 47 0.8% 81.0% 78.7% 
5-Fu 70 72 0.8% 81.7% 79.3% 
5-Fu 80 0 0.0% 0.0% 0.0% 
5-Fu 80 1 66.1% 59.7% 75.2% 
5-Fu 80 5 68.1% 62.6% 76.4% 
5-Fu 80 10 70.0% 63.0% 79.9% 
5-Fu 80 24 71.9% 63.2% 83.5% 
5-Fu 80 47 74.9% 65.9% 87.1% 
5-Fu 80 72 72.9% 66.0% 82.9% 
5-Fu 90 0 0.0% 0.0% 0.0% 
5-Fu 90 1 62.9% 59.7% 67.5% 
5-Fu 90 5 68.6% 65.2% 73.4% 
5-Fu 90 10 70.5% 68.3% 74.2% 
5-Fu 90 24 71.1% 68.8% 75.0% 
5-Fu 90 47 70.3% 66.5% 75.6% 
5-Fu 90 72 71.9% 69.2% 76.0% 
M 70 0 0.0% 0.0% 0.0% 
M 70 1 34.6% 42.3% 28.2% 
M 70 5 36.3% 44.4% 29.6% 
M 70 10 38.0% 46.5% 31.0% 
M 70 24 46.6% 48.6% 46.5% 
M 70 47 52.1% 57.7% 48.6% 
M 70 72 61.2% 67.2% 57.7% 
M 70 96 67.2% 70.0% 67.2% 
M 70 120 69.9% 72.7% 70.0% 
M 70 144 69.2% 75.5% 65.7% 
M 70 168 71.8% 78.3% 68.1% 
M 70 192 70.9% 74.0% 70.6% 
M 70 216 73.2% 69.4% 80.0% 
M 70 240 75.6% 71.5% 82.8% 
M 70 264 74.6% 73.6% 78.6% 
M 70 288 73.3% 75.7% 73.9% 
M 70 312 75.4% 77.8% 76.0% 
M 70 336 73.9% 79.9% 71.1% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
M 70 360 75.8% 81.9% 72.8% 
M 70 384 74.2% 84.0% 67.5% 
M 70 408 75.9% 72.0% 83.0% 
M 70 432 77.6% 73.4% 85.1% 
M 70 456 75.9% 81.8% 73.0% 
M 70 480 77.4% 83.6% 74.4% 
M 70 504 75.5% 78.3% 75.8% 
M 70 528 76.9% 79.7% 77.2% 
M 70 552 78.2% 81.0% 78.6% 
M 70 576 78.5% 87.3% 73.0% 
M 80 0 0.0% 0.0% 0.0% 
M 80 1 24.4% 21.2% 28.2% 
M 80 5 25.6% 22.2% 29.6% 
M 80 10 33.8% 23.2% 45.1% 
M 80 24 37.1% 27.8% 47.2% 
M 80 47 44.0% 32.6% 56.3% 
M 80 72 49.4% 33.9% 65.8% 
M 80 96 54.9% 42.4% 68.6% 
M 80 120 57.2% 44.1% 71.4% 
M 80 144 60.8% 45.9% 77.0% 
M 80 168 61.7% 47.6% 77.1% 
M 80 192 62.2% 45.8% 79.8% 
M 80 216 64.3% 47.4% 82.6% 
M 80 240 68.2% 45.4% 92.5% 
M 80 264 70.5% 53.9% 88.5% 
M 80 288 72.7% 55.6% 91.3% 
M 80 312 71.5% 50.3% 94.1% 
M 80 336 71.8% 48.1% 96.9% 
M 80 360 73.8% 49.4% 99.7% 
M 80 384 74.0% 54.1% 95.4% 
M 80 408 75.9% 55.5% 97.8% 
M 80 432 74.3% 56.9% 93.2% 
M 80 456 76.0% 51.2% 102.3% 
M 80 480 74.2% 52.3% 97.7% 
M 80 504 74.0% 49.8% 99.8% 
M 80 528 75.5% 50.7% 101.9% 
M 80 552 75.2% 55.0% 96.9% 
M 80 576 74.9% 52.6% 98.7% 
M 90 0 0.0% 0.0% 0.0% 
M 90 1 14.0% 14.1% 14.1% 
M 90 5 21.6% 21.8% 21.8% 
M 90 10 26.2% 29.9% 22.9% 
M 90 24 27.4% 31.3% 23.9% 
M 90 47 32.1% 32.7% 32.0% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
M 90 72 36.9% 34.1% 40.5% 
M 90 96 38.5% 42.6% 35.2% 
M 90 120 40.0% 37.2% 43.6% 
M 90 144 41.6% 38.6% 45.3% 
M 90 168 43.1% 47.1% 40.0% 
M 90 192 44.7% 48.8% 41.4% 
M 90 216 46.2% 50.6% 42.8% 
M 90 240 47.8% 52.3% 44.2% 
M 90 264 49.3% 54.0% 45.6% 
M 90 288 49.1% 52.2% 47.0% 
M 90 312 48.8% 50.3% 48.4% 
M 90 336 50.2% 51.7% 49.8% 
M 90 360 49.8% 53.1% 47.6% 
M 90 384 51.1% 54.5% 48.8% 
M 90 408 54.2% 55.8% 53.6% 
M 90 432 55.5% 57.2% 55.0% 
M 90 456 53.4% 58.6% 49.3% 
M 90 480 58.1% 60.0% 57.4% 
M 90 504 56.0% 54.4% 58.8% 
M 90 528 57.2% 62.4% 53.1% 
M 90 552 58.4% 63.8% 54.2% 
M 90 576 59.6% 65.2% 55.2% 
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APPENDIX – I 
Data to perform linear regression of initial burst from SA fibers in PBS with kinetic and 
thermodynamic parameters (DRP=Drug release percentage, SRT=Square root of time, 
SRIAT=Square root of interaction of affinity and time) 
DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
3.39% 2.24 0.08 7.69% 3.08 0.44 
5.32% 3.08 0.11 8.30% 4.90 0.70 
7.84% 4.90 0.18 7.47% 6.86 0.99 
12.20% 6.86 0.25 9.06% 8.49 1.22 
13.32% 8.49 0.31 5.43% 2.24 0.32 
13.15% 9.80 0.36 6.22% 3.08 0.44 
14.69% 10.95 0.40 9.26% 4.90 0.70 
3.80% 2.24 0.08 9.93% 6.86 0.99 
7.63% 3.08 0.11 15.24% 8.49 1.22 
10.34% 4.90 0.18 1.74% 2.24 0.26 
15.84% 6.86 0.25 3.48% 3.08 0.35 
18.17% 8.49 0.31 12.27% 4.90 0.56 
19.28% 9.80 0.36 17.88% 6.86 0.79 
20.36% 10.95 0.40 27.19% 8.49 0.97 
21.99% 12.00 0.44 33.32% 9.80 1.12 
23.62% 12.96 0.48 36.10% 10.95 1.26 
23.70% 13.86 0.51 35.36% 12.00 1.38 
24.60% 14.70 0.54 37.96% 12.96 1.49 
25.77% 15.49 0.57 37.05% 13.86 1.59 
25.68% 16.25 0.60 39.48% 14.70 1.68 
26.73% 16.97 0.62 41.91% 15.49 1.78 
28.05% 17.66 0.65 1.22% 2.24 0.26 
28.75% 18.33 0.67 9.48% 3.08 0.35 
28.48% 18.97 0.70 12.81% 4.90 0.56 
30.57% 19.60 0.72 19.75% 6.86 0.79 
6.33% 2.24 0.08 25.19% 8.49 0.97 
10.34% 3.08 0.11 30.80% 9.80 1.12 
16.19% 4.90 0.18 33.06% 10.95 1.26 
21.96% 6.86 0.25 36.73% 12.00 1.38 
25.20% 8.49 0.31 37.65% 12.96 1.49 
27.45% 9.80 0.36 38.15% 13.86 1.59 
29.27% 10.95 0.40 40.32% 14.70 1.68 
30.50% 12.00 0.44 44.25% 15.49 1.78 
32.92% 12.96 0.48 46.51% 16.25 1.86 
33.54% 13.86 0.51 48.77% 16.97 1.95 
33.35% 14.70 0.54 47.51% 17.66 2.02 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
35.97% 15.49 0.57 7.75% 2.24 0.26 
36.51% 16.25 0.60 12.32% 3.08 0.35 
37.45% 16.97 0.62 13.53% 4.90 0.56 
38.51% 17.66 0.65 18.28% 6.86 0.79 
39.09% 18.33 0.67 23.19% 8.49 0.97 
39.63% 18.97 0.70 24.76% 9.80 1.12 
40.58% 19.60 0.72 26.32% 10.95 1.26 
41.20% 20.20 0.74 27.89% 12.00 1.38 
41.02% 20.78 0.76 29.45% 12.96 1.49 
42.45% 21.35 0.78 31.01% 13.86 1.59 
42.66% 21.91 0.81 32.58% 14.70 1.68 
42.82% 22.45 0.83 34.14% 15.49 1.78 
43.38% 22.98 0.84 35.71% 16.25 1.86 
43.61% 23.49 0.86 35.51% 16.97 1.95 
44.40% 24.00 0.88 35.22% 17.66 2.02 
44.72% 24.49 0.90 36.61% 18.33 2.10 
45.16% 24.98 0.92 36.24% 18.97 2.17 
45.26% 25.46 0.94 37.55% 19.60 2.25 
45.62% 25.92 0.95 40.61% 20.20 2.32 
45.95% 26.38 0.97 42.00% 20.78 2.38 
46.40% 26.83 0.99 39.87% 21.35 2.45 
46.53% 27.28 1.00 44.61% 21.91 2.51 
46.46% 27.71 1.02 42.47% 22.45 2.57 
47.12% 28.14 1.03 43.69% 22.98 2.63 
47.46% 28.57 1.05 44.91% 23.49 2.69 
47.47% 28.98 1.07 46.12% 24.00 2.75 
48.05% 29.39 1.08 46.47% 24.49 2.81 
48.48% 29.80 1.10 46.47% 24.98 2.86 
48.58% 30.20 1.11 47.86% 25.46 2.92 
48.20% 30.59 1.12 47.51% 25.92 2.97 
1.68% 2.24 0.08 47.86% 26.38 3.02 
3.13% 3.08 0.11 48.56% 26.83 3.08 
6.16% 4.90 0.18 49.95% 27.28 3.13 
7.81% 6.86 0.25 50.64% 27.71 3.18 
9.51% 8.49 0.31 50.30% 28.14 3.23 
10.66% 9.80 0.36 51.69% 28.57 3.27 
11.54% 10.95 0.40 53.42% 28.98 3.32 
11.82% 12.00 0.44 55.16% 29.39 3.37 
13.92% 12.96 0.48 57.94% 29.80 3.42 
13.96% 13.86 0.51 59.68% 30.20 3.46 
15.19% 14.70 0.54 60.03% 30.59 3.51 
15.84% 15.49 0.57 9.86% 2.24 0.26 
16.18% 16.25 0.60 14.86% 3.08 0.35 
17.12% 16.97 0.62 18.28% 4.90 0.56 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
18.07% 17.66 0.65 21.78% 6.86 0.79 
18.73% 18.33 0.67 25.37% 8.49 0.97 
19.70% 18.97 0.70 27.28% 9.80 1.12 
20.69% 19.60 0.72 27.43% 10.95 1.26 
20.77% 20.20 0.74 29.25% 12.00 1.38 
20.82% 20.78 0.76 29.32% 12.96 1.49 
22.06% 21.35 0.78 31.05% 13.86 1.59 
22.12% 21.91 0.81 31.03% 14.70 1.68 
22.44% 22.45 0.83 32.68% 15.49 1.78 
23.06% 22.98 0.84 34.33% 16.25 1.86 
23.07% 23.49 0.86 35.98% 16.97 1.95 
24.26% 24.00 0.88 37.63% 17.66 2.02 
24.27% 24.49 0.90 37.52% 18.33 2.10 
24.55% 24.98 0.92 39.97% 18.97 2.17 
25.13% 25.46 0.94 38.93% 19.60 2.25 
25.70% 25.92 0.95 38.65% 20.20 2.32 
25.66% 26.38 0.97 41.80% 20.78 2.38 
26.81% 26.83 0.99 39.75% 21.35 2.45 
26.77% 27.28 1.00 41.05% 21.91 2.51 
27.01% 27.71 1.02 42.36% 22.45 2.57 
27.54% 28.14 1.03 43.66% 22.98 2.63 
27.76% 28.57 1.05 43.20% 23.49 2.69 
28.27% 28.98 1.07 44.42% 24.00 2.75 
29.09% 29.39 1.08 30.33% 24.49 2.81 
29.01% 29.80 1.10 31.20% 24.98 2.86 
29.50% 30.20 1.11 32.24% 25.46 2.92 
29.39% 30.59 1.12 33.11% 25.92 2.97 
8.46% 2.24 0.32 33.98% 26.38 3.02 
11.97% 3.08 0.44 34.33% 26.83 3.08 
12.90% 4.90 0.70 35.02% 27.28 3.13 
13.69% 6.86 0.99 36.24% 27.71 3.18 
14.36% 8.49 1.22 36.76% 28.14 3.23 
2.03% 2.24 0.32 37.63% 28.57 3.27 
4.00% 3.08 0.44 37.98% 28.98 3.32 
5.90% 4.90 0.70 38.67% 29.39 3.37 
9.03% 6.86 0.99 39.72% 29.80 3.42 
6.97% 8.49 1.22 40.41% 30.20 3.46 
5.73% 2.24 0.32 40.76% 30.59 3.51 
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APPENDIX – G 
Data for effect of temperatures on sorption rates of Diclofenac, 5-Fu and Metformin on 
WG fibers (DCF=Drug concentration on fibers, R=Repetition, D=Diclofenac, 
M=Metformin, DLT=Drug loading temperature) 
Drug DLT (°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
D 50 240 21.11 19.66 21.73 
D 50 180 21.09 20.21 21.14 
D 50 150 20.05 19.36 19.96 
D 50 120 19.74 19.69 19.03 
D 50 90 20.79 19.70 21.06 
D 50 60 20.68 19.96 20.59 
D 50 30 17.28 16.66 17.22 
D 50 15 15.94 14.50 16.74 
D 50 10 14.65 13.02 15.70 
D 50 5 11.60 11.92 10.82 
D 50 3 10.09 9.72 10.06 
D 50 1 9.60 9.01 9.81 
D 70 240 30.51 31.70 31.73 
D 70 180 29.43 31.16 30.90 
D 70 150 29.51 30.14 30.42 
D 70 120 28.54 26.95 28.30 
D 70 90 26.06 27.40 27.26 
D 70 60 25.12 26.02 26.08 
D 70 30 23.00 22.35 23.13 
D 70 15 22.14 21.20 22.10 
D 70 10 20.52 21.49 21.43 
D 70 5 15.85 15.23 15.85 
D 70 3 14.74 14.66 14.99 
D 70 1 10.96 13.66 12.56 
D 90 240 37.15 33.57 39.28 
D 90 180 34.66 34.07 33.89 
D 90 150 36.42 35.04 36.37 
D 90 120 36.35 34.00 37.27 
D 90 90 34.28 30.61 36.59 
D 90 60 33.07 30.73 34.11 
D 90 30 33.73 32.49 33.65 
D 90 15 31.23 28.28 32.96 
D 90 10 30.92 28.82 31.81 
D 90 5 27.86 26.16 28.46 
D 90 3 22.75 22.07 22.53 
D 90 1 15.82 14.02 17.00 
152 
 
Drug DLT (°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
5-Fu 50 240 1.19 1.30 1.11 
5-Fu 50 180 1.14 1.14 1.15 
5-Fu 50 150 1.19 1.23 1.17 
5-Fu 50 120 1.12 1.11 1.15 
5-Fu 50 90 1.11 1.17 1.07 
5-Fu 50 60 1.13 1.11 1.17 
5-Fu 50 30 1.12 1.23 1.03 
5-Fu 50 15 1.16 1.20 1.13 
5-Fu 50 10 1.10 1.17 1.05 
5-Fu 50 5 0.87 0.93 0.82 
5-Fu 50 3 0.59 0.65 0.54 
5-Fu 50 1 0.38 0.43 0.33 
5-Fu 70 240 1.42 1.36 1.38 
5-Fu 70 180 1.38 1.51 1.43 
5-Fu 70 150 1.42 1.34 1.37 
5-Fu 70 120 1.46 1.42 1.43 
5-Fu 70 90 1.48 1.40 1.43 
5-Fu 70 60 1.40 1.52 1.45 
5-Fu 70 30 1.42 1.30 1.35 
5-Fu 70 15 1.40 1.40 1.39 
5-Fu 70 10 1.32 1.34 1.31 
5-Fu 70 5 1.28 1.44 1.34 
5-Fu 70 3 1.07 1.26 1.15 
5-Fu 70 1 0.54 0.80 0.66 
5-Fu 90 240 0.52 0.58 0.47 
5-Fu 90 180 0.50 0.45 0.56 
5-Fu 90 150 0.51 0.56 0.47 
5-Fu 90 120 0.54 0.49 0.60 
5-Fu 90 90 0.51 0.47 0.56 
5-Fu 90 60 0.53 0.49 0.58 
5-Fu 90 30 0.50 0.47 0.54 
5-Fu 90 15 0.54 0.51 0.58 
5-Fu 90 10 0.51 0.49 0.54 
5-Fu 90 5 0.48 0.45 0.51 
5-Fu 90 3 0.44 0.39 0.49 
5-Fu 90 1 0.30 0.35 0.25 
M 50 240 1.67 1.54 1.82 
M 50 180 1.47 1.44 1.53 
M 50 150 1.40 1.34 1.49 
M 50 120 1.45 1.57 1.35 
M 50 90 1.35 1.26 1.47 
M 50 60 1.38 1.60 1.18 
M 50 30 1.38 1.51 1.26 
M 50 15 1.06 1.21 0.93 
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Drug DLT (°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
M 50 10 0.82 0.63 1.03 
M 50 5 0.62 0.56 0.69 
M 50 3 0.55 0.51 0.59 
M 50 1 0.29 0.24 0.35 
M 70 240 1.89 2.16 2.01 
M 70 180 2.08 1.88 1.96 
M 70 150 1.78 2.21 1.97 
M 70 120 2.19 1.78 1.97 
M 70 90 1.86 2.35 2.08 
M 70 60 2.28 1.76 2.00 
M 70 30 1.88 2.02 1.93 
M 70 15 1.73 2.00 1.85 
M 70 10 1.88 1.36 1.60 
M 70 5 1.49 1.23 1.35 
M 70 3 0.99 0.64 0.81 
M 70 1 0.37 0.55 0.45 
M 90 240 2.80 2.67 3.00 
M 90 180 2.72 2.41 3.09 
M 90 150 2.98 3.38 2.63 
M 90 120 2.58 2.54 2.68 
M 90 90 2.78 2.63 3.00 
M 90 60 2.47 2.24 2.74 
M 90 30 2.58 2.70 2.50 
M 90 15 2.45 2.39 2.56 
M 90 10 1.99 1.76 2.26 
M 90 5 1.34 1.23 1.47 
M 90 3 0.93 0.81 1.07 
M 90 1 0.65 0.81 0.50 
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APPENDIX – K 
Data for isotherms of Diclofenac, 5-Fu and Metformin on WG fibers (DCF=Drug 
concentration on fibers, DCS=Drug concentration in solution, R=Repetition, 
D=Diclofenac, M=Metformin, DLT=Drug loading temperature) 
Drug DLT(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
D 50 0.03 0.02 0.03 1.50 1.83 1.11 
D 50 0.00 0.01 0.02 2.44 2.84 1.94 
D 50 0.03 0.03 0.02 2.33 2.52 2.05 
D 50 0.05 0.02 0.02 5.50 4.85 5.93 
D 50 0.11 0.05 0.05 14.31 13.91 14.16 
D 50 0.33 0.31 0.25 18.05 16.68 18.72 
D 50 0.83 0.75 0.78 19.04 18.87 18.47 
D 50 2.34 2.16 2.15 21.33 19.59 22.25 
D 50 4.89 4.60 4.57 21.46 20.09 21.99 
D 50 9.99 9.39 9.34 21.24 19.30 22.35 
D 70 0.05 0.04 0.05 1.36 1.44 1.22 
D 70 0.03 0.03 0.00 2.24 1.65 2.73 
D 70 0.03 0.04 0.03 2.33 2.05 2.52 
D 70 0.03 0.03 0.04 6.42 5.14 7.44 
D 70 0.06 0.05 0.12 13.86 13.33 13.84 
D 70 0.20 0.21 0.33 18.33 18.26 17.68 
D 70 0.62 0.69 0.82 20.11 20.52 18.90 
D 70 2.04 2.08 2.32 22.64 23.29 21.10 
D 70 4.49 4.48 4.85 24.63 26.31 21.99 
D 70 9.07 9.21 9.93 26.74 26.95 25.48 
D 90 0.04 0.04 0.04 2.05 2.19 1.83 
D 90 0.03 0.04 0.04 3.30 3.13 3.34 
D 90 0.04 0.04 0.01 4.40 4.24 4.38 
D 90 0.04 0.04 0.03 7.59 7.58 7.30 
D 90 0.06 0.05 0.08 17.91 16.89 18.22 
D 90 0.25 0.25 0.23 28.06 28.14 26.88 
D 90 0.66 0.64 0.71 30.96 29.11 31.59 
D 90 2.05 2.06 2.21 34.35 34.50 32.85 
D 90 4.49 4.39 4.75 34.90 33.64 34.79 
D 90 9.19 9.17 9.83 37.28 37.27 35.83 
5-Fu 50 0.26 0.23 0.28 0.42 0.56 0.27 
5-Fu 50 0.49 0.44 0.52 0.67 0.60 0.72 
5-Fu 50 2.26 2.20 2.22 0.98 0.86 1.05 
5-Fu 50 4.55 4.39 4.54 1.15 1.15 1.11 
5-Fu 50 7.22 6.92 7.24 1.32 1.21 1.38 
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Drug DLT(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
5-Fu 50 9.53 9.14 9.54 1.45 1.34 1.50 
5-Fu 50 12.09 11.70 12.01 1.47 1.48 1.40 
5-Fu 50 13.84 13.42 13.72 1.56 1.65 1.42 
5-Fu 70 0.30 0.28 0.30 0.23 0.29 0.26 
5-Fu 70 0.49 0.52 0.52 0.35 0.41 0.39 
5-Fu 70 2.24 2.20 2.26 0.56 0.58 0.58 
5-Fu 70 4.48 4.50 4.58 0.86 0.74 0.82 
5-Fu 70 6.84 6.84 6.97 0.86 1.03 0.97 
5-Fu 70 9.11 9.48 9.48 1.11 1.05 1.10 
5-Fu 70 13.20 13.39 13.56 1.32 1.11 1.24 
5-Fu 70 16.57 16.73 16.98 1.38 1.21 1.32 
5-Fu 90 0.29 0.29 0.28 0.17 0.06 0.27 
5-Fu 90 0.51 0.50 0.50 0.24 0.25 0.23 
5-Fu 90 2.28 2.22 2.25 0.46 0.54 0.37 
5-Fu 90 4.62 4.49 4.57 0.65 0.74 0.54 
5-Fu 90 7.03 6.86 6.92 0.81 0.88 0.70 
5-Fu 90 9.56 9.48 9.27 0.92 0.80 1.01 
5-Fu 90 14.54 14.00 14.52 1.13 1.21 1.01 
5-Fu 90 14.34 15.68 12.44 1.20 1.15 1.19 
M 50 0.24 0.23 0.25 0.49 0.39 0.57 
M 50 0.48 0.48 0.46 0.77 0.67 0.83 
M 50 2.33 2.35 2.22 1.44 1.35 1.48 
M 50 4.75 4.71 4.60 1.78 1.66 1.84 
M 50 7.49 7.36 7.34 2.15 2.28 1.94 
M 50 9.98 9.79 9.78 2.46 2.36 2.46 
M 50 14.33 14.08 14.02 2.89 2.77 2.90 
M 50 19.95 19.51 19.61 3.12 2.88 3.24 
M 70 0.24 0.25 0.25 0.67 0.75 0.57 
M 70 0.47 0.45 0.47 1.26 1.14 1.32 
M 70 2.33 2.32 2.37 1.63 1.45 1.74 
M 70 4.68 4.65 4.76 2.13 1.94 2.23 
M 70 7.25 7.23 7.38 2.59 2.28 2.80 
M 70 9.62 9.71 9.86 2.91 2.59 3.11 
M 70 14.09 14.16 14.41 3.09 2.93 3.13 
M 70 19.30 19.43 19.75 3.33 3.03 3.50 
M 90 0.26 0.25 0.25 0.98 0.83 1.09 
M 90 0.49 0.48 0.48 1.47 1.37 1.50 
M 90 2.36 2.34 2.28 1.93 1.84 1.94 
M 90 4.75 4.75 4.56 2.37 2.25 2.38 
M 90 7.41 7.09 7.44 2.83 2.88 2.67 
M 90 10.05 9.91 9.80 3.26 3.26 3.13 
M 90 14.64 14.11 14.59 3.51 3.55 3.34 
M 90 16.69 16.44 16.29 3.78 3.76 3.65 
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APPENDIX – L 
Data for Diclofenac, 5-Fu and Metformin release from WG fibers in PBS (DLT=Drug 
loading temperature, DRP=Drug release percentage, R=Repetition, D=Diclofenac, 
M=Metformin) 
Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 50 0 0.00% 0.00% 0.00% 
D 50 1 78.44% 81.02% 77.44% 
D 50 5 81.96% 84.66% 80.91% 
D 50 10 83.71% 85.92% 83.18% 
D 50 24 84.78% 87.06% 84.21% 
D 50 48 88.09% 89.28% 88.69% 
D 50 72 89.64% 91.43% 89.65% 
D 50 96 90.51% 89.96% 92.88% 
D 50 120 91.85% 96.58% 88.97% 
D 50 144 92.51% 98.62% 88.27% 
D 50 168 93.65% 95.84% 93.35% 
D 50 192 94.11% 95.14% 94.98% 
D 50 216 94.46% 93.08% 97.74% 
D 50 240 95.28% 94.35% 98.12% 
D 50 264 95.42% 95.57% 97.19% 
D 70 0 0.00% 0.00% 0.00% 
D 70 1 73.21% 70.85% 71.31% 
D 70 5 76.03% 73.56% 74.05% 
D 70 10 78.03% 75.44% 75.97% 
D 70 24 80.74% 78.03% 78.59% 
D 70 48 81.83% 83.73% 81.95% 
D 70 72 83.59% 83.24% 82.58% 
D 70 96 88.43% 80.21% 83.47% 
D 70 120 83.10% 86.30% 83.86% 
D 70 144 86.80% 85.47% 85.28% 
D 70 168 86.60% 83.66% 84.28% 
D 70 192 92.55% 79.25% 85.04% 
D 70 216 89.20% 85.52% 86.48% 
D 70 240 95.77% 77.02% 85.53% 
D 70 264 95.46% 79.79% 86.75% 
D 90 0 0.00% 0.00% 0.00% 
D 90 1 64.83% 67.01% 63.96% 
D 90 5 66.02% 69.30% 64.07% 
D 90 10 66.60% 70.52% 64.03% 
D 90 24 67.56% 71.64% 64.85% 
D 90 48 70.44% 76.73% 65.57% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 90 72 72.31% 78.87% 67.21% 
D 90 96 75.63% 77.91% 74.89% 
D 90 120 74.97% 78.78% 72.67% 
D 90 144 77.14% 73.46% 82.38% 
D 90 168 75.77% 75.86% 77.21% 
D 90 192 77.72% 75.22% 81.79% 
D 90 216 80.15% 78.49% 83.43% 
D 90 240 82.07% 81.81% 84.00% 
D 90 264 83.47% 84.16% 84.47% 
5-Fu 50 0 0.00% 0.00% 0.00% 
5-Fu 50 1 35.26% 35.62% 35.62% 
5-Fu 50 5 41.41% 46.28% 37.37% 
5-Fu 50 10 47.77% 48.47% 48.03% 
5-Fu 50 24 54.35% 59.57% 50.23% 
5-Fu 50 48 65.56% 71.11% 61.33% 
5-Fu 50 72 68.38% 74.18% 63.96% 
5-Fu 50 96 80.02% 86.16% 75.50% 
5-Fu 50 120 87.69% 89.67% 87.48% 
5-Fu 50 144 91.16% 93.18% 90.99% 
5-Fu 50 168 94.64% 87.79% 103.40% 
5-Fu 70 0 0.00% 0.00% 0.00% 
5-Fu 70 1 44.52% 57.88% 50.69% 
5-Fu 70 5 64.52% 56.28% 59.80% 
5-Fu 70 10 72.05% 63.36% 67.03% 
5-Fu 70 24 79.79% 70.67% 74.48% 
5-Fu 70 48 83.31% 78.19% 79.94% 
5-Fu 70 72 86.82% 85.94% 85.51% 
5-Fu 70 96 90.33% 85.00% 86.79% 
5-Fu 70 120 84.94% 92.74% 87.95% 
5-Fu 70 144 105.82% 82.90% 93.41% 
5-Fu 70 168 91.96% 94.66% 92.37% 
5-Fu 90 0 0.00% 0.00% 0.00% 
5-Fu 90 1 59.50% 62.33% 57.88% 
5-Fu 90 5 60.23% 65.40% 56.28% 
5-Fu 90 10 65.26% 64.02% 67.82% 
5-Fu 90 24 72.60% 75.78% 70.89% 
5-Fu 90 48 80.16% 87.98% 73.96% 
5-Fu 90 72 81.32% 78.35% 85.94% 
5-Fu 90 96 80.18% 90.33% 71.64% 
5-Fu 90 120 81.01% 80.48% 83.18% 
5-Fu 90 144 83.95% 87.79% 81.80% 
5-Fu 90 168 84.68% 86.41% 84.65% 
M 50 0 0.00% 0.00% 0.00% 
M 50 1 75.35% 74.24% 79.54% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
M 50 5 81.49% 82.85% 83.46% 
M 50 10 83.16% 86.75% 82.96% 
M 50 24 89.31% 95.60% 86.67% 
M 50 48 90.73% 94.80% 90.37% 
M 50 72 92.30% 98.70% 89.65% 
M 50 96 93.49% 97.66% 93.14% 
M 50 120 94.83% 101.32% 92.21% 
M 50 144 97.96% 100.03% 99.89% 
M 50 168 97.01% 103.45% 94.54% 
M 50 192 102.35% 106.86% 102.01% 
M 70 0 0.00% 0.00% 0.00% 
M 70 1 63.05% 69.29% 59.39% 
M 70 5 75.86% 87.55% 67.27% 
M 70 10 81.87% 91.70% 75.39% 
M 70 24 85.58% 90.90% 83.75% 
M 70 48 89.28% 94.80% 87.41% 
M 70 72 92.99% 93.76% 96.02% 
M 70 96 91.85% 92.47% 94.98% 
M 70 120 95.31% 95.88% 98.63% 
M 70 144 98.78% 104.25% 97.35% 
M 70 168 97.40% 98.01% 100.76% 
M 70 192 98.20% 101.18% 99.23% 
M 90 0 0.00% 0.00% 0.00% 
M 90 1 50.93% 54.44% 49.49% 
M 90 5 58.29% 62.07% 56.88% 
M 90 10 61.04% 65.00% 59.56% 
M 90 24 63.79% 67.93% 62.25% 
M 90 48 66.54% 75.81% 59.98% 
M 90 72 69.29% 78.98% 62.42% 
M 90 96 72.04% 82.15% 64.86% 
M 90 120 74.79% 90.27% 62.35% 
M 90 144 77.53% 93.69% 64.55% 
M 90 168 80.28% 97.10% 66.74% 
M 90 192 83.03% 100.52% 68.94% 
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APPENDIX – M 
Data for Diclofenac, 5-Fu and Metformin release from WG fibers in AGJ (DLT=Drug 
loading temperature, DRP=Drug release percentage, R=Repetition, D=Diclofenac, 
M=Metformin) 
Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 50 0 0.00% 0.00% 0.00% 
D 50 1 12.11% 13.34% 11.12% 
D 50 2 13.32% 12.45% 14.45% 
D 50 4 15.63% 15.79% 15.79% 
D 50 6 17.50% 18.23% 17.12% 
D 50 8 17.78% 16.34% 19.57% 
D 50 12 19.59% 20.79% 18.79% 
D 50 16 19.26% 20.01% 18.90% 
D 50 24 20.42% 22.35% 18.90% 
D 70 0 0.00% 0.00% 0.00% 
D 70 1 10.42% 10.42% 10.32% 
D 70 2 11.46% 11.46% 11.35% 
D 70 4 14.49% 14.49% 14.35% 
D 70 6 15.24% 15.24% 15.08% 
D 70 8 14.94% 14.94% 14.79% 
D 70 12 16.48% 15.98% 16.07% 
D 70 16 17.07% 16.53% 16.63% 
D 70 24 18.11% 17.02% 17.39% 
D 90 0 0.00% 0.00% 0.00% 
D 90 1 14.41% 14.89% 14.22% 
D 90 2 16.86% 17.06% 16.99% 
D 90 4 20.74% 20.65% 21.26% 
D 90 6 22.52% 22.41% 23.09% 
D 90 8 22.95% 23.49% 22.88% 
D 90 12 24.26% 25.18% 23.83% 
D 90 16 24.53% 25.52% 24.03% 
D 90 24 26.00% 27.08% 25.45% 
5-Fu 50 0 0.00% 0.00% 0.00% 
5-Fu 50 1 16.57% 25.11% 8.37% 
5-Fu 50 2 26.51% 35.99% 17.57% 
5-Fu 50 4 37.28% 47.70% 27.62% 
5-Fu 50 6 48.88% 51.89% 46.87% 
5-Fu 50 8 53.03% 56.07% 51.05% 
5-Fu 50 12 65.45% 68.63% 63.60% 
5-Fu 50 16 70.42% 73.65% 68.63% 
5-Fu 50 24 75.40% 78.67% 73.65% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
5-Fu 70 0 0.00% 0.00% 0.00% 
5-Fu 70 1 48.16% 41.84% 55.44% 
5-Fu 70 2 56.77% 51.61% 63.08% 
5-Fu 70 4 63.35% 59.14% 68.83% 
5-Fu 70 6 66.26% 61.37% 72.50% 
5-Fu 70 8 73.08% 71.69% 75.95% 
5-Fu 70 12 75.41% 74.20% 78.14% 
5-Fu 70 16 77.97% 76.44% 81.07% 
5-Fu 70 24 82.70% 81.18% 85.89% 
5-Fu 90 0 0.00% 0.00% 0.00% 
5-Fu 90 1 55.63% 62.17% 50.21% 
5-Fu 90 2 61.98% 67.19% 58.02% 
5-Fu 90 4 66.44% 70.90% 63.32% 
5-Fu 90 6 71.37% 75.56% 68.63% 
5-Fu 90 8 75.65% 78.91% 73.93% 
5-Fu 90 12 79.22% 80.82% 79.23% 
5-Fu 90 16 80.25% 85.96% 76.16% 
5-Fu 90 24 83.82% 88.71% 80.62% 
M 50 0 0.00% 0.00% 0.00% 
M 50 1 23.70% 19.15% 28.72% 
M 50 2 31.60% 28.08% 35.74% 
M 50 4 43.60% 45.96% 42.13% 
M 50 6 53.71% 60.00% 48.51% 
M 50 8 61.29% 62.55% 61.28% 
M 50 12 72.04% 70.21% 75.32% 
M 50 16 77.09% 77.87% 77.87% 
M 50 24 87.84% 85.53% 91.91% 
M 70 0 0.00% 0.00% 0.00% 
M 70 1 18.96% 28.72% 9.57% 
M 70 2 22.75% 24.89% 21.06% 
M 70 4 32.61% 38.30% 27.57% 
M 70 6 41.71% 52.08% 32.17% 
M 70 8 47.77% 59.74% 36.77% 
M 70 12 57.63% 59.74% 56.68% 
M 70 16 64.45% 65.87% 64.34% 
M 70 24 78.86% 87.32% 72.00% 
M 90 0 0.00% 0.00% 0.00% 
M 90 1 15.32% 7.66% 11.37% 
M 90 2 18.38% 16.85% 17.44% 
M 90 4 29.11% 19.91% 24.27% 
M 90 6 26.04% 30.64% 28.06% 
M 90 8 36.77% 35.23% 35.64% 
M 90 12 49.02% 39.83% 43.98% 
M 90 16 62.81% 44.42% 53.08% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
M 90 24 78.13% 64.34% 70.52% 
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APPENDIX – N 
Data to perform linear regression of initial burst from WG fibers in PBS and in AGJ with 
kinetic and thermodynamic parameters (IBPBS=Initial burst in PBS, IBAGJ=Initial burst 
in AGJ, C=Concentration, A×C=Interaction between affinity and concentration) 
Drug T (°C) IBPBS (%) C (mol/kg) A×C 
D 50 79.2% 6.60E-02 2.50E+00 
D 70 72.0% 6.60E-02 2.82E+00 
D 90 65.5% 6.60E-02 3.05E+00 
D 90 72.2% 1.04E-01 4.79E+00 
5-Fu 50 60.1% 5.38E-03 5.30E-02 
5-Fu 70 51.2% 5.38E-03 5.73E-02 
5-Fu 90 35.6% 5.38E-03 6.15E-02 
5-Fu 90 49.9% 1.08E-02 1.23E-01 
M 50 76.9% 1.21E-02 2.40E-01 
M 70 64.3% 1.21E-02 3.25E-01 
M 90 52.0% 1.21E-02 3.71E-01 
M 90 62.8% 2.42E-02 7.43E-01 
 
Drug T (°C) IBAGJ (%) C (mol/kg) A×C 
D 50 0.15 6.60E-02 2.50E+00 
D 70 0.12 6.60E-02 2.82E+00 
D 90 0.10 6.60E-02 3.05E+00 
D 90 0.15 1.04E-01 4.79E+00 
5-Fu 90 0.56 5.38E-03 5.30E-02 
5-Fu 70 0.49 5.38E-03 5.73E-02 
5-Fu 50 0.17 5.38E-03 6.15E-02 
5-Fu 50 0.31 1.08E-02 1.23E-01 
M 50 0.24 1.21E-02 2.40E-01 
M 70 0.19 1.21E-02 3.25E-01 
M 90 0.11 1.21E-02 3.71E-01 
M 90 0.22 2.42E-02 7.43E-01 
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APPENDIX – O 
Data to perform linear regression of drug release after burst from WG fibers in PBS with 
kinetic and thermodynamic parameters (DRP=Drug release percentage, SRT=Square root 
of time, SRIAT=Square root of interaction of affinity and time) 
DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
3.55% 1.00 0.01 29.55% 4.90 1.01 
5.32% 2.24 0.01 35.18% 6.93 1.42 
6.40% 3.16 0.02 36.46% 8.49 1.74 
9.75% 4.90 0.03 37.64% 9.80 2.01 
11.31% 6.93 0.04 43.16% 10.95 2.25 
12.19% 8.49 0.05 42.11% 12.00 2.46 
13.54% 9.80 0.06 6.21% 1.00 0.21 
14.22% 10.95 0.07 12.64% 2.24 0.46 
15.37% 12.00 0.07 19.28% 3.16 0.65 
15.83% 12.96 0.08 30.60% 4.90 1.01 
16.18% 13.86 0.08 33.45% 6.93 1.42 
17.01% 14.70 0.09 45.21% 8.49 1.74 
17.15% 15.49 0.09 52.96% 9.80 2.01 
2.76% 1.00 0.01 56.47% 10.95 2.25 
4.70% 2.24 0.01 59.98% 12.00 2.46 
7.35% 3.16 0.02 6.02% 1.00 0.21 
10.75% 4.90 0.03 8.65% 2.24 0.46 
11.39% 6.93 0.04 16.63% 3.16 0.65 
12.28% 8.49 0.05 24.87% 4.90 1.01 
12.67% 9.80 0.06 29.81% 6.93 1.42 
14.11% 10.95 0.07 38.40% 8.49 1.74 
13.10% 12.00 0.07 40.13% 9.80 2.01 
13.87% 12.96 0.08 43.56% 10.95 2.25 
15.33% 13.86 0.08 46.98% 12.00 2.46 
14.36% 14.70 0.09 6.27% 1.00 0.04 
15.59% 15.49 0.09 7.97% 2.24 0.09 
1.20% 1.00 0.01 14.25% 3.16 0.12 
1.79% 2.24 0.01 15.70% 4.90 0.19 
2.76% 3.16 0.02 17.29% 6.93 0.27 
5.66% 4.90 0.03 18.51% 8.49 0.33 
7.55% 6.93 0.04 19.88% 9.80 0.39 
10.91% 8.49 0.05 23.07% 10.95 0.43 
10.24% 9.80 0.06 22.11% 12.00 0.47 
12.43% 10.95 0.07 27.55% 12.96 0.51 
11.05% 12.00 0.07 13.07% 1.00 0.04 
13.02% 12.96 0.08 19.20% 2.24 0.09 
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DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
15.47% 13.86 0.08 22.99% 3.16 0.12 
17.42% 14.70 0.09 26.77% 4.90 0.19 
18.83% 15.49 0.09 30.55% 6.93 0.27 
1.26% 1.00 0.01 29.38% 8.49 0.33 
1.25% 2.24 0.01 32.92% 9.80 0.39 
2.23% 3.16 0.02 36.46% 10.95 0.43 
7.69% 4.90 0.03 35.05% 12.00 0.47 
8.38% 6.93 0.04 35.87% 12.96 0.51 
10.67% 8.49 0.05 7.51% 1.00 0.04 
15.21% 9.80 0.06 10.32% 2.24 0.09 
16.95% 10.95 0.07 13.12% 3.16 0.12 
16.89% 12.00 0.07 15.93% 4.90 0.19 
16.10% 12.96 0.08 18.73% 6.93 0.27 
15.70% 13.86 0.08 21.54% 8.49 0.33 
16.01% 14.70 0.09 24.35% 9.80 0.39 
15.92% 15.49 0.09 27.15% 10.95 0.43 
0.74% 1.00 0.21 29.96% 12.00 0.47 
5.82% 2.24 0.46 32.76% 12.96 0.51 
13.23% 3.16 0.65 2.48% 1.00 0.04 
20.87% 4.90 1.01 7.71% 2.24 0.09 
22.04% 6.93 1.42 10.57% 3.16 0.12 
20.88% 8.49 1.74 15.27% 4.90 0.19 
21.73% 9.80 2.01 19.12% 6.93 0.27 
24.69% 10.95 2.25 19.91% 8.49 0.33 
25.43% 12.00 2.46 21.82% 9.80 0.39 
9.20% 1.00 0.21 23.66% 10.95 0.43 
16.51% 2.24 0.46 25.13% 12.00 0.47 
24.03% 3.16 0.65 28.08% 12.96 0.51 
 
  
165 
 
APPENDIX – P 
Data to perform linear regression of drug release after burst from WG fibers in AGJ with 
kinetic and thermodynamic parameters (DRP=Drug release percentage, SRT=Square root 
of time, SRIAT=Square root of interaction of affinity and time) 
DRP (%) SRT SRIAT DRP (%) SRT SRIAT 
2.19% 1.41 0.01 10.04% 1.41 0.29 
3.75% 2.00 0.01 20.92% 2.00 0.41 
4.60% 2.45 0.01 32.64% 2.45 0.50 
5.38% 2.83 0.02 36.82% 2.83 0.58 
6.79% 3.46 0.02 49.38% 3.46 0.71 
7.50% 4.00 0.02 54.40% 4.00 0.82 
9.55% 4.90 0.03 59.42% 4.90 1.01 
1.22% 1.41 0.01 7.32% 1.41 0.29 
3.56% 2.00 0.01 15.06% 2.00 0.41 
5.45% 2.45 0.01 19.04% 2.45 0.50 
5.73% 2.83 0.02 27.20% 2.83 0.58 
7.56% 3.46 0.02 31.59% 3.46 0.71 
7.23% 4.00 0.02 35.99% 4.00 0.82 
8.39% 4.90 0.03 38.29% 4.90 1.01 
1.04% 1.41 0.01 7.98% 1.41 0.06 
4.07% 2.00 0.01 20.11% 2.00 0.08 
4.81% 2.45 0.01 30.32% 2.45 0.10 
4.52% 2.83 0.02 37.98% 2.83 0.11 
5.81% 3.46 0.02 48.83% 3.46 0.14 
6.38% 4.00 0.02 53.94% 4.00 0.16 
7.15% 4.90 0.03 64.79% 4.90 0.19 
2.47% 1.41 0.01 3.83% 1.41 0.06 
6.40% 2.00 0.01 13.79% 2.00 0.08 
8.19% 2.45 0.01 22.98% 2.45 0.10 
8.63% 2.83 0.02 29.11% 2.83 0.11 
9.95% 3.46 0.02 39.06% 3.46 0.14 
10.22% 4.00 0.02 45.96% 4.00 0.16 
11.71% 4.90 0.03 60.51% 4.90 0.19 
6.42% 1.41 0.29 6.13% 1.41 0.06 
10.92% 2.00 0.41 13.02% 2.00 0.08 
15.90% 2.45 0.50 16.85% 2.45 0.10 
20.22% 2.83 0.58 24.51% 2.83 0.11 
23.83% 3.46 0.71 32.94% 3.46 0.14 
24.87% 4.00 0.82 42.13% 4.00 0.16 
28.47% 4.90 1.01 59.74% 4.90 0.19 
8.70% 1.41 0.29 6.41% 1.41 0.06 
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DRPAGJ (%) SRT SRIAT DRP (%) SRT SRIAT 
15.34% 2.00 0.41 14.52% 2.00 0.08 
18.29% 2.45 0.50 20.37% 2.45 0.10 
25.18% 2.83 0.58 25.27% 2.83 0.11 
27.53% 3.46 0.71 34.31% 3.46 0.14 
30.11% 4.00 0.82 37.71% 4.00 0.16 
34.89% 4.90 1.01 47.50% 4.90 0.19 
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APPENDIX – Q 
Data for effect of temperatures on sorption rates of Diclofenac, 5-Fu and Metformin on 
SP fibers (DCF=Drug concentration on fibers, R=Repetition, D=Diclofenac, 
M=Metformin, DLT=Drug loading temperature) 
Drug DLT(°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
D 50 240 42.34 41.94 41.30 
D 50 180 45.25 41.81 42.66 
D 50 150 42.87 40.88 41.04 
D 50 120 43.40 42.07 41.88 
D 50 90 39.03 41.94 39.68 
D 50 60 42.47 37.84 39.35 
D 50 30 36.91 38.24 36.82 
D 50 15 36.38 37.44 36.17 
D 50 10 29.90 31.36 30.02 
D 50 5 17.86 24.61 20.81 
D 50 3 16.94 19.18 17.70 
D 50 1 11.11 13.63 12.12 
D 70 240 52.51 53.98 53.19 
D 70 180 48.95 49.22 50.67 
D 70 150 43.89 45.91 43.66 
D 70 120 46.81 47.63 47.89 
D 70 90 46.29 46.31 48.16 
D 70 60 46.81 47.50 48.03 
D 70 30 46.35 48.16 46.44 
D 70 15 42.14 43.79 42.21 
D 70 10 35.46 38.77 33.61 
D 70 5 28.98 28.84 30.30 
D 70 3 20.36 21.43 20.11 
D 70 1 14.00 15.88 12.70 
D 90 180 76.21 72.37 72.80 
D 90 150 74.88 68.67 70.34 
D 90 120 73.56 65.49 68.14 
D 90 90 60.07 61.92 59.77 
D 90 60 60.33 61.52 59.71 
D 90 30 57.95 57.69 56.66 
D 90 15 49.48 50.54 49.01 
D 90 10 46.57 40.35 42.59 
D 90 5 39.69 36.12 37.15 
D 90 3 34.13 29.37 31.12 
D 90 1 21.96 20.64 20.88 
5-Fu 50 240 2.92 3.10 2.87 
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Drug DLT(°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
5-Fu 50 180 2.84 2.72 3.07 
5-Fu 50 150 2.75 2.67 2.95 
5-Fu 50 120 2.82 2.69 3.07 
5-Fu 50 90 2.78 2.90 2.78 
5-Fu 50 60 2.58 2.52 2.75 
5-Fu 50 30 2.06 2.00 2.20 
5-Fu 50 15 1.67 1.51 1.91 
5-Fu 50 10 1.33 1.36 1.36 
5-Fu 50 5 1.01 1.16 0.90 
5-Fu 50 3 0.82 0.75 0.93 
5-Fu 50 1 0.72 0.67 0.81 
5-Fu 70 240 2.70 2.64 2.87 
5-Fu 70 180 2.61 2.58 2.75 
5-Fu 70 150 2.57 2.55 2.69 
5-Fu 70 120 2.53 2.52 2.64 
5-Fu 70 90 2.46 2.67 2.35 
5-Fu 70 60 2.33 2.17 2.58 
5-Fu 70 30 2.06 2.26 1.94 
5-Fu 70 15 1.93 2.03 1.91 
5-Fu 70 10 1.79 1.94 1.71 
5-Fu 70 5 1.67 1.62 1.80 
5-Fu 70 3 1.25 1.19 1.36 
5-Fu 70 1 0.84 0.75 0.96 
5-Fu 90 240 2.32 2.17 2.20 
5-Fu 90 180 2.14 2.40 2.23 
5-Fu 90 150 2.11 2.20 2.12 
5-Fu 90 120 2.03 2.00 1.97 
5-Fu 90 90 2.29 1.85 2.03 
5-Fu 90 60 2.00 2.23 2.07 
5-Fu 90 30 2.20 2.11 2.12 
5-Fu 90 15 2.23 2.09 2.12 
5-Fu 90 10 2.23 2.00 2.07 
5-Fu 90 5 1.85 1.74 1.76 
5-Fu 90 3 1.54 1.62 1.55 
5-Fu 90 1 1.27 0.87 1.05 
M 50 240 3.93 4.20 3.83 
M 50 180 4.26 4.66 4.04 
M 50 150 4.28 4.27 4.45 
M 50 120 4.32 4.30 4.51 
M 50 90 4.19 4.43 4.12 
M 50 60 4.27 4.53 4.17 
M 50 30 4.24 4.48 4.17 
M 50 15 3.87 4.15 3.76 
M 50 10 2.81 3.08 2.64 
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Drug DLT(°C) Time (min) DCF R1 (mg/g) DCF R2 (mg/g) DCF R3 (mg/g) 
M 50 5 1.48 1.74 1.27 
M 50 3 1.30 1.50 1.14 
M 50 1 0.65 0.85 0.47 
M 70 240 4.79 4.17 4.39 
M 70 180 4.56 4.74 4.56 
M 70 150 4.64 4.61 4.53 
M 70 120 4.90 4.69 4.70 
M 70 90 4.35 4.40 4.29 
M 70 60 4.87 4.46 4.57 
M 70 30 4.59 4.69 4.54 
M 70 15 4.35 4.46 4.32 
M 70 10 4.51 3.39 3.87 
M 70 5 3.50 2.88 3.12 
M 70 3 2.25 2.05 2.11 
M 70 1 1.55 1.14 1.32 
M 90 240 4.92 5.39 5.05 
M 90 180 4.90 5.18 4.94 
M 90 150 5.13 4.90 4.91 
M 90 120 5.67 4.82 5.14 
M 90 90 5.47 5.10 5.18 
M 90 60 5.88 5.13 5.40 
M 90 30 5.41 5.31 5.26 
M 90 15 5.31 5.23 5.17 
M 90 10 4.90 4.74 4.72 
M 90 5 3.58 4.04 3.73 
M 90 3 2.67 2.95 2.75 
M 90 1 1.55 2.20 1.84 
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APPENDIX – R 
Data for isotherms of Diclofenac, 5-Fu and Metformin on SP fibers (DCF=Drug 
concentration on fibers, DCS=Drug concentration in solution, R=Repetition, 
D=Diclofenac, M=Metformin, DLT=Drug loading temperature) 
Drug 
DLT 
(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
D 50 0.37 0.38 0.37 7.52 6.62 8.73 
D 50 0.80 0.81 0.82 11.67 11.64 12.17 
D 50 2.06 2.09 2.12 22.63 23.68 22.49 
D 50 4.16 4.26 4.23 36.89 37.71 37.57 
D 50 6.53 6.64 6.69 45.25 43.13 49.22 
D 50 8.66 8.77 8.90 54.59 52.26 59.14 
D 50 13.19 13.58 13.33 66.39 66.95 68.53 
D 50 17.52 17.90 17.86 69.43 69.20 72.50 
D 70 0.34 0.33 0.33 9.47 10.72 8.60 
D 70 0.77 0.78 0.76 15.82 17.46 14.82 
D 70 2.02 2.04 1.99 26.71 28.18 26.33 
D 70 4.23 4.26 4.16 41.10 41.28 42.60 
D 70 5.80 5.63 5.60 49.72 53.19 48.29 
D 70 8.36 7.82 7.93 67.49 64.96 72.77 
D 70 12.75 12.36 12.31 77.60 84.94 73.43 
D 70 18.77 18.12 18.08 84.80 88.64 84.41 
D 90 0.29 0.32 0.30 9.92 10.98 9.26 
D 90 0.79 0.85 0.80 15.82 15.74 16.54 
D 90 2.20 2.21 2.16 28.14 28.18 29.24 
D 90 4.20 4.16 4.10 50.24 49.09 53.45 
D 90 6.49 6.54 6.38 71.96 76.60 70.25 
D 90 8.80 8.85 8.65 75.66 77.13 77.27 
D 90 13.59 13.48 13.26 85.38 81.50 92.75 
D 90 18.27 18.39 17.96 94.46 92.48 100.29 
5-Fu 50 0.48 0.49 0.49 1.02 0.87 1.22 
5-Fu 50 0.90 0.93 0.91 1.66 1.56 1.83 
5-Fu 50 2.35 2.41 2.38 2.68 2.52 2.95 
5-Fu 50 4.82 4.98 4.85 3.19 3.04 3.48 
5-Fu 50 6.17 6.46 6.13 3.15 3.30 3.13 
5-Fu 50 8.75 8.96 8.90 3.32 3.56 3.22 
5-Fu 50 11.03 11.17 11.34 3.75 3.56 4.08 
5-Fu 50 12.61 12.84 12.90 3.83 3.74 4.08 
5-Fu 70 0.45 0.48 0.44 1.30 0.35 0.81 
5-Fu 70 0.92 0.94 0.94 0.78 1.48 1.11 
5-Fu 70 2.37 2.42 2.42 1.65 1.39 1.49 
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Drug 
DLT 
(°C) 
DCS R1 
(mg/ml) 
DCS R2 
(mg/ml) 
DCS R3 
(mg/ml) 
DCF R1 
(mg/g) 
DCF R2 
(mg/g) 
DCF R3 
(mg/g) 
5-Fu 70 4.85 4.96 4.93 2.61 2.69 2.60 
5-Fu 70 6.35 6.50 6.46 3.04 2.78 2.85 
5-Fu 70 8.87 9.08 9.01 3.22 2.69 2.90 
5-Fu 70 12.80 13.13 12.99 3.65 3.30 3.41 
5-Fu 70 13.96 14.09 14.40 3.48 3.82 3.58 
5-Fu 90 0.51 0.52 0.50 0.43 0.35 0.52 
5-Fu 90 0.81 0.94 0.86 0.81 0.70 0.96 
5-Fu 90 2.35 2.42 2.34 1.41 1.56 1.30 
5-Fu 90 4.93 4.95 4.84 2.26 2.43 2.17 
5-Fu 90 6.33 6.43 6.25 2.68 2.87 2.61 
5-Fu 90 9.05 9.05 8.87 2.64 2.87 2.52 
5-Fu 90 13.11 13.11 12.85 3.28 3.56 3.13 
5-Fu 90 14.63 14.79 14.42 3.45 3.30 3.74 
M 50 0.23 0.23 0.25 3.01 2.98 3.16 
M 50 0.46 0.48 0.46 3.28 3.26 3.42 
M 50 2.24 2.35 2.22 3.92 3.94 4.07 
M 50 4.56 4.71 4.60 4.25 4.25 4.43 
M 50 7.20 7.36 7.34 4.61 4.87 4.53 
M 50 9.59 9.79 9.78 4.90 4.95 5.05 
M 50 13.77 14.08 14.02 5.32 5.36 5.49 
M 50 19.17 19.51 19.61 5.54 5.47 5.83 
M 70 0.24 0.24 0.25 3.19 3.34 3.16 
M 70 0.45 0.47 0.45 3.75 3.73 3.91 
M 70 2.28 2.33 2.32 4.10 4.04 4.33 
M 70 4.58 4.68 4.65 4.58 4.53 4.82 
M 70 7.09 7.25 7.23 5.03 4.87 5.39 
M 70 9.47 9.62 9.71 5.33 5.18 5.70 
M 70 13.85 14.09 14.16 5.51 5.52 5.73 
M 70 18.98 19.30 19.43 5.74 5.62 6.09 
M 90 0.25 0.25 0.25 4.07 4.59 4.24 
M 90 0.48 0.48 0.47 4.61 5.00 4.71 
M 90 2.34 2.28 2.26 4.82 5.44 5.03 
M 90 4.75 4.56 4.56 5.23 5.88 5.45 
M 90 7.09 7.44 7.12 6.11 6.43 6.14 
M 90 9.91 9.80 9.66 7.02 6.11 6.44 
M 90 14.11 14.59 14.06 6.53 7.10 6.68 
M 90 16.44 16.29 16.04 6.74 7.41 6.93 
 
  
172 
 
APPENDIX – S 
Data for Diclofenac, 5-Fu and Metformin release from SP fibers in PBS (DLT=Drug 
loading temperature, DRP=Drug release percentage, R=Repetition, D=Diclofenac, 
M=Metformin) 
Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 50 0 0.00% 0.00% 0.00% 
D 50 1 70.08% 63.62% 77.94% 
D 50 5 73.96% 68.88% 80.53% 
D 50 10 75.83% 69.77% 83.42% 
D 50 24 78.33% 72.51% 85.72% 
D 50 47 83.08% 78.10% 89.74% 
D 50 72 87.47% 83.99% 92.71% 
D 50 96 90.57% 86.61% 96.36% 
D 50 120 90.47% 86.70% 96.07% 
D 50 144 92.76% 88.95% 98.45% 
D 50 168 95.89% 91.70% 102.03% 
D 50 192 96.34% 91.70% 102.93% 
D 50 216 96.34% 91.70% 102.93% 
D 50 240 96.34% 91.70% 102.93% 
D 50 264 96.34% 91.70% 102.93% 
D 50 288 96.34% 91.70% 102.93% 
D 50 312 96.34% 91.70% 102.93% 
D 50 336 96.34% 91.70% 102.93% 
D 50 360 96.34% 91.70% 102.93% 
D 50 384 96.34% 91.70% 102.93% 
D 70 0 0.00% 0.00% 0.00% 
D 70 1 58.21% 62.35% 59.68% 
D 70 5 66.93% 61.29% 63.47% 
D 70 10 68.62% 63.43% 65.36% 
D 70 24 69.52% 65.77% 66.97% 
D 70 47 78.59% 75.89% 76.46% 
D 70 72 86.49% 81.25% 83.03% 
D 70 96 91.46% 86.48% 88.08% 
D 70 120 92.60% 84.98% 87.90% 
D 70 144 92.65% 86.65% 88.75% 
D 70 168 93.99% 89.96% 91.06% 
D 70 192 95.48% 93.03% 93.31% 
D 70 216 96.64% 91.24% 93.00% 
D 70 240 98.68% 93.34% 95.05% 
D 70 264 99.94% 95.16% 96.58% 
D 70 288 100.15% 97.67% 97.92% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 70 312 99.97% 94.80% 96.41% 
D 70 336 100.14% 99.70% 98.92% 
D 70 360 99.70% 95.46% 96.61% 
D 70 384 100.83% 96.49% 97.67% 
D 90 0 0.00% 0.00% 0.00% 
D 90 1 42.47% 43.78% 42.01% 
D 90 5 45.39% 47.06% 44.63% 
D 90 10 46.79% 48.16% 46.36% 
D 90 24 48.42% 49.94% 47.89% 
D 90 47 52.98% 53.58% 53.45% 
D 90 72 57.12% 58.60% 56.79% 
D 90 96 60.70% 62.07% 60.55% 
D 90 120 61.40% 62.80% 61.24% 
D 90 144 62.93% 63.81% 63.33% 
D 90 168 68.49% 69.63% 68.73% 
D 90 192 70.16% 71.69% 70.04% 
D 90 216 71.87% 72.98% 72.22% 
D 90 240 73.57% 74.97% 73.65% 
D 90 264 74.67% 76.00% 74.85% 
D 90 288 77.92% 78.65% 78.77% 
D 90 312 75.71% 77.02% 75.92% 
D 90 336 74.92% 76.51% 74.85% 
D 90 360 76.11% 77.54% 76.22% 
D 90 384 77.00% 78.72% 76.83% 
5-Fu 90 0 0.00% 0.00% 0.00% 
5-Fu 90 1 61.94% 46.46% 53.66% 
5-Fu 90 5 57.25% 56.49% 56.30% 
5-Fu 90 10 59.92% 66.90% 62.78% 
5-Fu 90 24 62.60% 69.96% 65.61% 
5-Fu 90 47 65.27% 73.01% 68.45% 
5-Fu 90 72 75.68% 68.32% 71.28% 
5-Fu 90 96 70.99% 78.74% 74.12% 
5-Fu 90 120 73.67% 81.79% 76.95% 
5-Fu 90 144 68.60% 84.85% 75.95% 
5-Fu 90 168 70.89% 87.14% 78.22% 
5-Fu 70 0 0.00% 0.00% 0.00% 
5-Fu 70 1 54.04% 51.55% 57.62% 
5-Fu 70 5 61.61% 58.78% 65.69% 
5-Fu 70 10 64.25% 66.24% 63.55% 
5-Fu 70 24 72.05% 73.93% 71.63% 
5-Fu 70 47 85.01% 86.53% 85.21% 
5-Fu 70 72 93.27% 99.60% 88.82% 
5-Fu 70 96 99.98% 99.08% 102.91% 
5-Fu 70 120 101.38% 103.00% 101.81% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
5-Fu 70 144 100.33% 102.25% 100.44% 
5-Fu 70 168 99.53% 102.25% 98.82% 
5-Fu 50 0 0.00% 0.00% 0.00% 
5-Fu 50 1 30.16% 28.12% 32.80% 
5-Fu 50 5 38.60% 38.88% 39.11% 
5-Fu 50 10 47.39% 45.41% 50.33% 
5-Fu 50 24 58.84% 61.55% 57.33% 
5-Fu 50 47 86.99% 83.07% 92.67% 
5-Fu 50 72 102.48% 96.14% 110.89% 
5-Fu 50 96 102.30% 95.61% 111.06% 
5-Fu 50 120 104.21% 99.54% 110.99% 
5-Fu 50 144 101.37% 94.09% 110.69% 
5-Fu 50 168 105.14% 106.93% 105.48% 
M 50 0 0.00% 0.00% 0.00% 
M 50 1 73.74% 75.23% 73.74% 
M 50 5 77.38% 76.46% 76.15% 
M 50 10 78.54% 77.08% 77.03% 
M 50 24 79.58% 82.00% 79.98% 
M 50 47 84.95% 84.53% 83.89% 
M 50 72 84.97% 87.99% 85.62% 
M 50 96 87.80% 87.50% 86.77% 
M 50 120 91.09% 90.77% 90.02% 
M 50 144 92.90% 91.07% 91.06% 
M 50 168 92.65% 89.73% 90.28% 
M 50 192 90.26% 97.09% 92.74% 
M 70 0 0.00% 0.00% 0.00% 
M 70 1 68.79% 70.77% 69.08% 
M 70 5 71.69% 72.78% 71.51% 
M 70 10 73.57% 74.71% 73.40% 
M 70 24 76.86% 77.55% 76.44% 
M 70 47 79.17% 74.93% 76.28% 
M 70 72 81.92% 76.97% 78.65% 
M 70 96 79.70% 83.41% 80.74% 
M 70 120 83.14% 78.14% 79.84% 
M 70 144 81.67% 86.82% 83.40% 
M 70 168 81.45% 86.38% 83.08% 
M 70 192 84.06% 84.28% 83.33% 
M 90 0 0.00% 0.00% 0.00% 
M 90 1 52.05% 49.67% 55.47% 
M 90 5 53.99% 51.52% 57.54% 
M 90 10 54.31% 52.15% 57.57% 
M 90 24 56.14% 53.28% 60.14% 
M 90 47 61.01% 58.54% 64.71% 
M 90 72 62.80% 62.16% 64.71% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
M 90 96 64.19% 66.43% 63.24% 
M 90 120 66.18% 59.42% 74.26% 
M 90 144 67.19% 62.72% 73.02% 
M 90 168 67.72% 61.88% 74.92% 
M 90 192 68.64% 63.88% 74.79% 
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APPENDIX – T 
Data for Diclofenac, 5-Fu and Metformin release from SP fibers in AGJ (DLT=Drug 
loading temperature, DRP=Drug release percentage, R=Repetition, D=Diclofenac, 
M=Metformin) 
Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
D 50 0 0.00% 0.00% 0.00% 
D 50 1 6.43% 7.28% 5.34% 
D 50 2 7.82% 8.01% 7.33% 
D 50 4 8.54% 7.76% 8.98% 
D 50 6 9.01% 8.39% 9.27% 
D 50 8 9.95% 9.51% 10.00% 
D 50 12 10.17% 10.67% 9.27% 
D 50 16 10.84% 10.43% 10.82% 
D 50 24 11.51% 11.06% 11.50% 
D 70 0 0.00% 0.00% 0.00% 
D 70 1 6.62% 7.81% 7.36% 
D 70 2 8.30% 9.10% 8.88% 
D 70 4 9.58% 10.27% 10.12% 
D 70 6 10.22% 10.97% 10.81% 
D 70 8 11.02% 11.31% 11.39% 
D 70 12 11.48% 11.77% 11.86% 
D 70 16 11.73% 12.36% 12.29% 
D 70 24 12.28% 12.77% 12.77% 
D 90 0 0.00% 0.00% 0.00% 
D 90 1 5.09% 5.38% 5.34% 
D 90 2 6.45% 6.76% 6.74% 
D 90 4 8.18% 9.09% 8.81% 
D 90 6 9.17% 9.31% 9.43% 
D 90 8 10.19% 10.33% 10.47% 
D 90 12 10.39% 10.53% 10.67% 
D 90 16 10.53% 12.09% 11.53% 
D 90 24 10.90% 11.18% 11.26% 
5-Fu 50 0 0.00% 0.00% 0.00% 
5-Fu 50 1 19.21% 20.92% 16.74% 
5-Fu 50 2 27.53% 27.20% 26.78% 
5-Fu 50 4 34.36% 38.08% 29.29% 
5-Fu 50 6 39.48% 41.43% 35.99% 
5-Fu 50 8 40.55% 40.59% 38.92% 
5-Fu 50 12 52.07% 51.89% 50.21% 
5-Fu 50 16 55.91% 55.65% 53.98% 
5-Fu 50 24 70.42% 71.97% 66.11% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
5-Fu 70 0 0.00% 0.00% 0.00% 
5-Fu 70 1 36.99% 36.27% 36.27% 
5-Fu 70 2 42.11% 39.89% 42.68% 
5-Fu 70 4 45.95% 40.73% 49.38% 
5-Fu 70 6 48.37% 44.08% 50.77% 
5-Fu 70 8 53.49% 50.21% 54.68% 
5-Fu 70 12 60.18% 59.42% 58.58% 
5-Fu 70 16 65.73% 66.39% 62.49% 
5-Fu 70 24 74.27% 68.07% 77.55% 
5-Fu 90 0 0.00% 0.00% 0.00% 
5-Fu 90 1 39.40% 45.06% 32.19% 
5-Fu 90 2 49.90% 56.01% 41.84% 
5-Fu 90 4 57.78% 61.16% 52.14% 
5-Fu 90 6 62.71% 66.31% 56.65% 
5-Fu 90 8 67.63% 71.46% 61.16% 
5-Fu 90 12 75.84% 83.05% 65.66% 
5-Fu 90 16 84.38% 88.84% 76.61% 
5-Fu 90 24 86.68% 88.20% 81.76% 
M 50 0 0.00% 0.00% 0.00% 
M 50 1 46.81% 47.87% 48.29% 
M 50 2 52.98% 62.23% 58.76% 
M 50 4 62.77% 70.13% 67.78% 
M 50 6 69.57% 77.55% 75.03% 
M 50 8 73.83% 83.30% 80.13% 
M 50 12 80.42% 93.11% 88.50% 
M 50 16 87.87% 98.38% 94.99% 
M 50 24 96.38% 108.91% 104.70% 
M 70 0 0.00% 0.00% 0.00% 
M 70 1 46.12% 45.74% 44.68% 
M 70 2 51.00% 49.57% 50.42% 
M 70 4 58.27% 57.66% 56.60% 
M 70 6 66.41% 65.74% 64.47% 
M 70 8 71.83% 71.70% 69.15% 
M 70 12 78.34% 77.23% 76.38% 
M 70 16 83.55% 81.28% 82.55% 
M 70 24 91.58% 90.00% 89.57% 
M 90 0 0.00% 0.00% 0.00% 
M 90 1 34.19% 31.46% 33.48% 
M 90 2 38.30% 33.65% 36.69% 
M 90 4 43.22% 40.49% 42.69% 
M 90 6 47.87% 47.60% 48.69% 
M 90 8 53.62% 48.15% 51.90% 
M 90 12 59.36% 55.80% 58.73% 
M 90 16 62.37% 58.54% 61.66% 
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Drug DLT (°C) Time (hour) DRP R1 (%) DRP R2 (%) DRP R3 (%) 
M 90 24 70.30% 67.57% 70.31% 
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APPENDIX – U 
Data to perform linear regression of initial burst from SP fibers in PBS and in AGJ with 
kinetic and thermodynamic parameters (DRP=Drug release percentage, SRT=Square root 
of time, SRIAT=Square root of interaction of affinity and time) 
Drug T (°C) IBPBS (%) C (mol/kg) A×C 
D 50 70.78% 2.20E-01 5.54E+00 
D 70 60.28% 2.20E-01 6.12E+00 
D 90 27.15% 2.20E-01 6.51E+00 
D 90 40.40% 3.24E-01 9.58E+00 
5-Fu 90 54.20% 2.69E-02 3.23E-01 
5-Fu 70 54.58% 2.69E-02 3.36E-01 
5-Fu 50 30.46% 2.69E-02 3.23E-01 
5-Fu 50 4.69% 1.35E-02 1.62E-01 
M 50 74.48% 3.32E-02 8.13E-01 
M 70 69.78% 3.32E-02 9.65E-01 
M 90 41.08% 3.32E-02 1.02E+00 
M 90 59.11% 4.41E-02 1.35E+00 
 
Drug T (°C) IBAGJ (%) C (mol/kg) A×C 
D 50 8.25% 2.20E-01 5.54E+00 
D 70 6.31% 2.20E-01 6.12E+00 
D 90 5.24% 2.20E-01 6.51E+00 
D 90 7.22% 3.24E-01 9.58E+00 
5-Fu 90 38.63% 2.69E-02 3.23E-01 
5-Fu 70 36.27% 2.69E-02 3.36E-01 
5-Fu 50 18.83% 2.69E-02 3.23E-01 
5-Fu 50 13.95% 1.35E-02 1.62E-01 
M 50 47.34% 3.32E-02 8.13E-01 
M 70 45.21% 3.32E-02 9.65E-01 
M 90 32.83% 3.32E-02 1.02E+00 
M 90 36.30% 4.41E-02 1.35E+00 
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APPENDIX – V 
Data to perform linear regression of drug release after burst from SP fibers in PBS with 
kinetic and thermodynamic parameters (DRP=Drug release percentage, SRT=Square root 
of time, SRIAT=Square root of interaction of affinity and time) 
DRPPBS (%) SRT SRIAT DRP (%) SRT SRIAT 
3.92% 2.24 0.04 23.53% 10.95 0.33 
5.81% 3.16 0.05 22.52% 12.00 0.36 
8.33% 4.90 0.08 24.81% 12.96 0.39 
13.14% 6.86 0.11 7.65% 2.24 0.07 
17.57% 8.49 0.14 10.31% 3.16 0.10 
20.70% 9.80 0.16 18.20% 4.90 0.15 
20.60% 10.95 0.18 31.29% 6.86 0.21 
22.91% 12.00 0.20 39.63% 8.49 0.26 
26.08% 12.96 0.21 46.41% 9.80 0.29 
26.53% 13.86 0.23 47.82% 10.95 0.33 
26.53% 14.70 0.24 46.76% 12.00 0.36 
3.82% 2.24 0.04 45.95% 12.96 0.39 
5.74% 3.16 0.05 8.53% 2.24 0.07 
7.36% 4.90 0.08 17.41% 3.16 0.10 
16.95% 6.86 0.11 28.98% 4.90 0.15 
23.59% 8.49 0.14 57.41% 6.86 0.21 
28.69% 9.80 0.16 73.05% 8.49 0.26 
28.51% 10.95 0.18 72.87% 9.80 0.29 
29.37% 12.00 0.20 74.80% 10.95 0.33 
31.69% 12.96 0.21 71.93% 12.00 0.36 
33.97% 13.86 0.23 75.74% 12.96 0.39 
33.66% 14.70 0.24 9.60% 2.24 0.07 
35.73% 15.49 0.25 14.98% 3.16 0.10 
37.27% 16.25 0.26 25.28% 4.90 0.15 
38.62% 16.97 0.28 54.78% 6.86 0.21 
37.11% 17.66 0.29 66.93% 8.49 0.26 
39.64% 18.33 0.30 77.19% 9.80 0.29 
37.30% 18.97 0.31 80.78% 10.95 0.33 
38.38% 19.60 0.32 89.04% 12.00 0.36 
1.87% 2.24 0.04 90.51% 12.96 0.39 
2.76% 3.16 0.05 2.43% 2.24 0.10 
3.81% 4.90 0.08 3.32% 3.16 0.15 
6.72% 6.86 0.11 6.31% 4.90 0.23 
9.37% 8.49 0.14 10.25% 6.86 0.32 
11.66% 9.80 0.16 12.00% 8.49 0.39 
12.10% 10.95 0.18 13.16% 9.80 0.46 
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DRPPBS (%) SRT SRIAT DRP (%) SRT SRIAT 
13.09% 12.00 0.20 16.44% 10.95 0.51 
16.64% 12.96 0.21 17.50% 12.00 0.56 
17.70% 13.86 0.23 16.71% 12.96 0.60 
18.80% 14.70 0.24 19.19% 13.86 0.64 
19.88% 15.49 0.25 2.45% 2.24 0.10 
20.59% 16.25 0.26 4.36% 3.16 0.15 
22.67% 16.97 0.28 7.43% 4.90 0.23 
21.25% 17.66 0.29 7.27% 6.86 0.32 
20.75% 18.33 0.30 9.66% 8.49 0.39 
21.51% 18.97 0.31 11.77% 9.80 0.46 
22.08% 19.60 0.32 10.86% 10.95 0.51 
4.08% 2.24 0.04 14.46% 12.00 0.56 
6.35% 3.16 0.05 14.13% 12.96 0.60 
8.12% 4.90 0.08 14.39% 13.86 0.64 
10.74% 6.86 0.11 1.53% 2.24 0.10 
12.87% 8.49 0.14 1.80% 3.16 0.15 
14.86% 9.80 0.16 3.22% 4.90 0.23 
14.95% 10.95 0.18 7.09% 6.86 0.32 
15.84% 12.00 0.20 8.58% 8.49 0.39 
16.46% 12.96 0.21 9.81% 9.80 0.46 
17.39% 13.86 0.23 10.99% 10.95 0.51 
17.43% 14.70 0.24 11.89% 12.00 0.56 
19.09% 15.49 0.25 12.25% 12.96 0.60 
19.63% 16.25 0.26 13.03% 13.86 0.64 
20.35% 16.97 0.28 1.16% 2.24 0.10 
19.79% 17.66 0.29 1.46% 3.16 0.15 
19.36% 18.33 0.30 2.81% 4.90 0.23 
20.01% 18.97 0.31 7.00% 6.86 0.32 
20.28% 19.60 0.32 13.02% 8.49 0.39 
2.67% 2.24 0.07 14.14% 9.80 0.46 
9.22% 3.16 0.10 13.82% 10.95 0.51 
12.08% 4.90 0.15 13.73% 12.00 0.56 
14.94% 6.86 0.21 14.87% 12.96 0.60 
17.80% 8.49 0.26 16.14% 13.86 0.64 
20.67% 9.80 0.29 
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APPENDIX – W 
Data to perform linear regression of drug release after burst from SP fibers in AGJ with 
kinetic and thermodynamic parameters (DRP=Drug release percentage, SRT=Square root 
of time, SRIAT=Square root of interaction of affinity and time) 
DRPAGJ (%) SRT SRIAT DRP (%) SRT SRIAT 
1.36% 1.41 0.02 8.16% 1.41 0.04 
2.06% 2.00 0.03 14.85% 2.00 0.06 
2.52% 2.45 0.04 19.88% 2.45 0.07 
3.44% 2.83 0.05 20.92% 2.83 0.09 
3.66% 3.46 0.06 32.22% 3.46 0.10 
4.32% 4.00 0.07 35.99% 4.00 0.12 
4.97% 4.90 0.08 50.21% 4.90 0.15 
1.49% 1.41 0.02 7.60% 1.41 0.04 
2.71% 2.00 0.03 8.65% 2.00 0.06 
3.38% 2.45 0.04 13.88% 2.45 0.07 
3.95% 2.83 0.05 15.13% 2.83 0.09 
4.41% 3.46 0.06 24.76% 3.46 0.10 
4.83% 4.00 0.07 30.62% 4.00 0.12 
5.31% 4.90 0.08 36.68% 4.90 0.15 
1.37% 1.41 0.02 10.27% 1.41 0.07 
3.40% 2.00 0.03 19.11% 2.00 0.09 
4.00% 2.45 0.04 26.22% 2.45 0.11 
5.02% 2.83 0.05 31.22% 2.83 0.13 
5.22% 3.46 0.06 39.43% 3.46 0.16 
6.07% 4.00 0.07 45.78% 4.00 0.19 
5.80% 4.90 0.08 55.31% 4.90 0.23 
1.18% 1.41 0.02 4.79% 1.41 0.07 
1.56% 2.00 0.03 11.91% 2.00 0.09 
1.71% 2.45 0.04 19.89% 2.45 0.11 
2.47% 2.83 0.05 25.21% 2.83 0.13 
2.56% 3.46 0.06 31.60% 3.46 0.16 
2.91% 4.00 0.07 36.70% 4.00 0.19 
3.23% 4.90 0.08 44.57% 4.90 0.23 
10.30% 1.41 0.04 3.15% 1.41 0.07 
18.03% 2.00 0.06 9.03% 2.00 0.09 
22.85% 2.45 0.07 14.91% 2.45 0.11 
27.68% 2.83 0.09 18.05% 2.83 0.13 
35.73% 3.46 0.10 24.76% 3.46 0.16 
44.10% 4.00 0.12 27.63% 4.00 0.19 
46.35% 4.90 0.15 36.11% 4.90 0.23 
5.02% 1.41 0.04 4.47% 1.41 0.07 
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DRPAGJ (%) SRT SRIAT DRP (%) SRT SRIAT 
8.79% 2.00 0.06 10.77% 2.00 0.09 
11.16% 2.45 0.07 15.80% 2.45 0.11 
16.18% 2.83 0.09 19.71% 2.83 0.13 
22.74% 3.46 0.10 25.93% 3.46 0.16 
28.18% 4.00 0.12 29.04% 4.00 0.19 
36.54% 4.90 0.15 36.78% 4.90 0.23 
 
 
 
 
